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Abstract 
Chitin is a glycopolymer consisting of β-(1, 4)-linked N-acetyl-D-glucosamine 
residues that occurs widely in nature and is a constituent of many organisms that are 
pathogenic to humans, including insects, fungi, and parasitic nematodes. As these 
organisms depend on the ability to break down chitin at key points of their life-cycle, 
inhibitors of the enzymes termed chitinases that catalyse the hydrolysis of chitin, are 
of considerable interest as potential drugs and insecticides. Although chitin is absent 
from mammalian physiology, two human chitinases along with several chitin-binding 
proteins (chi-lectins) have been associated with the onset or transmission of several 
major human diseases such as asthma, Legionnaire’s disease and osteoarthritis. 
Therefore, selective inhibitors of chitinases are now of considerable interest as new 
drug leads and biochemical probes. 
Until recently, few broad spectrum chitinase inhibitors had been identified. The 
natural cyclopentapeptide, argifin, has been shown to be a potent inhibitor of several 
bacterial-type family 18 chitinases including Aspergillus fumigatus chitinase B1 
(AfChiB1). With the aid of high resolution X-ray structures we have designed and 
prepared linear fragments of the natural product cyclopentapeptide argifin using a 
combination of SPPS and solution phase synthesis. This has allowed us to determine 
that the N­methyl guanylurea motif serves as a starting point for the generation of 
novel, drug-like, peptidomimetic inhibitors family 18 chitinases. We have also 
demonstrated that the cis configuration about the Arg(MC)-N-MePhe peptide bond is 
essential to retain any significant biological activity. This dipeptide motif is also 
found in another naturally occurring cyclopentapeptide, banyasin A, extracted from 
the cyanobacteruim Nostoc sp. Banyasin A also contains a rare β-amino acid, 3-
amino-2-methyl-5E-octenoic acid (Amoa), in which the stereochemistry at the C3 and 
C5 of Amoa has not been resolved. The diastereoselective synthesis of Amoa for the 
preparation of banyasin A has also been established using chiral oxazolidinone-based 
aldol chemistry, which has allowed us to successfully prepare a single diastereoisomer 
of the natural product cyclopentapeptide incorporating this β-amino acid. New 
methodology for the preparation of argifin has also been developed to reduce the 
propensity towards the formation of undesired side products and to prepare the natural 
product on a larger scale. 
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1 Introduction 
1.1 Chitin and Chitoligosaccharides 
Chitin (1) (Fig. 1) is a fibrous and insoluble biopolymer which exists widely in nature 
and consists of β-(1, 4)-linked N-acetyl-D-glucosamine residues. It has been found to 
be a constituent of many organisms that are pathogenic to humans. Chitin is the main 
component of fungal cell walls contributing to structural rigidity,1 has been found in 
the exoskeletons of many insects and crustaceans2 and exists in the eggshells of 
parasitic nematodes.3 
HO HO HO 
O OHO O 
OH O OHO 
HO HO AcHN AcHN AcHN n 
(1)

Figure 1: The structure of chitin

Chitin has been found to exist in three main forms, α, β, and γ which differ from each 
other in terms of their secondary structures.4 α -Chitin is the most abundant and stable 
of the three forms and is found in fungal cell walls and arthropods. It consists of an 
anti-parallel stacked structure with strong hydrogen bond interactions between chains. 
The β-form consists of parallel sugar chains and is limited to squid pens and diatoms. 
The structure of γ –chitin consists of repeating patterns of one anti-parallel and two 
parallel sheets as found in the coccon fibres of the Ptinus beetle and the stomach of 
the myopsid squid, Loligo and is the least common of the three forms.5 
1.2 Chitin metabolism in nature 
The class of enzymes that are responsible for the degradation of chitin are termed 
chitinases. Chitin-containing organisms depend on the hydrolysis of chitin by 
chitinases at key points of their life-cycles. In order for fungal cells to mature, chitin 
1 
contained within the cell wall is degraded to allow cell growth. An illustration of this 
has been reported by Cabib et al who have demonstrated that the lyses observed in 
daughter cells of the fungus, Saccharomyces cerevisiae was caused by a chitinase that 
partially degrades the chitin septum in the process of cell separation.1 The expression 
of chitinases continues to take place within the eggs of the plant parasitic nematode 
Meloidogyne artiellia, and is required for the degradation of chitin which is a major 
structural constituent contained within the eggshell of this nematode.6 Chitin synthesis 
is critical for normal growth and development of nematodal eggshells and the removal 
of chitinase activity has been reported to delay the emergence of juveniles of M. 
artiellia.6 Chitin is also present in the exoskeleton of insects and suppots the cuticles 
of the epidermis and trachea. Insect growth and morphogenesis is strictly dependant 
on the capability to remodel chitin-containing structures and therefore, insects 
repeatedly produce chitinases in different tissues.2 
1.3 chitinase classification 
There are two main families of chitinases that differ from each other in terms of 
structure, mechanism of chitin hydrolysis and amino acid sequence and are termed as 
family 18 and 19 endo-glycosyl hydrolases.7, 8 Family 18 chitinases are divided into 
two sub-classes, “bacterial type” and “plant type” family 18 chitinases and are 
structurally distinct from one another. Family 18 “bacterial type” exo-chitinases 
cleave oligosaccharide substrates at specific β-(1,4)-glycosidic bonds resulting in the 
formation of acetylchitobiose (NAG2) or acetylchitotriose (NAG3)
9. Family 18 “plant 
type” chitinases are endo-chitinases cleaving random β-(1,4)-glycosidic bonds 
releasing oligosaccharide chains or varying length.9-11 With regards to family 18 
chitinases, the active sites of “bacterial type” chitinases tend to be more enclosed 
compared to “plant type” chitinases (Fig 2).12, 13 
2 
Figure 2: The active site of bacterial­type exo­chitinase , Serratia marcescenes chitinase B (left in 
blue) and plant­type endo­chitinase, Hevamine (right in red), (Image courtesy of Prof. D.M.F van 
Aalten, University of Dundee 
1.4 Family 19 chitinases 
Class I, II and IV chitinases from plants belong to family 19 chitinases. Initially, 
family 19 chitinases were considered to contain chitinases exclusively belonging to 
plant species. These are highly conserved and show substantial sequence and active 
site homology.14 The first report of a family 19 chitinase found in organisms other 
than higher plants was by Onho et al.14 In this study, the specificity of chitinase C-1 
of Streptomyces griseus HUT6037 for the hydrolysis of β-1,4-glycosidic linkages, in 
partially acetylated chitosan, was investigated and was found to be different from that 
of other microbial chitinases. The chiC gene, specifying chitinase C-1, was cloned 
and its nucleotide sequence was determined. The gene encodes a polypeptide of 294 
amino acids with a calculated size of 31.4 kDa. Comparison of the amino acid 
sequence of the deduced polypeptide with that of other proteins revealed a C-terminal 
catalytic domain displaying considerable sequence similarity to the catalytic domain 
of plant class I, II and IV chitinases of the glycosyl hydrolase family 19. The N-
terminal domain of the deduced polypeptide exhibits sequence similarity to substrate-
binding domains of several microbial chitinases and cellulases but not to the chitin-
binding domains of plant chitinases. High-performance liquid chromatography 
3 
analysis of the hydrolysis products from N-acetyl chitotetraose revealed that chitinase 
C-1 catalyses hydrolysis with inversion of the anomeric configuration. 
The properties of chitinase C were compared with those of family 18 bacterial 
chitinases and the distribution of family 19 chitinases in Streptomyces species has 
been investigated.15 The specific hydrolysing activity of chitinase C against soluble 
and insoluble chitinous substrates was markedly higher than those of bacterial family 
18 chitinases. Chitinase C was insensitive to allosamidin, an extensively studied 
chitinase inhibitor (see section 1.8.1), whereas the family 18 bacterial chitinases were 
sensitive. A search for family 19 chitinases was also made in various other 
Streptomyces species. Chitinases insensitive to allosamidin were detected in culture 
supernatants of all tested Streptomyces species. Southern hybridization analysis using 
labelled DNA fragments corresponding to the catalytic domain of chitinase C strongly 
suggested that these species have genes similar to the chiC gene of S. griseus 
HUT6037. DNA fragments corresponding to the major part of the catalytic domains 
were amplified by PCR. The amplified fragments encoded amino acid sequences very 
similar to that of the corresponding region of chitinase C. It was concluded that 
Streptomyces species generally possess family 19 chitinases which are very similar to 
chitinase C. Comparison of their amino-acid sequences with those of plant family 19 
chitinases revealed that Streptomyces family 19 chitinases are of the class IV type in 
terms of the presence and positions of amino-acid sequences. 
The distribution of family 19 chitinases in the class Actinobacteria, and the 
phylogenetic relationship of Actinobacteria family 19 chitinases with those of other 
organisms has also been investigated.16 Forty-nine strains were examined, twenty-two 
of which formed clear zones on agar plates containing colloidal chitin and thus 
appeared to produce chitinases. These twenty-two chitinase positive strains were 
subjected to Southern hybridization analysis by using a labelled DNA fragment 
corresponding to the catalytic domain of ChiC, and the presence of genes similar to 
chiC of S. griseus HUT6037 was detected in at least 13 strains. The presence of 
family 19 chitinase genes in these 13 strains were confirmed by PCR amplification 
and sequencing of the DNA fragments corresponding to the major part of the catalytic 
domains of the family 19 chitinase genes. Phylogenetic analysis suggested that there 
is a close evolutionary relationship between family 19 chitinases found in 
4 
Actinobacteria and plant class IV chitinases. It has been postulated that the general 
occurrence of family 19 chitinases genes in Streptomyces and the high sequence 
similarity among the genes found in Actinobacteria suggests that the family 19 
chitinase gene was first acquired by an ancestor of the Streptomycineae and spread 
among the Actinobacteria through horizontal gene expression. 
A mechanism for chitin hydrolysis has been proposed for family 19 chitinases that 
results in hydrolysis, via an inverting mechanism17 (Scheme 1). The X-ray structure of 
barley seed endochitinase reveals that there are two acidic residues (Glu 67 and Glu 
89) in the active site. It is often reported that a single displacement mechanism for 
family 19 chitinases account for inversion of the anomeric product and the 
requirement for two acidic residues to be largely separated within the active site. This 
single displacement mechanism needs one acidic residue to act as a general acid (Glu 
67) and the other as a general base (Glu 89). Residue Glu 89 would then activate 
water and cause concerted nucleophilic attack at the C1’ as shown in Scheme 1. 
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Scheme 1: The hydrolysis of chitin by Family 19 chitinases 
For family 19 chitinases, the proposed single displacement mechanism involves an 
intermediate which strongly mimics an oxocarbenium ion. Such an intermediate has 
been proposed for hen egg white lysozyme (HEWL), a family 19 barley chitinase. 
The key difference that the second acidic residue is within a few Angstroms of the 
oxocarbenium ion resulting in stabilisation of the charge by forming a covalent bond 
5 
at the C1’ position or an ion pair.18, 19 Stablisation of this charge has been postulated 
to increase enzymatic rate through theoretical studies of HEWL.20 
The degradation of chitin by family 19 chitinases has also been investigated using 
molecular dynamics simulations,17 examining the binding of a NAG6 substrate (Fig. 
3) and two potential hydrolysis intermediates a NAG6 oxazoline ion and a NAG6 
oxocarbenium ion) to a family 19 barley seed endochitinase. It was concluded that the 
NAG6 substrate binds with all sugars in a chair conformation allowing protonation by 
Glu 67 of the anomeric oxygen linking sugar residues D and E. A hydrogen bond 
formed between Asn 199 and the N-acetyl group of sugar D leading to the prevention 
of forming an oxazoline ion intermediate. The acidic residue Glu 89 is placed in a 
flexible loop region causing a conformational change to occur within the active site 
and allowing the oxocarbenium ion intermediate to be 4-5 Å closer to Glu 89. 
Coordination of water molecule to Glu 89 and Ser 120 activates this water molecule 
for nucleophilic attack resulting in a product with an inverted anomeric configuration, 
as observed (Scheme 1). Potential inhibitors that mimic the transition state of the 
more planar oxocarbenium ion could in theory, be more selective against family 19 
chitinases than family 18 chitinases. 
6 
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Figure 3: Hydrogen bonds conserved in NAG6 substrate bound to barley chitinase, conserved 
residues depicted with * 
1.5 Family 18 chitinases 
Family 18 chitinases comprise of enzymes from mammals, insects, plants, nematodes, 
fungi and bacteria and are evolutionary diverse. Class III and V family 18 chitinases 
are found to be distributed amongst higher plants.15 The “plant-type” family 18 
chitinases are endo-chitinases cleaving β-(1,4)-glycosidic bonds at random positions 
within the oligosaccharide chain, thus leading to oligosaccharide products of varying 
length.9-11 The “bacterial type” enzymes are usually exo-chitinases, cleaving specific 
β-(1, 4)-glycosidic bonds along the oligosaccharide chain to release acetylchitobiose 
(NAG2) or acetylchitotriose (NAG3) progressively from the non-reducing end of 
chitin.9 
7 
Aspergillus funigatus chitinase B1 (AfChiB1) possesses most of the conserved 
residues of bacterial family 18 chitinases and is one of several extensively studied 
enzymes in this family for which X-ray studies of inhibitor complexes have been 
obtained. With regards to this enzyme, chitin binds by stacking of the N-
acetylglucosamine (NAG) units on several conserved aromatic residues that line a 
groove leading to the active site. For AfChiB1 and other bacterial type enzymes, the 
core sugar binding sites are denoted -2, -1, +1 and +2. Positions -1, +1 and +2 
correspond to exposed Trp384, Trp137 and Phe251 residues respectively with chitin 
cleavage occurring between subsites -1 and +1. 
The “plant type” family 18 chitinases are generally smaller and usually contain less 
clearly identifiable subsites compared to the “bacterial type” enzymes. The “bacterial 
type” enzymes possess several conserved residues that line the active site pocket 
including a MXYD motif defining the bottom of the active site pocket. All family 18 
chitinases contain the conserved DXDXE active site structural motif that is essential 
for activity.21-24 
Tews et al25 have proposed a “substrate-assisted” catalysis mechanism for family 18 
chitinases based on X-ray crystallographic data of three different chitinolytic enzymes 
complexed with substrates or inhibitors. This led to the conclusion that substrate 
hydrolysis involves a protein acid and the carbonyl oxygen atom of the C2-N­acetyl 
group of the substrate’s -1 sugar. This requires a distortion of this sugar ring towards a 
boat conformation. Important elements of the proposed mechanism were inferred 
from modelling studies and structures of glycosidases that do not belong to family 18. 
The model did not however account for the roles of several highly conserved residues 
in family 18 chitinases that are known to be important for catalytic activity.26 These 
issues were addressed by Brameld and Goddard26 and van Aalten et al.21 Brameld 
investigated the complexation of different NAG6 substrate conformations, and 
reaction intermediates to chitinase A from the bacterium Serratia marcescens 
(SmChiA) by molecular dynamic simulations. They concluded that substrate 
distortion to a boat conformation at subsite -1 of the active site is critical in the 
mechanism of family 18 chitinases. van Aalten et al have shown that chitin hydrolysis 
occurs via substrate-assisted catalysis, supported by solving the X-ray structure of 
SmChiB, complexed with chitooligosaccharide substrates (Fig. 4) and allosamidin and 
8 
by obtaining X-ray crystallographic data of reaction intermediates complexed to 
SmChiB. This revealed that catalytic hydrolysis of substrates proceeds with an overall 
retention of configuration at the C1 carbon and also that distortion of the sugar ring 
tends towards a boat conformation (Scheme 2).21 With this evidence in hand, a model 
for the binding of NAG6 to family 18 chitinases has been proposed
26 (Fig. 5). 
Protonation of the NAG6 substrate by Glu 315 is likely to occur only in the -1 boat 
binding mode. The -1 sugar residue is distorted to a boat conformation by tight 
binding of the N-acetyl group and steric constraints between sugar residues +1 and +2 
and the enzyme binding cleft. In addition, the planes of sugar residues -1 and +1 are 
twisted 90° relative to one another, placing strain on the glycosidic linkage. 
Figure 4: Binding of NAG5 to SmChiB showing oxazoline intermediate generated by substrate 
assisted catalysis 
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Figure 5: The binding of NAG6 to family 18 chitinases 
Chitin hydrolysis by family 18 chitinases is proposed to occur as follows. Chitin binds 
to the active-site groove with the GlcNAc units stacking onto the solvent-exposed 
tryptophan residues causing the –1 sugar to adopt a boat conformation (Scheme 2). 
Chitin binding also causes reorientation of the Asp 175 side chain, which results in 
the replacement of the associated hydrogen bond to the carboxyl group of Asp 173 
with hydrogen bonds to the carboxyl group of the catalytic acid Glu 177 and the -1 C2 
acetamido group of the substrate. Nucleophilic attack of the carbonyl oxygen of the 
acetamido group of the anomeric C1 carbon of the same pyranose ring occurs 
simultaneously with protonation of the glycosidic oxygen by the catalytic acid, which 
generates a leaving group from the reducing end of chitin as well as formation of an 
oxazolinium ion intermediate. There is reorientation of Asp175 to an “up 
conformation” which in turn causes hydrogen bonding of Asp175 to Glu177 and the 
oxazolinium nitrogen and stabilization of the positive charge on the intermediate. The 
final step involves hydrolysis of the oxazolinium ion which regenerates the N-acetyl 
group with overall retention of stereochemistry at the anomeric C1 carbon as well as 
re-protonation of the catalytic acid Glu177, and reorientation of Asp175, therefore 
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regenerating its hydrogen bond with Asp173. Formation of the oxazolinium ion 
intermediate in family 18 chitinases has been supported by molecular mechanics 
calculations27 with mutation studies giving evidence that the formation and 
stabilization of the intermediate is assisted by Tyr245 which forms a hydrogen bond 
to the N-acetyl oxygen,22 by generating an interaction with the oxazolinium oxygen21, 
25 and causes formation of a β-anomer hydrolysis product. 
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Scheme 2: The hydrolysis of chitin by family 18 exo­chitinases. 
Further studies that support a mechanism resulting in retention of configuration at the 
anomeric carbon have been obtained through using binary complexes of the 
pseudotrisaccharide allosamidin with hevamine,28 Serratia marcescens chitinase B 
(SmChiB),21 Coccidioides immitis chitinase (CiChi)29 and SmChiA.30 These 
complexes have the allosamizoline aglycone moiety in an equivalent position to the 
oxazolinium ion reaction intermediate.21 A specific, structurally well-defined water 
molecule, located opposite the leaving group (O7 oxygen) relative to the C1 anomeric 
carbon, is a putative C1 attacking group whose position is consistent with retention of 
the C1 stereochemistry.21 NMR studies of family 18 chitinases A1 and D from 
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Bacillus circulans WL-12 also support a molecular mechanism retaining the 
configuration at the anomeric position.31 
1.6 Chitin binding proteins and mammalian chitinases 
Although chitin is absent in humans, the human genome does however encode 
chitinases, along with other chitin binding proteins (chi-lectins). It has been 
speculated that expression of chitinases by the human genome is a defence 
mechanism against chitin-containing pathogens that previously were significantly 
harmful to humans.32 Chitin-binding proteins (chi-lectins) which, although are not 
catalytically active do show substantial sequence homology to members of glycosyl 
family 18 that includes most non-plant chitinases. 
The first human chitinase was detected initially on the basis of its capacity to 
hydrolyse artificial chitotrioside substrates and was therefore named chitotriosidase 
and is synthesised by activated macrophages.33 Elevated levels of chitotriosidase, has 
been detected in the plasma and tissues of patients who suffer from Gaucher’s disease, 
which is a lysosomal storage disease.34 Increased activity of this enzyme is due to 
massive production and secretion by the lipid-laden macrophages that accumulate in 
such patients. 
The chi-lectin termed human cartilage glycoprotein-39 (HC-gp39) is a 39-kDa 
secreted lectin,32 initially identified in articular chondrocytes, synovial cells, 
marcrophages and smooth muscle cells. The protein is overexpressed in many 
pathological conditions involving extensive connective tissue remodelling or 
increased deposition of connective tissue components, such as arthritic cartilage and 
inflamed or hypertensive synovium and fibrotic liver. Increased serum levels of 
HCGP39 have been reported for certain types of breast and colon cancer and are 
related to poor prognosis. A similar correlation has been found in patients with 
maligment gliomas, where serum levels may be indicative of the tumour burden. In 
patients with rheumatoid or osteoarthritis, serum HCGP39 levels show some positive 
correlation with progression of the disease and decreased following treatment, 
suggesting that the protein is involved in the disease process. The physiological role 
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of chi-lectins in general is less well established, although these reports suggest that 
elevated levels of chi-lectins are associated with remodelling and localised 
inflammation and are involved in immune system response to fungal or nematodal 
infection.32 
Shortly after the discovery of chitotriosidase, another mammalian chitinase was 
identified as a chitin-fragmenting hydrolase.35 The enzyme was capable of cleaving 
artificial chitin-like substrates such as crab-shell chitin and chitin present in the fungal 
cell wall and was characterised by an acidic isoelectric point and therefore, named 
acidic mammalian chitinase (AMCase). AMCase is relatively abundant in man and is 
predominantly concentrated within the gastrointestinal tract and the lung and 
therefore, postulated to play a role in digestion and/or defence. 
Recently, Zhu et al revealed that the acidic mammalian chitinase (AMCase) is 
induced via a T-helper-2 (Th2)-specific interleukin-13 (IL-13) –mediated pathway in 
epithelial cells and macrophages in an aeroallergen asthma model and that the enzyme 
is expressed in exaggerated quantities in human asthma.36 
The expression of AMCase during pulmonary Th2 inflammation was evaluated, 
elicited by sensitization and aerosol challenge with the aeroallergen ovalbumin 
(OVA) in mice. An increase in AMCase mRNA and protein along with 
bronchoalveolar lavage fluid chitinase activity was detected in the lungs of antigen-
sensitized/challenged animals but not the controls, with effects lasting for over 7 days. 
Analysis of lung tissue from sensitized/challenged mice revealed AMCase protein in 
both epithelial cells and macrophages. AMCase RNA has been shown to be far more 
prevalent in human asthmatic lung autopsies than in non-asthmatic controls (Fig. 6). 
Interestingly, in terms of potential novel treatments for asthma, when either 
allosamidin or anti-AMCase serum were administered, the quantities of eosinophils 
and lymphocytes detected in the BAL fluid were significantly reduced (Fig 7). Further 
research linking hAMCase with prevalence of asthma was recently reported with links 
between common polymorphisms of hAMCase with cases of child and adult 
asthmatics.37, 38 The high correlation of cases of asthma with these mutations points 
strongly towards this enzyme having an important effect in human disease.39, 40 
Although asthma is usually seen as a relatively well-treated disease, cases are 
becoming apparent whereby mutations in key enzymes can cause common 
13 
medications to become ineffective,41-43 thus leading to the need for novel therapeutics 
in this area. 
Antisense Sense 
Non-Asthma 
Asthma 
Asthma 
Figure 6: AMCase mRNA staining in lung autopsies from asthmatic and non­asthmatic patients.

Slide (e) shows a lung biopsy from an asthmatic patient.
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Figure 7: Graphs from Zhu et al36 showing the quantity of eosonophils and lymphocytes in 
murine BAL after sensitisation post­treatment with anti­AMCase (a). Inhibitory effects of 
allosamidin on BAL cellularity after OVA sensitization. 
1.7 Chitinase inhibitors in disease research 
Many organisms depend on the breakdown of chitin at key points of their life-cycle as 
well as reports of the involvement of chitinases and chi-lectins in a variety of human 
diseases. Inhibitors of chitinases are now of considerable interest as potential 
fungicides, insecticides, nematocides,44 chemotherapeutic agents against asthma and a 
variety of tropical diseases. Such diseases include filariases and malaria,45 
Legionnaires' disease,46 San Joaquin Valley Fever (Coccidiodomycosis)47 and 
aspergillosis.48, 49 Potential inhibitors may also serve as molecular probes to help 
understand the pathogenesis of these disorders. 
1.8 Existing Inhibitors 
Most known chitinase inhibitors are classical reversible inhibitors that compete with 
the substrate by blocking its binding site, usually mimicking the stacking to one or 
more of the subsite tryptophans through pi-pi or other hydrophobic interactions and 
generating hydrogen bonds with potential partners in the active site. Carbohydrate 
oligomers as well as chitooligosaccharides are capable of binding to the active site of 
family 18 chitinases, but long carbohydrate polymers become readily degraded by the 
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enzyme, whilst short oligosaccharides exhibit low binding affinities.50 The synthesis 
of carbohydrate oligomers is extremely challenging, limiting the development of 
drug-like compounds of this type. Despite this, over the last two decades there have 
been the generation of numerous natural-product and natural-product derived family 
18 chitinase inhibitors that have been identified, synthesised and characterised. In 
recent years, numerous crystal structures of chitinase-inhibitor complexes have been 
published, most of which are of the “bacterial-type” chitinases.21, 29, 30, 51-57 Co-
crystallisation of natural product inhibitors has served as a vital tool to generate 
structural data that has provided information as to how the these scaffolds bind to the 
active site of target enzymes and how these natural products may be chemically 
modified to optimize inhibitor binding. 
1.8.1 Allosamidin 
Allosamidin (2) (Fig. 8) is a pseudosaccharide which was first isolated from the 
mycelium of Streptomyces sp.57 and is the most extensively studied chitinase 
inhibitor. Allosamidin shows various biological properties as a chitinase inhibitor 
which include inhibition of cell separation in fungi,58, 59 toxicity towards insect larvae 
and blocking of malaria parasite penetration into the mosquito midgut.60 
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Figure 8: The structure of allosamidin

Most recently, allosamidin has been shown to ease lung inflammation in a mouse 
model of asthma.36 In general, allosamidin has been reported as a competitive 
chitinase inhibitor,61 although there have been reports of allosamidin acting as a non-
competitive inhibitor.62 The structure of allosamidin consists of two N-
acetylallosamine residues and an aminocyclitol aglycone. Investigation of the 
biosynthesis of allosamidin in Streptomyces sp. has revealed that both N-
acetylallosamine units are derived from D-glucosamine, whereas the oxazoline group 
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is derived from L-Arg and L-Met63 (Fig. 9). The binding of allosamidin to various 
chitinases has been determined by X-ray crystallography; with heavamine,28 
SmChiB,21, 53 CiChi,29 HCHT,52 SmChiA,30 and AfChiB155 (Fig. 11). IC50 values have 
been reported (Table 1) for allosamidin with a number of mammalian, insect and 
yeast chitinases, varying from strong inhibition of HCHT52 and Bombyx mori 
chitinase59 to relatively weak inhibition of Saccharomyces cerevisiae chitinase.60 
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Figure 9: Biosynthesis of allosamidin 
Allosamidin has been found to bind to many family 18 chitinases in an analogous 
fashion. With regards to binding with AfChiB1, the two N-acetylallosamine units 
occupy the same subsites in an identical fashion to the corresponding N-acetyl 
glucosamine substrate units of the natural substrate. The allosamizoline unit binds in 
the subsite as an exact mimic of the oxazolinium ion reaction intermediate making 
hydrogen bonds from the allosamizoline nitrogen and oxygen to the side chains of 
Asp175 and Tyr245, respectively.21, 28, 52, 53 Also, Asp175 is in the “up conformation” 
making an additional hydrogen bond with Glu177, similar to that observed in the 
reaction intermediate for the natural substrate. Allosamidin also exhibits many 
conserved interactions that are only consistent with “bacterial-type” family 18 
chitinases which include conserved stacking interactions with Trp52 and Trp384 and 
hydrogen bonds formed between the allosamizoline C6-hydroxy and the side chain of 
Asp246. There is also hydrogen bonding between the allosamizoline C4-hydroxy and 
the backbone nitrogen of Trp137. Other distinct hydrogen bonds are formed between 
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allosamidin and active site residues of AfChiB1 which are almost fully conserved 
amongst family 18 chitinases. 
Figure 10: X­ray structure of allosamidin complexed with AfChiB1 
Various analogues of allosamidin have been isolated from Streptomyces sp and 
evaluated against various chitinases for inhibition (Table 1).64 Such compounds 
include methylallosamidin (3),65 N-demethylallosamidin (4), methyl-N-
demethylallosamidin (5), glucosallosamidins A (6) and B (7) and 
didemethylallosamidin (8)66 (Fig. 10). Compound (4) was shown to be a stronger 
inhibitor of human chitotriosidase (HCHT) than allosamidin, although the binding of 
(4) with HCHT is similar to allosamidin. The increased affinity of (4) can be 
explained by the removal of the methyl group of allosamidin, generating less 
repulsion and increased rotational freedom of the nearby side chains of Asp173 and 
Asp175. 
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Figure 11: Naturally occuring allosamidin analogues 
Chitinase (2) (3) 
Compound 
(4) (5) (6) (7) 
HCHT 40 2.6 1.9 - - 8.0 
Mouse AMCase 400 - - - - -
Neurospora crassa 1600 - - - - -
Trichoderma harzianum 1300 1900 1300 - - 2600 
Bombyx mori 48 65 81 - - 65 
Candida albicans 30/10000 14000 1200 960 5300 1300 
Saccharomyces 54000 58000 490 640 49000 800 
cerevisiae 
Trichoderma sp. 1300 1900 1300 210 1400 2600 
Table 1: IC50 values (nM) of allosamidin and derivatives against various chitinases 
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1.8.1.1 Synthesis of allosamidin 
The synthesis of allosamidin involves many synthetic challenges, most importantly 
ensuring β-selectivity in the assembly of the pseudotrisaccharide skeleton and the 
preparation of the rare sugar D-allosamine. The first report for the total synthesis of 
allosamidin was by Griffith and Danishefsky,67, 68 shortly before the synthesis 
revealed by Vasella and Trost,69 The preparation of allosamidin by Danishefsky 
inspired the development of highly innovative synthetic solutions to deal with the 
problems that allosamidin posed. The development of a novel “azaglycosylation” 
method was employed specifically to prepare the β-linked N-acetylallosoamine-
containing pseudotrisaccharide skeleton of allosamidin.67, 68 Danishefsky’s 
asymmetric synthesis of (13) employed the same meso-diol (9) used by Trost and van 
Vranken for the racemic synthesis of (13). Danishefsky’s synthesis of (13) (Scheme 
3) involved resolution and desymmetrisation of (9) by conversion to the diacetate, and 
subsequent hydrolysis with electric eel acetylcholinesterase to give monoacetate (10). 
Protection of (10) as the TBS ether prior to deacetylation and conversion to carbamate 
(11) was necessary as the enzymatic hydrolysis step of monoacetate (10) gave the 
opposite enantiotopic sense to that anticipated. Desilylation of (11), and subsequent 
treatment with TFA and Et3N, gave oxazolidinone (12). The Trost synthesis of (13) 
also used intermediate (12) which enabled Griffith and Danishefsky to take advantage 
of the conditions used by Trost, for the subsequent steps, and enabled the complete 
synthesis of (13) in 7% overall yield. 
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Reagents and conditions: i) Ac2O, Et3N, DMAP, CH2Cl2, 89% ii) electric eel acetylcholinesterase, NaN3, pH 6.9 
phosphate buffer, 95% iii) TBS-Cl, imidazole, CH2Cl2; NH3, MeOH, 100%, iv) ClCO2Ph, pyridine, CH2Cl2, 0 °C; 
NH3, MeOH, 82% v) aqueous HF, CH3CN, 94% vi) Et3N, TFAA, -78 °C to r.t., 63%. 
Scheme 3: Synthesis of (13) by Griffith and Danishefsky 
The disaccharide unit of allosamidin was prepared starting from readily available tri-
O-acetyl-D-glucal (14) allowing elaboration of the appropriate glycosyl donor and 
acceptor units (Scheme 4). Compound (14) was subjected to Ferrier-type 
rearrangement70 with thiophenol and the resulting glycal was subsequently 
deacetylated and reprotected to generate the benzylidene derivative (15). Oxidation 
of (15) with 3,3-dimethyldioxirane and Et3NH, gave the intermediate sulfoxide which 
underwent 2,3-sigmatropic rearrangement71 to give (16) in 96% yield which was 
subsequently benzylated and treated with N,N­dibromobenzenesulfonamide to furnish 
donor (18) which would be utilised for the subsequent azaglycosylation step. 
The required acceptor, (17) was prepared by protection of the axial hydroxy group of 
(16) as the SEM ether followed by benzylidene acetal cleavage and regioselective 
benzylation. 
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Scheme 4: Preparation of disaccharide 20 
Reagents and conditions: i) PhSH, BF3.Et2O, ii) NaOMe, MeOH; PhCH(OMe)2, TsOH, DMF, 73%; iii) 3,3-
dimethyldioxirane, DCM, -78 °C; Et2NH, THF, 96%; iv) NaH, THF, BnBr, Bu4NI, 96%; v) Br2NSO2Ph, DCM, 0 
°C; NH4I, EtOH, 63%; vi) SEMCl, 
iPr2NEt, DCM, 100%; vii) Na, NH3; Bn2SnO, MeOH, reflux, CsF, BnBr, DMF, 
69%; viii) KHMDS, DMF; -40 °C to r.t., 81%; ix) repeat 57%. 
The protected disaccharide (19) was assembled via KHMDS-promoted coupling of 
(17) and (18) in 81% yield which then converted to the bromosulfonamide donor (20). 
The critical azaglycosylation step was performed using previous KHMDS-mediated 
coupling conditions between benzylated allosamizoline (22) and donor (20), which 
simultaneously established the stereochemistry of the allosamine residue, gave (23) in 
42% yield (Scheme 5). Deprotection of the SEM ether and benzylidene acetal of (23) 
under acidic conditions was followed by reductive cleavage of the sulphonamide and 
benzyl ether protection. The synthesis was then completed by peracetylation and 
removal of all O-acetates with methanolic NH3, to give the natural product (2). 
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42%; iii) 5% aq. HCl-MeOH; Na, NH3, -78 °C; Ac2O, pyridine, 36%; iv) NH3, MeOH, 79% 
Scheme 5: Conversion to allosamidin 
The general racemic synthetic strategy of (13) by Trost72 allowed the preparation of 
(13) by four other groups in the racemic form and as a single enantiomer. The 
preparation of the aglycone unit has also been established using similar approaches to 
that of Griffith and Danishefky starting from cyclopentene-derived starting materials 
as reported by Ganem et al., 73 Imperiali and Shrader74 and Iwata et al.75 (Scheme 6). 
Ganem utilised the desymmetrisation of a meso-epoxide derived from (9) or a closely 
related derivative. Asymmetric Cr(III)-salen-catalysed ring opening of epoxide (24) 
with TMSN3 furnished the orthogonally protected cyclopentenol (25)
76 which was 
subsequently transformed to the acceptor (21) used by Danishefsky, employing a 
previously reported method developed for the racemic synthesis of (13) by the Ganem 
group, 73 in an impressive overall yield of 25% (9 steps). The desymmetrisation by 
Imperiali74 used the methodology of Danishefsky’s protocol to generate the 
allosamizoline ring system by a highly stereoselective Hg(II)-mediated cyclisation of 
aminoimidate (26) which was subsequently subjected to radical oxygenation to give 
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(27). The synthesis of (13) by Iwata77 employed a C2 symmetric bis-sulfoxide as a 
chiral auxiliary to effect the asymmetric desymmertrisation of a meso-cyclopentenol 
(28) derived from (9). Compound (28) was converted to oxazolidinone (30) and 
elaborated to (13) by methods originally reported by Trost. 
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Scheme 6: Ganem, Imperiali and Iwata’s approaches to aglycone (13) starting from (9) 
Preparation of the aglycone (13) has also been achieved from carbohydrate-based 
starting materials, the first of which was described by Nakata et al78 using D-
glucosamine. The key step utilises a popular general protocol for the preparation of 
aminocyclopentitols79 and was utilised to generate the cyclopentane core by an 
intramolecular cycloaddition of a nitrile oxide to an olefin. The oxime (34) was used 
as the substrate in Tatsuta’s synthesis which was prepared as shown in Scheme 7. 
Treatment of the glucosamine derivative (31) with 1% HCl-MeOH gave a mixture of 
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anomeric methyl glycosides which were subsequently converted to the primary iodide 
(32). Compound (32) underwent Zn-promoted reductive β-elimination and gave 
mainly 5-enofuranose (33). Treatment of (33) with ethanethiol, followed by silylation 
and cleavage of the intermediate thioacetal, gave the parent aldehydes sugar, which 
reacted with hydroxylamine hydrochloride to furnish (34). Optimum conditions for 
the crucial cycloaddition reaction involved the utilisation of aqueous NaOCl in 
CH2Cl2 to give the single isooxazoline (35). Oxidative cleavage of (35) gave (36) 
which was subsequently reduced to the single diol diastereoisomer, (37). Removal of 
the phthaloyl group of (37), followed by followed by N-benzyoxycarbonylation and 
cyclisation furnished oxazolidinone (38). The original protocol reported by Trost and 
van Vranken72 allowed the complete synthesis of allosamidin by Tatsuta et al . 
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Reagents and conditions: i) 1% HCl-MeOH, 60 °c, ii) I2, PPh3, imidazole, 90%, iii) Zn, THF; iv) EtSH, HCl, 67% 
from 32, v) TBSOTf, 2,6-lutidine, DCM, 90%, vi) HgCl2, CaCO3, aqueous acetone, 81%, vii) NH2OH.HCl, 
pyridine, 81%, viii) aqueous NaOCl, DCM, 91%, ix) O3/O2, DCM-MeOH, 60%, x) Zn(BH4)2, THF-Et2O, 100%, 
xi) N2H4.H2O, EtOH; BnOCOCl, Na2CO3; NaH, THF, 60%. 
Scheme 7: Tatsuta’s synthesis of aglycone 2 using sugar derivative (31) 
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More reports for the synthesis of aglycone 13 starting from D-glucose and other 
carbohydrate derived molecules have been presented by Ferrier80 and by Simpkins,81 
utilising similar methodologies to that of Tatsuta. The synthesis of aglycone (13) by 
Ferrier led to the preparation of allosamidin following shortly after that reported by 
Griffith and Danishefsky. 
More recently, a regio- and stereo-controlled synthesis of the (-)-allosamizoline unit 
of allosamidin has been reported by Donohoe and Rosa82 that includes 13 steps with 
22% overall yield starting from D-glucosamine hydrochloride (Scheme 8). The key 
synthetic steps employed towards the preparation of (49), involved ring-closure 
metathesis to form the cyclopentene core, halocyclisation to afford the oxazoline ring, 
and finally stereoselective alkene radical addition followed by an isomerization 
reaction to install the hydroxymethyl group. Commercially available D-glucosamine 
(39) was protected to give primary iodide (40) in 75% yield which was subsequently 
protected using commercially available iodomethyl methyl ether to obtain the bis-
protected product (41) in 76% yield. Vasella reductive ring cleavage83 of (41) with Zn 
in THF/H2O under reflux gave the unstable, yet pure aldehyde which was subjected to 
Wittig olefination to give the bis-alkene (42). Subsequent ring closure metathesis of 
(42) afforded cyclopentene (43) in very good yields. Utilisation of Basha’s 
procedure84 successfully provided methylcarbamate (44) in excellent yield which was 
subjected to halocyclisation with N-iodosuccinimide to furnish the iodo-oxazoline 
(45) in very good yields. The allyl-oxazoline (46) was achieved stereoselectively as a 
single diastereoisomer using a two-step procedure which involved Keck allyl 
addition, followed by the alkene isomerisation. The allyl-oxazoline (46) was subjected 
to in situ ruthenium hydride-catalysed isomerisation to give a E:Z (2.3:1) mixture of 
propenyl oxazoline (47) in quantitative yield. Reductive ozonolysis of the propenyl-
oxazoline (47) led to the formation of hydroxymethyl-oxazoline (48) in 83% yield 
which was subsequently converted to (-)-allosamizoline (49) after MOM deprotection 
with acid. 
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DCM, 75%, iv) MOMI, Proton sponge, THF, 76%, v) Zn, THF/H2O, 100%, vi) Ph3P=CH2, PhMe, 90 °C, vii) cat. 
Grubbs II, PhMe 90 °C, 80%, viii) EtMgBr, Et3N, DCM, Me2NH, 96%, ix) NIS, THF/H2O, 80%, x) allyltributyltin, 
AIBN, cyclohexane, 81% xi) ethyleneoxytrimethylsilane, cat. Grubbs II, DCM, 100%, xii) O3, DCM/MeOH, then 
NaBH4, 83%, xiii) HCl, MeOH, 95%. 
Scheme 8: The synthesis of (49) by Donohoe and Rosa82 
Takahashi et al85 established the absolute configuration of the aglycone through the 
preparation of (13) which also formed part of the total synthesis of allosamidin86 
(Scheme 9). Utilising the chiralities of C2, C3 and C4 of D-glucosamine, enabled the 
preparation of (13). The limitation of this strategy is that the formation of (13) 
involved over 14 steps. Takahashi however, has reported the first total synthesis of 
allosamidin by the use of chitin as a starting material86 to prepare the required 
disaccharide donor unit. Kazuhara and co-workers report partial enzymatic or 
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chemical degradation of colloidal chitin to N,N’-diacetylchitobioside (50) or other 
useful oligosaccharide fragments by the use of innovative and efficient methodologies 
(Scheme 9). Compound (50) was then converted to the thioglycoside donor (51), with 
the essential stereochemical inversion at C3 and C3’ by using the same methods 
reported for the synthesis by Vasella and Trost et al. The coupling of (51) and (22) 
involved using TfOH-NIS and proceeded in 40% yield, due to significant competing 
elimination of thiophenol from (51) to give glycal (52). Compound (52) was subjected 
to dephthaloylation, N­acetylation and hydrogenolysis to furnish (2). 
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Scheme 9: The synthesis of allosamidin by Takahashi et al 86 and Kuzuhara et al 87 
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In summary, the syntheses of allosamidin has been reported by several laboratories 
but their complexity severely limits the availability of allosamidin, as well as the rapid 
generation of analogues. This has driven the search for more synthetically accessible 
inhibitors, with ideally increased “drug-like”/Lipinski properties.88 
1.9 Other natural product inhibitors 
Houston et al56 and Dixon et al89, 90 have reported the preparation of cyclic peptide 
based family 18 chitinase inhibitors and their evaluation against bacterial, fungal and 
mammalian type family 18 chitinases. X-ray crystallography, along with enzymatic 
kinetic data, has led towards a more valuable insight into the binding mode of these 
compounds, most of which mimic interactions with key catalytic residues in a similar 
fashion to that of the natural substrate and allosamidin. 
1.9.1 CI­4 
HN 
N 
O 
O 
H 
N 
NH 
H2N 
(53) 
Figure 12: The structure of CI­4 
CI-4 (53) (Fig. 12) is a cyclic proline-containing dipeptide, cyclo (L-Arg-D-Pro). The 
natural product is produced by the marine bacterium Pseudomonas sp IZ208 and was 
isolated by Izumida and identified as a chitinase inhibitor. Izumida et al91 prepared 
CI-4 and the two stereoisomers (54) and (55) (Fig. 13) and evaluated them against 
chitinase from Bacillus sp. Compound (53) only gave 17.2% inhibition for this 
enzyme at a concentration of 1 mM, and the L-L diastereoisomer (54) only showed a 
slight increase in potency. Using the agar plate method,91 Izumida et al. also detected 
chitinase inhibitory activity for (53) and (54) at a concentration of 50 µg per disk 
where weaker inhibition was observed for (55). Compound (53) has been shown to 
block morphological changes in the fungus Candida albicans, preventing the 
development of the fungus into its infectious filamentous form. It also prevented cell 
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separation in Saccharomyces cerevisiae, by inhibition of chitinases contained within 
these organisms.91, 92 
H2N 
H 
N N 
HN 
O 
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NH 
Arg Pro 
L L (54) 
D L (55) 
Figure 13: Stereoisomers of CI­4 
The structure of (53) bound to chitinase B from Serratia marcescens (ChiB) (Fig. 14) 
shows that binding occurs in a similar way to allosamidin and the catalytic reaction 
intermediate of the natural substrate, with the proline unit and the cyclic dipeptide 
backbone of the similarly sized two-ring structure coinciding with the oxazolone and 
pyranose rings of the reaction intermediate, respectively.56 The hydrogen bond 
between the D-Pro carbonyl oxygen and the Tyr245 hydroxy group also imitates the 
corresponding hydrogen bond involving the oxazoline nitrogen of the reaction 
intermediate. Likewise, the hydrogen bond between the L-Arg carbonyl oxygen and 
the main chain nitrogen of Trp137 reproduces the corresponding interaction that 
involves the hydroxy group of the pyranose moiety. Additionally, a water-mediated 
hydrogen bond is observed between the L-Arg backbone nitrogen to the carboxyl 
group of Asp246, mimicking the direct hydrogen bond from the hydroxymethyl group 
of the intermediate to the Asp residue. An additional hydrogen bond involes the L-Pro 
backbone nitrogen and the side chain of Glu175. 
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Figure 14: X­ray crystal structure of SmChiB­CI­4 
Although (53) is a relatively poor inhibitor (IC50=1.2 mM), this compound is an 
interesting lead as synthesising analogues of (53) would be relatively easy. Four 
cyclic dipeptide compounds related to (53) (Fig. 15) were assayed against SmChiB 
with inhibition in the mM range (Table 2).93 The preparation of CI-4 was originally 
reported by Izumida et al91 and uses DCC-mediated coupling of Boc-L-Arg(Mtr)-OH 
with D-Pro-OBn to give the fully protected dipeptide (56), which was then 
deprotected by treatment with TFA-anisole to remove the Boc and Mtr groups. 
Cyclisation was achieved by heating an aqueous solution at pH 6 at 80 °C followed by 
isolation of the final compound in 43% yield starting from (56) (Scheme 10). The 
preparation of stereoisomers of the natural product was achieved in an analogous 
fashion. 
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Scheme 10: Synthesis of CI­4 
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Figure 15: Structures of CI­4 related derivatives 
Compound (54) (58) (59) (60) (53) 
IC50 (mM) 6.3 5.0 1.1 2.4 1.2 
Table 2: IC50 values (mM) of CI­4 and related derivatives against SmChi 
High-resolution structures were determined for the four derivatives (Fig. 16). Cyclo-
(L-Arg-L-Pro) (54) has lower affinity for ChiB than (53), but both interact with the 
enzyme active site in a similar way with (54) interacting with the protein via two 
direct hydrogen bonds. The activity of cyclo-(Gly-L-Pro) (58) shows that this 
template alone is sufficient enough for binding. The histidine analogue (59) has an 
increase in affinity due to two extra hydrogen bonds formed with the protein, although 
this forces the cyclic dipeptide into an unfavourable conformation. The addition of a 
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tyrosine residue to give (60) also increases the affinity compared to (58) but shows 
that the tyrosine side chain is not extended enough for it to create pi-stacking 
interactions to the solvent exposed aromatic residues in the enzyme binding site. 
Comparison of the four derivatives with allosamidin shows that the four derivatives 
lack interaction with the conserved residue Asp142, which interacts with the 
allosamizoline moiety of allosamidin via strong hydrogen bonds contributing to the 
fact of CI-4 and derivatives of are four times less potent than allosamidin itself. 
A B 
C D 
Figure 16: X­ray crystal structures of A) SmChiB­cyclo­Gly­L­Pro, B) SmChiB­cyclo­L­Arg­L­

Pro, C) SmChiB­cyclo­L­His­L­Pro, D) SmChiB­cyclo­L­Tyr­L­Pro
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1.9.2 Argadin
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Figure 17: Structures of argadin 
Argadin (68) was isolated from a fungal strain Clonostachys sp. FO-7314,94 and 
consists of a modified Arg residue, a D-Pro, a backbone-cyclised L-Asp-β-
semialdehyde, a L-His and an L-aminoadipic acid residue (Fig. 17). Argadin has been 
shown to arrest the moulting of cockroach larvae upon injection into the ventral 
abdominal part.94 In the crystal structure obtained for argadin with SmChiB, AfChiB1 
(Fig. 18) and HCHT, there are four distinct hydrogen bonds, the aminoadipic carbonyl 
to the hemiaminal nitrogen, aminoapidic nitrogen to the hemiaminal hydroxy group 
and two bonds from the aminoadipic carboxyl group to the Arg side chain. The 
binding pattern of the His group of (68) mimics that of the natural substrate in a 
similar fashion to that observed with argifin (74) (see section 1.9.3). The L-His 
residue forms hydrogen bonds to the side chains of Asp175 and Tyr245, however the 
Asp175 is in the “down conformation” pointing towards Asp173. Additional 
hydrogen bonds are formed from the hemiaminal carbonyl to the side chain of 
Asp246 and two hydrogen bonds are formed between L-Arg and the side chain of 
Arg301. Mutation studies with AfChiB1 have identified that stacking interactions with 
Trp384, Trp137 and Phe251 (corresponding to the -1, +1 and +2 subsites) play a key 
role in the binding and specificity of the cyclopentapeptide.54 
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Figure 18: X­ray structures of argadin­AfChiB1 complex 
The synthesis of argadin has been reported by Dixon et al90 (Scheme 11). This 
involved anchoring the growing peptide precursor to the solid support via the histidine 
side chain, one-step incorporation of the modified arginine side chain by 
guanidination of an ornithine residue and final introduction of the sensitive cyclic 
hemiaminal moiety by oxidative cyclisation of a fully deprotected homoserine-
containing derivative. The choice of linear sequence and cyclisation point was chosen 
so as to place the potentially turn-inducing proline residue mid-way along the 
precursor linear sequence. 
For the synthesis, Fmoc-His-OAll (62) was loaded onto 2-chlorotrityl chloride 
polystyrene resin to give (63) with loading that was deliberately kept low so as to 
minimise potential dimerisation/oligomerisation at the backbone cyclisation step 
(Scheme 11). Resin-bound pentapeptide (64) was then assembled from (63) by 
standard Fmoc SPPS using PyBOP95 activation for coupling, except for the coupling 
of Fmoc-Orn(Dde)-OH to D-Pro residue, for which PyBrOP96 was employed. 
Removal of the C-terminal allyl ester using (Pd(Ph3P)4/PhSiH3)
97 and N-terminal 
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Fmoc protection was followed by cyclisation upon treatment with 2 eq of PyBOP for 
2 x 2h to give the fully protected resin-bound cyclic peptide (65). Selective removal 
of the Dde group was achieved by brief treatment with hydrazine monohydrate prior 
to introduction of the derivatised Arg side chain through reaction with 10 eq of the 
known reagent acetyl methylthiourea hydroiodide98 to give (66) with quantitative 
conversion for the on-resin guanidination cycle. Final resin cleavage with 
concomitant removal of the trityl and tert-butyl ester side-chain protection was 
achieved by treatment with TFA/DCM/TIPS (10:9:1) followed by purification using 
reverse phase HPLC gave (67) in 10% overall yield for the 15 solid phase steps, on 
the basis of the original resin loading. Oxidative cyclisation by treatment of (67) with 
4 eq of IBX in DMSO for 12 h led to the formation of diastereoisomers (5:1) of (68). 
Attempted isolation of each diastereoisomer failed as each rapidly converted to the 
same equilibrium mixture, and so argadin was therefore isolated as such in 71% yield 
from (67). While numerous examples of peptide natural products containing a 
homologous glutamic acid-derived hemiaminal have been reported99, 100 the synthesis 
of argadin is the first report of a molecule that incorporates a five-membered variant. 
HPLC analysis of an authentic sample of argadin revealed the same equilibrium 
composition of diastereoisomers. The complex of synthetic argadin with AfChiB1 
shows the binding of the same single diastereoisomer to the active site as originally 
reported.54 
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Scheme 11: The synthesis of argadin90 
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1.9.3 Argifin
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Figure 19: The structure of argifin 
Argifin (74) (Fig. 19) was originally isolated from Gliocladium fungal culture98,101 
and is a cyclopentapeptide composed of two β-linked Asp residues, an MePhe 
residue, a D-Ala residue and an unusual N-methyl carbamoyl-derivatised Arg residue. 
Steady-state kinetic measurements in the presence of increasing amount of substrate 
with synthetic argifin shows that inhibition of the enzyme occurs competitively with a 
Ki of 17 nM. There was no inhibition shown with (74) containing an un-derivatised 
Arg side chain (absence of N-methyl-carbomoyl group) which highlights the 
importance of this group for binding to family 18 chitinases. Crystal structures of (74) 
with AfChiB1 (Fig. 20), SmChiB54 and HCHT,102 show that the N-methyl-carbamoyl 
group binds to subsites -1, +1 and +2, strongly interacting with the side chains of 
Trp48 and Trp384, its nitrogen hydrogen bonding to the carboxyl groups of Asp175 
and Glu177, whereas its oxygen hydrogen bonds to the hydroxy group of Tyr245. The 
binding pattern of the N-methyl carbamoyl group resembles that of the natural 
substrate in which the N-acetyl group of the distorted -1 sugar overlaps with the N-
methyl-carbamoyl group thereby retaining the hydrogen bonds to Asp175 and 
Tyr245. The published AfChiB1-argifin crystal structure also shows that all of the 
peptide bonds in argifin are in the trans form with the exception of the cis Arg(MC)-
MePhe bond and is a key feature towards the inhibitory properties of argifin.103 
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Figure 20: X­ray crystal structure of Argifin­AfChiB1 complex 
The first preparation of argifin89 (Scheme 12) was achieved using solid-phase peptide 
synthesis on 2-chlorotrityl polystyrene resin, using Fmoc chemistry. The linear 
pentapeptide was synthesized using 2 eq of Fmoc-protected amino acid and PyBOP 
activation, except for the coupling of Fmoc-Arg(Pmc)-OH to the hindered MePhe 
residue to where PyBrOP was employed. Cleavage from the resin with 1% TFA/DCM 
gave (72) in 46% yield based on the original resin loading. The choice of Asp 
protecting group was found to be critical in the assembly of the linear precursor; in 
preliminary studies with the alternative sequence H-D-Ala-Arg(Pmc)-MePhe-
βAsp(OBn)-OH, HPLC and ES-MS analysis revealed essentially quantitative 
formation of a product resulting from aspartimide formation at the non-terminal Asp 
residue. The subsequent choice of (72) as linear precursor limited the exposure of the 
sensitive Asp residue to a single cycle of Fmoc synthesis, while the use of tert-butyl 
rather than benzyl ester protection was expected to reduce significantly base-induced 
aspartimide formation.104 
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Cyclisation of (71) to the fully protected cyclic pentapeptide was very successful and 
highly efficient in dilute DCM solution using PyBOP activation and DIPEA as base. 
Optimum results were obtained with a single equivalent of PyBOP and a final peptide 
concentration of 1mM giving an isolated yield of 96% after simple extractive work-
up. Under these conditions, HPLC analysis revealed almost quantitative formation of 
(72) after 16 h, with no evidence of oligomeric side products. Efficient cyclisation 
was presumed to result from the choice of the linear sequence that maximises the 
possibility of favorable ‘precyclised’ conformations by placing potential turn-
inducing residues (MePhe, D-Ala) in the second and fourth positions of the sequence, 
respectively. To complete the synthesis, the protecting groups were cleaved using 
TFA/thioanisole/DCM/water (16:2:1:1) for 2 h. Introduction of the N-methyl-
carbamoyl group to the Arg side chain was achieved by treatment of the deprotected 
cyclic pentapeptide (73) with 3 eq of N-succinimidyl-N-methylcarbamate and 6 eq of 
DBU as base in DMF at 40 °C for 2 h to furnish (74) in 65% yield after HPLC 
isolation and in 17% overall yield from the linear peptide (71). No diacylated or 
isomeric products were observed. All analyses were identical to those reported by 
Shiomi et al101 for the natural product. 
Argifin offers a very attractive new scaffold for the development of novel inhibitors 
of this class of enzymes through solid phase peptide synthesis. 
In order to improve the efficiency of the production of argifin, and develop SAR 
around the argifin scaffold, a new all solid phase synthesis of (74) and analogues has 
recently been developed, highlighting the importance of the essential cis Arg(MC)-
MePhe dipeptide motif and identifying a significant side reaction during the previous 
synthesis that is eliminated via a novel side chain deprotection procedure. The 
flexibility of the synthetic strategy has been demonstrated by the preparation of a 
series of compounds inspired by the X-ray structure of (74) in complex with 
AfChiB1.103 
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Scheme 12: synthesis of argifin 
The biological evaluation of both cyclopentapeptides are summarized in Table 3.

Inhibition and binding constants for (68) were lower than that for (74)

The values presented in Table 3 show that chitinases have a significant preference for

(68) over (74) (except with AfChiB1).102 This can be explained by the fact that 
argadin has a more compact structure and, therefore, displays deeper binding in the 
active site which displaces more water molecules, allowing a larger contact surface 
with the protein (130-148 Ǻ2) compared to (74) (112-133 Ǻ2). The reason why argifin 
has a stronger inhibition value over argadin with AfChiB1 can be explained by Trp384 
adopting a different conformation upon binding of (74). This in turn causes 
maximisation of stacking with the guanylurea moiety.102 Gouda et al have studied the 
interaction of argifin and argadin with SmChiB.105 Energy analysis from their study 
41

suggests that argadin binds to SmChiB better than argifin due to increased van der 
Waals interactions. Argadin has over 4 Kcal/mol-1 more van der Waals interactions 
with W220 and W403 than argifin, indicating that these residues are thought to be 
involved towards the more favourable binding of argadin with SmChiB. The mutation 
of W220A of SmChiB led to a loss in affinity to argadin compared to argifin which 
also highlights the importance of these residues.105 
Chitinase Argifin (74) Argadin (68) 
Lucilia Cuprina IC50 = 3.7 µM IC50 = 150 nM 
AfChiB1 IC50 = 0.027 µM106 IC50 = 0.5 µM 
HCHT IC50 = 4.5 µM102 IC50 = 13 nM 
SmChiB Ki = 33 µM Ki = 20 nM 
AfChiB1 Kd = 0.46 µM Kd = 0.81 µM 
Table 3: IC50, Ki and Kd values of argifin and argadin against a range of chitinases 
1.9.4 Methylxanthines 
Methylxanthines have been found to exist in sixty different plant species and include 
well-known compounds such as caffeine (75), theophylline (76) and theobromine (77) 
(Fig. 21). 
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Figure 21: The structures of methylxanthines, caffeine (75), theophylline (76), theobromine (77), 
pentoxifylline (78) 
42

The screening of a commercially available library of 880 drug molecules at 100 µM 
against the family 18 chitinase, AfChiB1 led to the identification of theophylline, 
caffeine and the methylxanthine drug, pentoxifylline (78) as chitinase inhibitors with 
moderate potency (IC50 values of 1500, 469 and 126 µM respectively).
107 
Theophylline, caffeine and pentoxifylline have also been tested against HCHT with 
reported IC50 values of >500, 257 and 98 µM respectively. Theophylline has also been 
previously reported to act as a bronchodilator, and to exhibit several anti-
inflammatory activities related to asthma.108 Crystallographic data of caffeine and 
theophylline bound to AfChiB1(Fig. 22) revealed that both compounds bind in an 
identical fashion in the -1 subsite, mimicking the oxazolinium ion intermediate by 
forming hydrogen bonds to the side chains of Tyr245 and the main chain of Trp137 
which are also conserved residues amongst family 18 chitinases. Further water-
mediated hydrogen bonds are observed from the O2 oxygen to Asp246 and Arg301. 
In addition to the methylxanthine in the -1 subsite, an additional ordered inhibitor 
molecule is observed occupying a position equivalent to the -3 sugar in the 
allosamidin complex. This additional methylxanthine molecule also makes stacking 
interactions with Trp52, which is conserved in other “bacterial-type” chitinases such 
as SmChiA, HCHT and AMCase. The xanthine ring also appears to make stacking 
interactions with Trp385, which is conserved in all active family 18 chitinases and 
also interacts with the allosamizoline moiety in the allosamidin complex. For 
theophylline, an extra hydrogen bond interaction is observed to the side chain of 
Asp175. Compared to theophylline, caffeine contains an additional 7-methyl group, 
which appears to increase inhibition three-fold to an IC50 of 469 µM. In the 
AfChiB1complex, caffeine binds identically to theophylline, but with the suprising 
result that addition of a 7-methyl group not only results in a loss of hydrogen-bond for 
the xanthine N-7 with Asp175 but also forces Asp175 in the “down” conformation 
compared to the “up” conformation in the allosamidin complex.107 Residue Glu177 
moves away to avoid steric clashes of the terminal carboxylate with the N7-methyl. 
Again, an additional ordered inhibitor molecule is observed in the -3 subsite. Of the 
three compounds, pentoxifylline is the most potent inhibitor with a Ki of up to 37 µM 
against AfChiB1. These molecules are small and drug–like though the largest of the 
three molecules, pentoxyfylline, only covers a small part of the AfChiB1 active site 
from the -1 to just beyond the -2 subsite (Fig 22).107 By comparison, other more 
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potent chitinase inhibitors such as allosamidin and argifin/argadin (which cover the -1 
to -3 subsite and -1 to +2 respectively), occupy further subsites. 
The relatively simple synthesis of xanthine-type molecules related to these types of 
compounds enabled the scope for the generation of a variety of analogues of this 
kind,109 one of which was compound (79) (1-(2-(theobromin-1-yl)ethyl)-theobromine) 
referred to as C2-dicaffeine (Fig. 23). C2-dicaffeine showed a significant increase of 
affinity to AfChB1 with an IC50 of 4.8 µM, inhibition.
107 Compared to caffeine, C2-
dicaffeine also acts as a much improved inhibitor than pentoxifylline, enhancing 
inhibition of AfChiB1 by twenty-five fold. The inhibition of AfChiB1 by C2-dicaffeine 
was further investigated and confirmed that his compound is a much more effective 
inhibitor than pentoxyfylline, previously the most effective purine-based chitinase 
inhibitor of AfChiB1. With the aid of X-ray crystallography the binding mode of C2-
dicaffeine with AfChiB1 (Fig. 22) revealed that Asp175 was pointing down into the 
catalytic core similarly to the other xanthine derived complexes. Also the “primary” 
caffeine moiety is sandwiched between Trp137 and Trp384 whereas the “secondary” 
caffeine stacks with Trp52. The crystal structure also revealed two major differences 
from the known xanthine binding mode. Firstly, C2-dicaffeine is shifted out of the 
active site by about 1.5 Å and secondly, both purine rings are flipped by 180° around 
their N-1 linker bond. This binding mode significantly improves stacking between the 
secondary caffeine and Trp52.107 Observed are two conformations for the binding of 
C2-dicaffeine,
107 a major conformer and a minor conformer. Both conformers are 
approximate mirror images to each other and were discovered by further inspection of 
the ligand electron density. Both conformations form the same hydrogen bonds and 
occupy the same space within the active site. The significant difference between the 
two binding modes is involved in the tilt of the purine rings compared to their 
stacking partners and the torsion angles of the ethylene linker. The linker also 
prevents the two caffeine rings from efficiently stacking. Significant tilting of the 
primary caffeine against its tryptophan residue is displayed by the major ligant 
conformation whilst the minor conformer has an unfavourable angle between Trp52 
indole and is secondary caffeine. The disorder and tilting of the aromatic rings 
suggests that C2-dicaffeine is in a strained conformation in the observed complex, 
which is not efficient for tight binding. The molecule has a relatively low molecular 
weight (Mr = 278) together with the fact that it possesses six hydrogen bond acceptors 
and no hydrogen bond donors, it obeys Lipinski’s rule of five.88 C2-dicaffeine has 
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become the starting point towards the generation of family 18 chitinase inhibitors due 
to the ease of derivatising the linker as well as introducing substitutions on the 
xanthine rings.110 
A B 
C D 
Figure 22: X­ray crystal structure of A) Caffeine­AfChiB1, B) Theophylline­AfChiB1, C) 
Pentoxifylline­AfChiB1, D) C2­dicaffeine­AfChiB1 
O N N
O 
N N NN 
O
N N O 
(79) 
Figure 23: The structure of C2­dicaffeine (79) 
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C3-dicaffeine (80) (Fig. 24) was designed and synthesised to overcome the issues that 
C2-dicaffeine possessed. Extension of the linker by a single methylene was proposed 
to add flexibility to the molecule allowing for a less rigid bound conformation within 
the active site.110 
N 
N 
O 
N 
N 
O 
N 
N 
N 
NO 
O 
(80)

Figure 24: The structure of C3­dicaffeine (80)

1.9.5 Styloguanidines 
Kato et al111 first isolated styloguanidine (81) itself along with two brominated 
analogues (82) and (83) (Fig. 22) from the sponge of Stylotella aurantiu, collected in 
the Yap Sea. These compounds possess a unique hexacyclic bis-guanidine structure. 
Also isolated was the isomeric alkaloid palau’amine (84) which had previously been 
obtained by Kinnel et al112, 113 from Stylotella agminata, collected in the Western 
Caroline Islands. It had been reported that (81­84) showed inhibitory activity towards 
a bacterial chitinase from Schwanella sp. and also inhibited the moulting of cyprid 
larvae of barnacles. The total synthesis of styloguanidine has not yet been established 
though the preparation of the tetracyclic core of these molecules and several other 
advanced intermediates has been recently reported by the group of Overman114-116 
who disclosed the formation of key intermediated by alkene-enamide ring-closing 
metathesis.116 Other synthetic efforts towards the styloguanidines and related bis-
guanidine natural products have been reviewed by Hoffmann and Lindel117 and by 
Weinreb.118 No other crystallographic or enzymological data have so far been 
published about this class of compounds with respect to their chitinase inhibitory 
activity. 
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Figure 25: Structure of styloguanidine (81), the brominated products (82) and (83) and 
palau'amine (84) 
1.9.6 Psammaplins 
Psammaplin A (85) (Fig. 23) belongs to a family of compounds that are 
biosynthetically derived from bromotyrosine and cysteine and exhibit antibacterial 
and antitumour properties as these class of compounds have been proven to inhibit 
both DNA methyltransferase and histone deacetylase activity.119, 120 Compound (85) 
was originally isolated from the sponge of Psammaplysilla purpurea, collected in the 
region of Tonga by Quinoa and Crews121, 122and Jiminez and Crews122 who 
subsequently identified the compound independently from other sources such as 
51 Scheuer123 and Schmitz.124 It was later reported by Tabudrava et al that (85) is a 
modest inhibitor of Bacillus sp. chitinase (IC50 = 68 µM) giving non-competitive 
inhibition at low concentrations and uncompetitive inhibition at higher concentrations. 
Evaluation of (85) with SmChiB shows that (85) exhibits a non-competitive inhibitor 
profile with Ki of 148 µM and an IC50 of 100 µM. The two closely related derivatives 
psammaplin K (86) and L (87), and a dimeric analogue, bisaprasin (88) (Fig. 23) 
showed no significant inhibition of Bacillus sp. chitinase. Further members of the 
psammaplin family have since been isolated by Pina et al119 but no chitinase 
inhibitory activity has been established. The crystal structure of SmChiB in complex 
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with (85) shows undefined electron density in the active site consistent with 
conformational flexibility and disordered binding of the inhibitor. Asp175 is partially 
in the “up conformation” pointing towards Glu177 indicating partial binding in the -1 
subsite. The precise binding mode (84) with family 18 chitinases has thus so far not 
yet been established due to the lack of structural data. 
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R2 
85 (Psammaplin A) R1 = R2 = H

86 (Psammaplin K) R1 = H R2 = OH

87 (Psammaplin L) R1 = R2 = OH

88 (Bisaprasin) R1 = H R2 = dimer

Figure 26: Psammaplins used to test for chitinase inhibitory activity 
The first synthesis of (85) (Scheme 13) was achieved in four steps, starting from 3-
bromotyrosine.125 This general approach was utilised towards the preparation of 
psammaplin A-type derivatives by Nicolaou et al.126 Monobromination of tyrosine 
derivative (89) with KBr-KBrO3, gave 3-bromotyrosine derivative (90) in 81% yield, 
which was treated with trifluoroacetic anhydride to give trifluoromethyloxazolone 
(91) and subsequently hydrolysed to α-keto acid (92) (60% over the two steps). 
Compound (92) was converted to the protected oxime (93) by condensation with O­
(tetrahydro-2H-pyran-2-yl)-hydroxylamine and coupled with cystamine via activation 
as the N­succinimide ester. Cleavage of the THP protection group then gave (85) in 
36% yield over the 4 steps starting from (92). Nicolaou’s approach was exploited in 
the preparation, via catalytically-induced disulfide exchange, of a 3828-membered 
library of psammaplin A analogues which were screened for their antibacterial 
properties. The chitinase inhibitory activities of these molecules have not yet been 
reported so far. 
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O O OH 
i) Br ii) Br 
OH OH O 
NNH2 HO 
NH2 
HO HO 
CF3
(89) (90) (91) 
O O

Br
 Br iii) OH iv) OH v) 
(85) 
O N 
HO HO THPO 
(92) (93) 
Reagents and conditions: i) KBr-KBrO3, H2O, 81%, ii) TFAA, 80 °C, iii) 70%, TFA, 60% (2 steps), iv) THP-
ONH2, EtOH, v) EDC, NHS, 1,4-dioxane, Et2N, cystamine.HCl (0.5 eq), 1,4-dioxane-MeOH; HCl, DCM-MeOH, 
60 °C, 36% from 92. 
Scheme 13: Synthesis of psammaplin A 
1.9.7 Inhibitors identified via phage display 
A very recent study has reported the screening of a phage display library with 
disulfide-cyclized peptides against SmChiA and SmChiB.127 In this study, Ki values 
were determined for all peptides against SmChiA and SmChiB, revealing that all 
peptides were competitive with respect to the substrate with inhibition in the lower 
micromolar range. Each inhibitor was also tested against other family 18 chitinases 
and also, the family 19 chitinase from jack bean, Canavalia ensiformis. No significant 
inhibition was observed for these peptides towards other chitinases. Of the inhibitory 
peptides investigated, one was found to selectively inhibit SmChiA and two others 
were selective inhibitors of SmChiB.127 
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1.10 New leads and novel natural product inhibitors of family 18 
chitinases 
Banyasin A (94) (Fig. 24) has been isolated from the water bloom of the 
cyanobacterium Nostoc sp. 128 Compound (94) was isolated as a glassy material. With 
the aid of mass spectrometry and NMR experiments, Pluotno and Carmeli128 
determined that banyasin A is a cyclic pentapeptide consisting of L-Ala, L-Asp, L-
Me-Phe, L-N8-(N-methylcarboxyamide)-Arg (MC-Arg) and a rare β-amino acid, 3-
amino-2-methyl-5E-octenoic acid (Amoa) with the stereochemistry of Amoa at C3 
and C5 remaining unresolved. As banyasin A contains the essential MC-Arg-N-Me-
Phe dipeptide motif as argifin it would be of considerable interest to synthesise and 
evaluate banyasin A as a potential family 18 chitinase inhibitor and to investigate the 
mode of binding of this molecule to family 18 chitinases. 
As argifin and banyasin A are the only cyclic peptide natural products so far reported 
to contain these particular moieties, it is also of interest to investigate the potential of 
this unit alone, or smaller related fragments, as templates for the possible 
development of chitinase inhibitors. 
Previous synthetic approaches of argifin are not compatible with large-scale synthesis 
(required for in vivo or in vitro studies). The development of an approach which also 
eliminates side reactions observed previously, and allows scale up, would permit 
further studies on argifin or related compounds. 
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Figure 27: The structure of Banyasin A, key Arg(MC)­MePhe dipeptide motif depicted in red,

Amoa depicted in blue

1.11 Aims 
1) To dissect the argifin scaffold and identify the pharmocophore unit. 
2) To investigate the total, diasteroselective synthesis of banyasin A and evaluation as 
a potential chitinase inhibitor. 
3) To develop new methodology towards the preparation of argifin that avoids the 
formation of side products and allows scaling up of the synthesis. 
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2 Results and disscusion 
2.1 The synthesis of banyasin A 
2.1.1 Retrosynthetic analysis of banyasin A 
Our proposed synthetic route to banyasin A is outlined in Scheme 14. 
The approach features anchoring of the growing peptide precursor to the solid support 
via the protected aspartic acid. Cyclisation at the point indicated would place the 
potential cis Arg(MC)-MePhe amide motif found in argifin (see section 1.9.3) mid-
way along the precursor linear sequence, as well as potentially recreating a β-turn 
about the Arg(MC) and MePhe residues as seen in the X-ray structure of the Argifin-
AfChiB1complex. Finally, acylation of the arginine side chain, in an analogous 
fashion to that employed for the preparation of argifin, would allow incorporation of 
the key Arg(MC) moiety to complete the synthesis. 
Orthogonality is required between the solid phase linker (P1) and the side chain 
protecting groups (P2 and P4). This could be achieved by employing 2-chlorotrityl 
chloride polystyrene resin (P1), which can be cleaved under mild acidic conditions 
together with Pmc (P4) and tBu ester (P2) protecting groups which are stable to mild 
acid conditions. Fmoc protecting groups would be used as temporary Nα-protection 
(P3), and removed under basic conditions during the linear assembly. Removal of the 
Pmc and tBu groups under strong acidic conditions could be achieved prior to the 
essential acylation step, after cyclisation. 
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Scheme 14: Retrosynthesis of Banyasin A 
2.1.2 Approach towards synthesising the rare β­amino acid, Amoa 
The configuration at C3 and C5 of the Amoa residue in banyasin A has not so far 
been established. Therefore, it is necessary to synthesise each of the four 
diastereoisomers of Amoa in order to determine the correct configurations in the 
natural product. The first step towards the total synthesis of banyasin A is therefore to 
synthesise the Amoa fragment in a diastereoselective fashion. 
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The preparation of Amoa could be achieved using various synthetic routes. One 
method considered could potentially generate the desired β-amino acid as a mixture of 
racemic anti and syn diastereoisomers starting from diethyl acetamidomalonate (95) 
(Scheme 15).129 The known amino acid derivative (97) has not yet been prepared as a 
single stereoisomer before. Compounds (100) and (101) can be prepared in the 
racemic form from (95), using pent-3-enyl bromide potentially to furnish (96).130 
Protection and conversion of (97) to the β analogue may be achieved by employing 
Arndt – Eistert methodology to give 99.131 Formation of the ester enolate and 
treatment with methyl iodide should then give (100) or (101) as a mixture of racemic 
anti and syn diastereoisomers.131, 132 The enantioselective synthesis of an α-amino acid 
derivative such as (97) could be achieved by the methods described by O’Donnell133-
137 139 and by Corey138, which employ phase-transfer-catalysed alkylation of 
benzophenone imines of glycine esters. Although some preliminary studies were 
carried out into the strategy of Scheme 15, it was felt that an approach that provides 
each Amoa diastereoisomer selectively would ultimately be more effective. 
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Scheme 15: Possible synthetic route towards the preparation of Amoa 
2.1.3 Initial investigations towards the preparation of Fmoc­Amoa­OH 
We initially chose to focus on the (2R, 3R)-Amoa diastereoisomer as this 
configuration corresponds to that contained in many related β-amino acids that occur 
in cyclic peptide natural products.140-142 The preparation of these natural products 
utilised diastereoselective aldol reactions in order to access the desired β-amino acid. 
Therefore, our initial strategy for the synthesis of Amoa diastereoisomers (Scheme 
16) was to use a syn­diastereoselective aldol reaction, using the Evans chiral 
oxazolidinone, (R)-4-(phenylmethyl)-2-oxazolidinone (102). The synthesis of (2R, 
3R)-Amoa (107) would involve first the acylation of (102) with propanoyl chloride 
followed by diastereoselective aldol addition with the appropriate aldehyde E-3-
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hexenal. Conversion of the secondary hydroxy of (104) to an azide function could 
then be achieved by activation and nucleophilic displacement. Chemoselective 
reduction of azide (105) using the Staudinger (aza-Wittig) approach would lead to the 
free amine (106) and, finally, cleavage of the oxazolidinone would complete the 
synthesis of Amoa (107). Protection of the free amino function employing a Fmoc 
group would furnish (108), allowing this amino acid to be introduced into the linear 
peptide using standard solid-phase peptide synthesis. 
O O O O O OH O O N3 
O NH O N O N O N 
Ph Ph Ph Ph 
(102) (103) (104) (105) 
O HN 
O 
OO O NH2 O NH2 
O N HO HO 
Ph 
(106) (107) (108) 
Scheme 16: Initial synthetic strategy for the synthesis of Fmoc­(2R, 3R)­Amoa­OH (108) 
Synthesis towards Fmoc-(2S, 3S)-Amoa-OH (108a) would be achieved using the 
same conditions starting from the acylated auxiliary, (S)-4-(phenylmethyl)-2-
oxazolidinone (102a) (Scheme 17). 
O NH 
O 
Ph 
O HN 
HO 
O 
O 
same conditions as for the preparation of (108) 
(102a) (108a) 
Scheme 17: Synthetic strategy for the preparation of Fmoc­(2S, 3S)­Amoa­OH (108a) 
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The synthesis of the syn Fmoc-(2R, 3S)-Amoa-OH (110) and Fmoc-(2S, 3R)-Amoa-
OH (112) diastereoisomers would involve introducing the amino function by a 
“double inversion” strategy (Scheme 18). This involves conversion of the hydroxy 
group of (104) to a leaving group with inversion of configuration. Displacement of the 
leaving group using a nucleophilic azide source, would furnish the desired azide (109) 
with overall retention of configuration starting from (104). 
O O OH O O Y O O N3 
O N O N 
O N 
Ph Ph 
Ph 
Y = activated hydroxyl (104) 
or bromide (109) 
O HN 
HO 
O 
O 
(110) 
O O OH 
O N same conditions as for the preparation of (110) HO 
O HN 
O 
O 
Ph 
(111) (112) 
Scheme 18: Synthetic strategy towards the preparation the two syn­Amoa diastereoisomers

Fmoc­(2R, 3S)­Amoa­OH (110) and Fmoc­(2S, 3R)­Amoa­OH (112)

2.1.4 Synthesis of (E)­3­hexenal 
The aldehyde (117) required for the aldol reaction could in principle, be prepared in 
two ways either by selective reduction of a carboxylic acid derivative, or controlled 
oxidation of the corresponding alcohol. Both general methods were investigated. 
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2.1.4.1 Synthesis of (E)­3 hexenal by selective reduction 
Our initial synthetic approach was to form the corresponding Weinreb amide (114) 
derivative from (E)-3-hexanoic acid (113) by coupling of N, O-
dimethylhydroxylamine using the isobutyl chloroformate method. This reaction gave 
an unsatisfactory yield (20%) of (114) and mainly generated the formation of the 
isobutyl ester (115) (Scheme 19) via breakdown of the intermediate mixed anyhydride 
(116)143 (Scheme 20). The synthesis was performed alternatively, using PyBOP 
activation144 which furnished (114) in 60% yield (Scheme 19B). 
OH 
O 
i) 
N 
O 
O 
O 
O 
A 
(113) (114) (115) 
20% 
B OH 
O 
ii) 
N 
O 
O 
(113) (114) 
60% 
Reagents and Conditions A) i) (E)-3-hexanoic acid, DIPEA, isobutyl chloroformate, N,O-dimethylhydroxylamine 
hydrochloride, -20 °C to room temperature, DCM, overnight. B) ii) (E)-3-hexanoic acid, N,O-
dimethylhydroxylamine, DIPEA, PyBOP, DCM, room temperature, overnight. 
Scheme 19: Methodologies employed for the preparation of Weinreb amide derivative (114) 
58 
O O OO 
N Cl O O OOH 
(116) 
N

O 
N 
O O 
O 
NO O 
CO2 
O 
O 
(115) 
Scheme 20: Mechanism for the formation of ester (115) via breakdown of the intermediate mixed 
anhydride (116) 
The reduction of the Weinreb amide145 derivative (114) to the corresponding aldehyde 
was attempted using LiAlH4
146 but the reduction proved to be unsuccessful (Scheme 
21). Proton NMR and TLC of the product after workup showed there had been no 
reaction and only recovery of unchanged (114) was observed. 
N 
O 
O 
i) 
O 
(114) (117) 
Reagents and conditionsi) LiAlH4, THF, 0 °C, Ar, 1.5 h 
Scheme 21: Attempted selective reduction of (114) to aldehyde (117) using LiAlH4 
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151 
2.1.4.2 Synthesis of (E)­3­hexenal by oxidation of (E)­3­hexen­1­ol 
The oxidation of the commercially available homoallylic alcohol, (E)-3-hexen-1-ol 
(118), to (117) was investigated thoroughly. The first approach was oxidation using 
pyridinium chlorochromate.147 The reaction failed to form any aldehyde and led to 
full recovery of the alcohol upon work up. An attempt to oxidise (118) using a 
catalytic amount of TEMPO and trichloroisocyanuric acid148 again led to no reaction 
with almost full recovery of starting material (117), as did oxidation with TPAP and 
NMO149. van den Nieuwendijk et al150 have reported that the oxidation of homoallylic 
alcohols proved to be difficult using various, well-established oxidative methods.150, 
Successful oxidation of homoallylic alcohols may however be achieved by 
employing Dess-Martin reagent. Using van den Nieuwendijk’s conditions, the 
efficient oxidation of (118) to (117) was achieved with yields of up to 85% (Scheme 
22). Work-up of this particular reaction proved to be difficult due to the formation of 
tedious emulsions, which tended to lead to loss of product. Repeated filtering and 
washing with a solution of sodium thiosulfate in NaHCO3 (5-6 times) was required to 
remove completely the Dess-Martin by-products, whose presence was shown by a 
white cloudy solution upon concentration of the organic extract and by the presence 
of aromatic signals in 1H NMR. The aldehyde was obtained as a solution in DCM 
after distilling off as much solvent as possible. Reaction yield was determined by 1H 
NMR and the aldehyde was used without delay due to its instability and tendency to 
polymerise. 
O 
OH 
O 
I 
O 
OAc 
OAc 
AcO 
(118) (117) 
Reagents and conditions: Dess-Martin reagent, DCM, Ar, room 
temperature, 3 h, 85% yield. 
Scheme 22: Synthesis of (E)­3­hexenal (117) via Dess Martin oxidation of (E)­3­hexen­1­ol (118) 
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2.1.5 Investigation of the Evans’ boron­mediated aldol reaction using the chiral 
auxiliary, (4S)­4­benzyl­oxazolidin­2­one (102) 
Utilisation of boron-mediated aldol reactions has been proven to be a powerful 
method to generate compounds requiring highly stereoselective carbon-carbon bond 
formation and with high diastereoselective control. Reaction of (Z)-boron enolates 
with aldehydes leads to the generation of syn-aldol products.152 Control of the 
absolute stereochemistry can be achieved by utilisation of covalently attached chiral 
auxiliaries.152 The application of these chiral auxiliaries to generate stereo specific 
enolate species is usually refered to as the Evans aldol reaction. 
The main features of the Evans aldol reaction are firstly, enolisation of an N-acyl 
oxazolidinones using typically 1.1 equiv Bu2BOTf, 1.2 eqiv DIPEA, 0 °C, 30 min 
which forms (Z)-enolates with excellent selectivity.153 Once generation of the enolate 
is achieved, these can be treated with a wide variety of aldehydes to furnish syn aldol 
products in high yield and diastereoselectivity. Evans and co-workers initially utilised 
chiral auxiliaries such as (S)-4-isopropyl-oxazolidin-2-one (119) (Scheme 23), 
derived from (S)-valinol and, (1S,2R)-4-methyl-5-phenyl-oxazolidin-2-one (120), 
derived form (1R, 2S)-norephradrine.153 The general transition state for the reaction is 
outlined in Scheme 24. 
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R1 
Bu2BOTf (1.1 equiv) 
DIPEA (1.2 equiv) 
DCM, 0°C 
O N 
O O 
R1 
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O N 
O O 
R1 
OH 
R2 
(119)	 Z­enolate oxidative work­up syn aldol product 
BBu2 OO O	 O O O O OH 
R1 Bu2BOTf (1.1 equiv) R1 R
2 H

O N DIPEA (1.2 equiv) O N
 R2 
­78°C to rt R1 DCM, 0°C DCM 
O N 
Ph Me Ph Me	 Ph Me oxidative work­up 
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Scheme 23: General Evans boron mediated aldol reaction using auxiliaries (119) and (120) 
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Scheme 24: The general transition state obtained during the Evans aldol reaction to furnish syn

products

The Evans aldol reaction has been applied synthetically for the preparation of

numerous natural products. An example shown in scheme 25 is the preparation of

Glucolipsin A, a compound found to possess glycokinase-activating properties154

which was discovered by researchers at the Bristol-Myers Squibb. The absolute

stereochemistry of the natural product remained unidentified until Furstner and co-

workers confirmed the absolute stereochemistry via the synthesis of the natural

macrolide.154 Their preparation involved the utilisation of the Evans aldol reaction to

provide the desired syn aldol product with good yield and excellent

diastereoselectivity (scheme 25).

OH 
HO OH 
O O Bu2BOTf, Et3N O O OH 12 
­5 °C, DCM; then add O OO N O N 
12 
O O 
O OPh Me Ph Me

O
 O O 
12 68% yield 
single diasteriosomer 
HO OH 
OH 
Glucolipsin A 
Scheme 25: The preparation of Glucolipsin A by utilisation of Evans aldol reaction 
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The Mukaiyama aldol reaction utilises Lewis acid-mediated addition of enol silanes to 
carbonyl compounds leading to anti-aldol products155 (Scheme 26). 
O 
HR1 R3 
OSiMe3 
R2 
Lewis acid or base 
(stoichiometric or catalytic) 
aqueous work­up 
R1 
OH 
R2 
O 
R3 R1 
OH 
R2 
O 
R3 
+ 
anti syn 
Scheme 26: General scheme for the Mukaiyama aldol reaction 
Stoichiometric amounts of Lewis acids such as TiCl4, SnCl4, AlCl3, BCl3.OEt2 and 
ZnCl2 were required to effect the transformation.
155, 156 The development of several 
Lewis acid and Lewis base catalysts has also been achieved.157 The enol silane 
component can be derived from aldehydes, ketones, esters and thioesters. 
Unsubstituted, mono- and disubstituted enol silanes have also been investigated and 
the most commonly used carbonyl reactants were aldehydes although it has been 
found that ketones and acetals also react under appropriate conditions.158 By carefully 
The mechanism of the reaction depends on the reaction conditions used.155, 
choosing the conditions and reactants, the diasteroselectivity of the reaction can 
favour the formation of anti-aldol products.158 
Classical conditions utilise TiCl4 in equimolar quantities
156. It has been shown that the 
Lewis acid activates the aldehyde by coordination followed by rapid carbon-carbon 
bond formation. The stereochemical outcome of the reaction also largly depends on 
the size of the substituents that are covalently bonded to the aldehyde and to the enol 
silane.155, 156 When R2 is small and R3 is bulky, the reaction leads to the anti product 
independent of the double bond geometry (Scheme 26). Alternatively, syn products 
can be produced if R2 is large and when the aldehyde is capable of chelation.156 
Methodology towards the preparation of aldol products with anti-configuration has 
been achieved to overcome some of the problems that previous methods possess, such 
as availability of reagents and the generality of reactants and conditions required for 
the reaction. Several laboratories have described the preparation of anti-aldol products 
through utilisation of either titanium159, 160 or boron enolates.161-165 An example of 
anti-aldol chemistry via boron mediated enolisation has been reported by Abiko et 
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156 
al
161 who utilised chiral sulfonamide-esters such as (124) (Scheme 27). By varying 
the alkyl boron triflate, aldehyde and using either Et3N or DIPEA, Abiko et al found 
that anti-aldol products were formed in yield (98%) and high diastereoselective 
control (98: 2 in favour of the anti-diastereoisomer) when using 2.0 eq of 
dicyclohexylboron triflate, 2.4 eq of Et3N and employing isobutyraldehyde (1.1 eq) as 
the carbonyl source. Similar results were achieved when a variety of aldehydes were 
exposed to these conditions, demonstrating the efficiency of the anti-aldol reaction 
which has been utilised as a reaction to achieve the desired stereoselectivity, in the 
preparation of many synthetically challenging molecules.166-172 
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>95:5 (anti:syn)

Reagents and conditions: i) MesSO2Cl, Et3N, DCM, 100% ii) BnBr, K2CO3, MeCN, reflux, 7 h, 95% iii) EtCOCl, 
pyridine, DCM, 0 °C to room temperature, 100% iv) (c-Hex)2BOTf, Et3N, -78 °C, 2 h, DCM then RCHO, 3 h, 70-
98%. 
Scheme 27: Anti­aldol chemistry 
For our approach to Amoa, acylation of oxazolidinone (102) to (103), was achieved 
successfully, according to the published procedure by reaction of (102) with 
propanoyl chloride and n­BuLi.173 This preparation proved to be highly efficient and 
(103) was obtained in nearly quantitative yield, usually without the need for 
purification by column chromatography. Diastereoselective aldol reaction between 
(103) and aldehyde (117) was first attempted using dibutyl boron triflate and Et3N at -
78°C, as described by Evans.173 Enolate formation was indicated by formation of a 
deep orange colour.174 As mentioned previously, (117) was used without delay on 
preparation, due to its instability and tendency to polymerise. Work-up of the aldol 
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reaction and purification by flash chromatography on silica gel, led to the recovery of 
both acylated and non-acylated oxazolidinone. In order to confirm that the enolate 
was being correctly generated, a test reaction was carried out under the same 
conditions, but replacing (117) with benzaldehyde. Work-up and purification of the 
reaction as before led to the isolation of the desired syn-aldol (126) in 72%, with only 
a small amount of unchanged (103) being recovered. Enolisation of (103) using LDA, 
followed by addition of aldehyde (117) proved to be unsuccessful with high recovery 
of (103) (~90%) and with no indication for the presence of (104). The aldol reaction 
was repeated, under previous Evans’ conditions using excess (117) (5 eq), as previous 
reports have disclosed that the use of excess aldehyde is required in some reactions 
that utilise boron-mediated aldol conditions of this type.175 In this case, after the usual 
work-up and purification, the desired aldol product was obtained in low yield (12%), 
together with recovery of a large amount of (103) (58%). The general reaction scheme 
for the boron-mediated aldol reaction is shown in Scheme 28. The results obtained 
from investigating the boron-mediated aldol reaction with aldehyde (117) or 
benzaldehyde are summarised in Table 4. 
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O NH 
O 
i) 
Ph Ph 
(102) (103) 
Reagents and conditions: i) n-BuLi, 15 min, -78 °C, anhydrous DCM, propanoyl chloride, room temperature, 3 h, 98% 
Scheme 28: Acylation of oxazolidinone (102) to (103) 
Scheme 29: General Boron­mediated aldol reaction scheme 
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Aldehyde 
(eq) 
Base (Et3N) 
(eq) 
Bu2BnOTf 
(eq) 
Yield (%) R group 
1.1 1.3 1.2 0 
5 1.3 1.2 12 (58) 
1.1 1.3 1.2 72 
Table 4: Aldol reaction yields using dibutylboron triflate with benzaldehyde or (E)­3­hexenal, 
yield of recovered (103) shown in parentheses. 
2.1.6 Investigation of the Evans’ boron­mediated aldol reaction using the chiral 
auxiliary, (4R)­4­benzyl­oxazolidin­2­one (102) 
Due to unsuccessful results using the boron enolate method, we decided to investigate 
soft enolisation techniques by utilising a titanium reagent, which is a well-known 
alternative for diastereoselective aldol reactions, and does not require the use of 
excess aldehyde.175 
There are many reports on the use of titanium mediated enolisation techniques in 
prefence to employing Bu2BOTf. The methodology led to the successful preparation 
of syn­aldol products in high yield and diastereoselectivity. Evans reported the 
formation of titanium-mediated enolates from an acylated benzyl oxazolidinone 
which could react with a variety of representative electrophiles that include 
unsaturated nitriles, ketones and esters.176 Evans has also demonstrated that the use of 
TiCl4 and DIPEA as base can lead to the desired products with excellent yields and 
diastereoselective control similar to boron-mediated aldol methods.177 Crimmins has 
also investigated the use of TiCl4 for performing aldol reactions and showed that 
diasteroselectivity could be switched between obtaining Evans syn and non-Evans-syn 
products depending on which amine base was employed and also Lewis acid 
stoichiometry,178 a finding that has also been supported by Thornton179, 180 and 
Duthaler.181 
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Typical procedures use TiCl4 and a base such as DIPEA for the enolisation process as 
is generalised in Scheme 29. A test reaction using (103) and benzaldehyde was 
therefore conducted. Compound (103) was treated with TiCl4 (2.0 eq) and DIPEA (1.5 
eq) at 0°C to form the enolate species (shown by the development of a deep red 
colour), followed by addition of benzaldehyde at -78 °C.175 After 1 h reaction, the 
usual work-up and chromatography gave the desired product (128) in good yield 
(72%). As Crimmins has reported that use of a chiral base, (-)-sparteine, may give 
superior results,175 it was decided to try both sets of conditions in parallel for the 
reaction with aldehyde (117). Compound (103) was treated with TiCl4 (2.0 eq) and 
either DIPEA or (-)-sparteine (1.1 eq) at 0°C, as described by Crimmins.175 After 
cooling to -78°C and addition of (117), the reaction was allowed to proceed for 3 h. 
At this point, TLC of both reactions showed the presence of some unchanged (103) 
but also the clean formation of significant quantities of (127). However, after work-up 
and chromatography, in both cases, only a low yield of (104) was obtained together 
with significant amounts of (103). For the reaction utilising DIPEA as base, a yield of 
13% was obtained, and when employing (-) sparteine, 18% yield. Based on these 
results, we suspected that the product might be undergoing a retro-aldol reaction 
(Scheme 30) upon purification by chromatography, due to the acidic nature of the 
silica gel. Therefore it was decided to repeat one of these experiments, with 
neutralisation of the silica gel with 0.1% pyridine prior to purification. As the reaction 
yield appeared to be only slightly improved by using (-)-sparteine as base compared 
to DIPEA, it was decided to use DIPEA for further investigations. This gave 
exclusive formation of the desired aldol product (128) in 51% yield, with very little 
unchanged (103). 
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Scheme 30: General titanium­mediated aldol reaction scheme 
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Scheme 31: Acid­catalysed retro­aldol reaction of (127) to (103) 
The results of the experiments using TiCl4 are summarised in Table 5. Yields of 
recovered (103) are shown in parentheses. Although Crimmins has reported that the 
use of (-)-sparteine compared to DIPEA accelerates the rate of reaction and gives 
better reaction yields, possibly due to bidentate coordination of (-)-sparteine to the 
metal centre,175 this was not observed in reactions with oxazolidinone (103) with 
(117). As well as giving a significantly better yield, the use of TiCl4 is also more cost 
effective than dibutylboron triflate. It is possible that the poor yields from the boron 
chemistry may also have been due to the instability of the aldol product on 
chromatography but this was not investigated. 
68 
Aldehyde (eq) Base (eq) TiCl4 (eq) Yield (%) R group 
1.1 1.1 
(DIPEA) 
2.0 80 
1.1 1.1 
((-)-sparteine) 
2.0 18 (57%) 
1.1 1.1 
(DIPEA) 
2.0 13 (41%) 
1.1 1.1 
(DIPEA) 
2.0 51* 
Table 5: Aldol reaction yields using a soft enolisation approach with benzaldehyde or (E)­3 
hexenal, yield of (103) shown in parentheses. * Silica gel neutralised with 0.1% pyridine prior to 
purification 
The configuration of (128) was determined by X-ray crystallography (Fig. 28) as 
(127) was not obtained in the crystalline form. The X-ray structure of (128) revealed 
that the non­Evans syn product (4-(R)-benzyl-3-((2S,3S)-3-hydroxy-2-methyl-3-
phenylpropanoyl)oxazolidin-2-one (128), (Fig. 28) was formed, by using conditions 
of, 2.0 eq TiCl4 and 1.0 eq DIPEA. The X-ray crystal structure of (126) was obtained 
and reveals formation of the desired Evans-syn product using dibutylboron triflate and 
Et3N (Fig. 28). Comparison of the 
1H NMR spectrum of (104), using Crimmins’ 
optimised conditions (see section 2.1.8), to that obtained using boron-mediated 
enolisation methods indicates that the two reaction conditions lead to the generation 
of the Evans syn product. We can therefore conclude that the use of titanium 
tetrachloride is more robust method to perform diastereoselective aldol chemistry than 
dibutylboron triflate. Furthermore, dibutylboron triflate is more expensive, more 
sensitive to moisture and requires the use of excess aldehyde compared to reactions 
performed using titanium tetrachloride. 
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A 
B

C 
Figure 28: X­ray structure of A) non­Evans­syn product (128), B) the Evans­syn product (126) 
and C) the hydrogen bonded lattice structure of (126) 
Early reports on the generation of enolates from N-propanoyl-4-alkyloxazolidinones 
always use 1.0 eq TiCl4 and and 1-1.2 eq base.
176, 182, 183 Under these conditions, the 
reaction is expected to proceed via a non­chelated intermediate as observed with 
boron enolates (Scheme 31a) and results in the formation of syn products. A report by 
Duthaler suggests that in­situ formation of amine hydrochloride from TiCl4 and base 
inhibits the generation of chelated transition states furnishing syn products.181 
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Thornton has shown that utilisation of Ti(OiPr)3 as Lewis acid, results in a chelated 
transition state resulting in the formation of non­Evans products.179 Thornton also 
states that the use of norephradine-derived auxiliaries should give high 
diastereoselectivities in either chelation or non-chelation processes.179 
Crimmins has also investigated the use of acyloxazolidinethiones as it was expected 
that the greater affinity of sulfur for titanium should favour the formation of a 
chelated transition state.175, 178 Crimmins has shown that using 1 eq of TiCl4 and 1 eq 
DIPEA, syn products are formed using acyloxazolidinethiones but that the addition of 
an extra equivalent of Lewis acid generates a different, chelated enolate that results in 
the formation of the non­Evans syn product175 (Scheme 31b). 
The formation of the non­Evans syn product can be rationalised based on these 
reports. Addition of 2.0 eq TiCl4 (an extra equivalent of Lewis acid) leads to the 
formation of a chelated transition state thus yielding the non­Evans syn product 
(scheme 31c). Using Evans conditions for the generation of boron-enolates,173 a non-
chelated transition state is formed giving the Evans­syn product (Scheme 31a). 
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Scheme 32: Transition states formed using various enolisation techniques leading to Evans­syn or 
non­Evan­syn products A) transition state using dibutyl boron triflate, B) transition state using 
1.0 eq of TiCl4, C) transition state using 2.0 eq of TiCl4 
2.1.7 Investigations of the aldol reaction using the chiral auxiliary, (4R, 5S)­
methyl­5­phenyl­2­oxazolidinone (129) 
Due to the difficulty in carrying out the displacement of the activated hydroxy, by a 
nucleophillic azide source (see section 2.1.9), an alternative diastereoselective 
approach towards the synthesis of Amoa was investigated (Scheme 32). This involves 
the use of a norephedrine derived chiral auxiliary (129), acylation using propanoyl 
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chloride to give (130), followed by diastereoselective aldol condensation, with 
neutralisation of the silica gel prior to purification, to give the desired aldol product 
(131). Compound (131) could then undergo a Mitsunobu type reaction using a 
nucleophilic azide source to furnish azide (132) with inversion of configuration. 
Reduction of azide (132) would generate the free amine (133). Cleavage of the methyl 
oxazolidinone derivative, followed by N-Fmoc protection, would then lead to the 
amino acid derivative (108). The synthesis of the other three diastereoisomers of 
Fmoc-Amoa-OH could be achieved in an analogous manner using (129) using 
methodology described earlier (section 2.1.3). 
O O O OH O O N3 
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O NH O NO N 
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(133) (107) 
Scheme 33: Alternative diastereoselective synthesis for Fmoc­(2R, 3R)­Amoa 
The acylation of (129) with propanoyl chloride proceeded smoothly to afford (130) in 
60-96% yield. The aldol reaction between (130) and aldehyde (117) using 2.0 eq 
TiCl4 and 1.1 eq DIPEA, resulted in the formation of two diastereoisomers (53% 
yield) and recovered unchanged starting material (7%). Purification of the crude 
mixture by column chromatography with neutralisation of silica gel with 0.1% 
pyridine proved to be difficult. However, the isolation of a single diastereoiosomer 
was achieved (0.25 g, 25%), along with a mixture of diastereoisomers (0.27 g, 27% 
yield) in a 1:2 ratio by 1H NMR analysis. Based upon these results, we concluded that 
the reaction of (130) with aldehyde (117) prodeeded with moderate yield (53%) but 
with poor diastereoselectivity and led to the formation of two diasteroisomers (35% 
O O NH2 O NH2 
O N HO 
HO 
O HN 
O 
O 
(108) 
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minor diasteroisomer, 65% major diasteroisomer determined by 1H NMR analysis, 
and comparison of each component by TLC). Though at this point, we were unable to 
determine which diastereoisomer was isolated, we speculated that each one 
corresponded to either the non­Evans syn, or the Evans syn product. Only by 
comparison of the isolated diastereoisomer, to the product obtained after optimisation 
to give the single, Evans’ syn product (see section 2.1.8) by 1NMR, could we 
conclude that the isolated compound corresponded to the non­Evans syn product 
(135) (Fig. 29). 
To investigate whether the stoichiometry of TiCl4 and DIPEA affected the 
diastereoselective ratio of products, two test reactions were conducted. 
In the first case, (130) was treated with TiCl4 (2.0 eq), DIPEA (1.1 eq) and 
benzaldehyde (1.1 eq) under the same conditions as before. Work-up and purification 
of the crude product by column chromatography led to the recovery of unchanged 
starting (130) (10%) and two diastereoisomers (68 mg, 47% yield). Once again, 
complete separation of these diastereoisomers proved to be difficult, though one 
component was isolated (45mg, 31% yield) along with a mixture of diastereoisomers 
(23 mg, 16% yield), in a 1:2 ratio, by 1H NMR analysis. These results indicate that the 
reaction indeed proceeds with moderate yield (47%) but with poor control under these 
conditions to give the non­Evans syn, or the Evans syn product. Comparison by 1H of 
the isolated diastereoisomer to that obtained after diastereoselective optimisation of 
the reaction (see section 2.1.8), again confirmed that the major component 
corresponded to formation of the non­Evans syn product (134) (Fig. 29). 
O N 
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Figure 29: The structure of both non­Evans­syn products (134) and (135)
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In the second case, (130) was treated with TiCl4 (1.1 eq), DIPEA (2.5 eq) and 
benzaldehyde (1.1 eq) under the same conditions as before. Purification of the crude 
mixture, after the usual work-up, led to the formation of diastereoisomers (62% 
yield), in a 1:3 ratio of the Evans syn: Evans non­syn determined by 1H NMR. In this 
case, no unchanged starting material was recovered. All results obtained for the above 
experiments have been summarised in Table 6. It is worth noting that there have been 
no published examples for using titanium-enolate methodology with norephedrine-
derived auxiliaries. 
Aldehyde 
(eq) 
Base (eq) TiCl4 (eq) Yield (%) Evans syn : 
non­Evans syn 
R group 
2.0 1.1 
(DIPEA) 
2.0 53 (7%) 35 : 65 
1.1 1.1 
(DIPEA) 
2.0 47 (10%) 22 : 78 
1.1 2.5 
(DIPEA) 
1.1 62 (0%) 26 : 74 
Table 6: Aldol reaction yields using TiCl4/DIPEA with benzaldehyde or (E)­3­hexenal, yield of 
(130) shown in parentheses. 
2.1.8 Successful, diastereoselective synthesis of (4R, 5S)­3­((2R, 3S)­E­3­hydroxy­
2­methyloct­5­enoyl)­4­methyl­5­phenyloxazolidin­2­one 
Crimmins has reported the use of a combination of reagents, that delivers aldol 
products with desired Evans syn diastereoselectivity along with excellent yields for 
both acyloxazolidinones and acyloxazolidinethiones.184 In this report, the reaction of 
(130) with 1.0 eq TiCl4, 1.0 eq (-)-sparteine, 1.0 eq 1-methylpyrolidin-2-one and 1.1 
eq of aldehyde led to the formation of products in excellent yield (97-99%) and 98:2 
diastereoselectivity of Evans syn: non­Evans syn respectively. The use of 1.05 eq 
TiCl4, 1.1 eq DIPEA and 1.0 eq N-methyl pyrolidinone led to exclusive formation of 
the desired Evans syn aldol product with yields of up to 99%. 
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To test these results using auxiliary (129), compound (130) was treated with 1.05 eq 
TiCl4, 1.1 eq DIPEA, 1.0 eq NMP and 1.1 eq benzaldehyde (Scheme 33). Unlike 
previous experiments, addition of benzaldehyde was performed at 0 °C instead of –78 
°C as described by Crimmins. Work-up and purification of the reaction mixture by 
column chromatography afforded (136) as a single diastereoisomer in 47% yield 
along with recovered, unchanged starting material (130) (10%). As these results were 
promising, the reaction of (130) with aldehyde (117) under the same conditions was 
carried out giving (131) as a single diastereoisomer in 61% yield and no recovery of 
starting material (Scheme 33). With (131) and (135) in hand, we were able to draw 
conclusions as to what diastereoisomers were formed and isolated in previous 
experiments (see section 2.1.7). Repeating the reaction led to isolation of (131) in 60-
72% yield with exclusive formation of the desired Evans syn product. 
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O O OH 
i) 
OO N 
Ph Ph 
(130) (136) 47% 
(130) 10% 
O N 
O 
Ph 
ii) 
(130) 
O OH 
(131) 61% 
Reagents and conditions: i) TiCl4 (1.05 eq), DIPEA (1.1 eq), N­methylpyrolidin-2-one (1.0 eq), N2, 0 °C, 40 min 
benzaldehyde (1.1 eq), 3 h ii) TiCl4 (1.05 eq), DIPEA (1.1 eq), N­methylpyrolidin-2-one (1.0 eq), N2, 0 °C, 40 min, (117) 
(2.0 eq), N2, 0 °C, 6 h 
Scheme 34: Optimised conditions for the diastereoselective formation of (131) and (136) 
76

2.1.9 Investigations into introducing an amino functional group using (R)­4­
benzyl­3­((2S, 3R)­E­3­hydroxy­2­methyloct­5­enoyl)oxazolidin­2­one 
(127) 
Having successfully prepared aldol (127) (see section 2.1.6), the introduction of the 
required nitrogen function was investigated. Activation of the secondary hydroxy of 
(127) (Scheme 34) and nucleophilic displacement was attempted using various 
methods. Activation of the hydroxy by conversion to the corresponding mesylate 
(140) (MsCl, Et3N)
185 was attempted first (Scheme 34a), with the successful 
formation of the mesylate being confirmed by mass spectrometry. Attempted 
displacement of the crude mesylate using excess NaN3 in DMF proved to be 
unsuccessful185 (Scheme 34a). The reaction was initially performed at room 
temperature for 72 h, followed by heating at 60°C for a further 24 h, and finally 
heating at reflux for 24 h. No change was observed by TLC, and mass spectrometry of 
the final recovered material indicated the presence of (140) only. It was then decided 
to activate the hydroxy of (127) by conversion to the triflate (141) using 
trifluoromethanesulfonic anhydride186 (Scheme 34b). Reaction of the triflate with 
excess NaN3 also did not prove to be successful. The reaction was performed using 
two sets of conditions, at 60°C and at room temperature. At 60 °C, TLC showed the 
formation of a complex mixture and 1H NMR and mass spectrometry indicated the 
presence of possible elimination products and recovered (127). At room temperature, 
1H NMR and mass spectrometry of the crude product showed only recovered (127). 
A Mitsunobu-type reaction (Ph3P, DEAD) also proved to be unsuccessful, using 
DPPA as the nucleophile source for azide introduction,142 (Scheme 34c), (127) was 
isolated along with reduced DEAD, triphenylphosphine oxide and possible 
elimination products in low yield. 
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ii) (127) O NO N 
Ph Ph 
(140) (105) 
(141) 
c) v) 
a) i) Et3N, MsCl, DCM, 0 °C, 3 h iv) NaN3 DMF, room temperature to reflux, 3 days 
b) iii) Pyridine, (OTf)2O, 0 °C, 3 h iv) NaN3, DMF, room temperature to 60 °C, 36 h 
c) v) DEAD, PPh3, DPPA, THF, room temperature, overnight 
Scheme 35: Investigations towards the conversion of (127) to azide (105) 
This transformation had been used successfully by Kiho et al142 in a closely related 
system (137) containing oxazolidinone (130), where the benzyl group is replaced with 
a methyl (Fig. 30). We can speculate that, in our case, the displacement reactions 
failed due to the steric bulk of the benzyl group of (127) which might hinder 
nucleophilic attack of the mesylate or triflate by NaN3 and also under Mitsunobu 
conditions using DPPA as a nucleophilic azide source. This explanation is supported 
by work by Pearson et al187 who found that NaN3 displacement of a mesylate or a 
triflate formed from the aldol product (138) containing the benzyl oxazolidinone, 
could not be achieved (Fig 30). However, introduction of an azido group was 
successful once the oxazolidinone was converted to a less bulky Weinreb amide 
derivative (139).187 
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Figure 30: Aldol products obtained according to Kogen (137) and Rinehart (138) and conversion 
of (138) to the weinreb amide derivative (139) 
Based on the results above, it was decided to remove the oxazolidinone group of 
(127) and then esterify the resulting acid in preparation for hydroxy activation and 
nucleophilic displacement using Mitsunobu conditions.187 Cleavage of the 
oxazolidinone under standard conditions (LiOH, H2O2)
173 and esterification of the 
resulting crude carboxylic acid using TMSCHN2
188 led to the expected methyl ester 
(142), although in low yield (22%), such that it was not feasible to attempt the 
Mitsonobu transformation (Scheme 35). 
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HO 
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i) ii) 
(127) (142a) (142) 
Reagents and conditions: i) 27% H2O2, LiOH, THF:H2O (v/v 4:1), 0°C, N2, 1.5 
h ii) TMSCHN2, Et2O, room temperature, N2, 1 h 
Scheme 36: Preparation of (142) 
2.1.10 Investigations into introducing an amino functional group using (4R, 5S)­
3­((2S, 3R)­E­3­hydroxy­2­methyloct­5­enoyl)­4­methyl­5­
phenyloxazolidin­2­one (135) 
With (135) in hand, we investigated the introduction of the amino function using 
similar methods as described by Kiho et al142 . 
Our first approach involved activation of the hydroxy by conversion to the 
corresponding mesylate (142) (MsCl, Et3N)
185 with the successful formation of the 
mesylate being confirmed by 1H NMR. Attempted displacement of the crude 
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mesylate using excess NaN3 in DMF proved to be unsuccessful.
185 Work-up of the 
reaction followed by analysis of the reaction mixture by 1H NMR, revealed 
exclusively the formation of eliminated product (143) and recovered, unchanged 
starting mesylate (142) (Scheme 36a). It was then decided to use methods described 
by Kiho et al employing Mitsunubu methodology.142 Compound (135) was treated 
with DEAD, PPh3 and DPPA, at room temperature for 16 h. Purification of the crude 
reaction mixture by column chromatography led to the isolation of the desired product 
(132a) in very poor yield (6%) and eliminated product (143) (13%) along with the 
recovery of unchanged starting material (135) (39%) (Scheme 36b). The reaction was 
repeated using the same conditions but performed at a lower temperature of 0 °C. 
Usual work-up and purification led to the isolation of eliminated product (143) (51%) 
and the desired azide (132a) (11%), with no recovery of unchanged starting material 
(scheme 36c). 
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O N i) ii) O N 
Ph 
O N
O
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O O OH O O OMs 
Ph 
(135) (142) (143) 
b) O O N3 
iii) 
(135) O N 
Ph 
(132a) (6%) 
(143) (13%) 
(135) (39%) 
c) 
(135) 
iv) (132a) (11%) 
(143) (51%) 
Reagents and conditions: i) Et3N, MsCl, DCM, 0 °C, 3 h ii) NaN3, DMF, N2, 16 h iii) DEAD, PPh3, N2, room 
temperature, 15 min then DPPA, 16 h iv) (135), DEAD, PPh3, N2, 0 °C, 15 min, DPPA, room temperature, 16 h. 
Scheme 37: Investigations towards the conversion of (135) to azide (132a) 
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2.1.11 Investigations into introducing amine functionality to (4R,5S)­3­((2R,3)­E­
3­hydroxy­2­methyloct­5­enoyl)­4­methyl­5­phenyloxazolidin­2­one (131) 
Kimura et al describe the synthesis of Kulokekahilide-1141 (Fig. 31), a cytotoxic 
depsipeptide from the cephalaspidean mollusc of Philinopsis speciosa. This molecule 
consists of eight amino acid residues, one of which is a β-amino acid (2R, 2R)-Amha, 
depicted in green, Fig. 31) that is structurally similar to Amoa. 
N 
N O 
O O 
OHN O 
O NO O
O 
N O
N 
H 
2R,3R­Amha 
Figure 31: The structure of Kulokkahilide­1, 2R, 3R­Amha β­amino acid frgament depicted in 
green 
The preparation of (2R,2R)-Amha described by Kimura et al involves utilising Evans 
boron diasteroselective aldol methodology (Scheme 37). Introduction of the azide was 
achieved by conversion of the secondary hydroxy of (144) to a tosylate (145) and 
subsequent nucleophilic displacement with NaN3 or tetramethylguadinium azide to 
generate the required azide (146) with inversion of configuration. 
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(130) (144) (145) 
O O N3 O NH2 
iii) iv) 
O N HO 
Ph 
(146) (147) 
Reagents and conditions: i) Bu2BOTf, DIPEA, DCM, 0 °C, then butanal, -78 °C ii) p­TsCl, pyridine iii) 
tetramethylguadinium azide, DCM or NaN3, 15-crown-5, DMF iv) H2O2, LiOH then HCl and H2, Pd-C, AcOH-H2O. 
Scheme 38: The preparation of the β­amino acid, 2R,3R­Amha fragment of Kulokkahilide­1 
Alvarado et al have reported the synthesis of another cyclic depsipeptide, ulongamide 
A 1140 (Fig. 32), isolated from the marine cyanobacteria Lyngbya sp. Their methods 
also describe the use of Evans boron aldol chemistry with the norephedrine derived 
auxiliary (148) and subsequent azide introduction by employing Mitsunobu 
methodology employing HN3 as a nucloephilic azide source to generate the key azido 
intermediate (150) (scheme 38). Similar methods towards the synthesis of protected 
β-amino acids have been described by Lelais et al employing mitsunobu methodology 
for hydroxy activiation and HN3 for nucleophilic displacement to generate the desired 
azido compounds.189 
HN 
S 
N NO 
O 
OO HN N O 
O 
Ulongamide A 1 
Figure 32: The structure of Ulongamide A1 
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(148) (149) (150) 
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O N3 
HO 
O HN 
O 
Ov) 
HO 
O NH2iv) 
(151) (152) (153) 
Reagents and conditions: i) Bu2BOTf, DIPEA, DCM, 0 °C, then butanal, -78 °C ii) DEAD, PPh3, HN3, toluene iii) H2O2, 
LiOH, H2O iv) H2/Pd-C, methanol v) (Boc)2O, Et3N, H2O/p-dioxane 
Scheme 39: The synthesis of (2S, 3S)­β­amino acid fragment (153) of a ulongamide 
We attempted to apply the conditions reported by Kimura and co-workers. Our first 
approach was to generate tosylate (154) by treatment of (131) with p­toluenesulfonyl 
chloride under basic conditions and at room temperature for 16 h. Work-up of the 
reaction and analysis by 1H NMR revealed that no reaction had occurred with 
exclusive recovery of unchanged starting material. The reaction was repeated using 
the same conditions but increasing the temperature of the reaction to 40 °C. Work-up 
of the reaction mixture as before did not indicate formation of the desired tosylate, but 
exclusive recovery of unchanged starting material (Scheme 39a). 
We next focused our attention on employing methods described by Alvarado and 
Seebach. The formation of HN3 has to be approached with caution due to its 
instability and reported toxicity.140, 189 Hydrazoic acid was formed according to the 
procedure described by Sanford et al190 by treating NaN3 in water with conc. H2SO4. 
Extraction of the solution with chloroform gave a solution of HN3 which was used 
immediately for the subsequent step. Compound (131) was treated with DEAD, PPh3 
and HN3 solution and stirred at room temperature for 16h. Work up of the reaction 
mixture followed by purification led to the formation of eliminated material (29%) 
and recovery of unchanged starting (131) (60%), (Scheme 39b). 
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The reaction of (131) under Mitsunobu conditions, employing DPPA as a nucleophilic 
azide source was now investigated once again.142 Reaction conditions were kept as 
those investigated during preliminary studies using compound (135), (see section 
2.1.10), with the exception of performing the reaction at -20 °C for 1 h and then at 
room temperature for 15 h. Evaporation of the solvent under reduced pressure 
followed by purification of the crude product by column chromatography led to the 
formation of the desired azide (132) in moderate yield (50%), along with isolation of 
eliminated product (155) (17%) and unchanged starting material (131) (18%) 
(Scheme 39c). 
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ii) 
(155) (21%) 
(131) (60%) 
O O N3 
c) (131) 
iii) O N 
Ph 
(132) (50%) 
(155) (17%) 
(131) (18%) 
Reagents and conditions: i) p-TsOH, pyridine ii) DEAD, PPh3, HN3, toluene, N2, 0 °C to room temperature, 16 h iii) 
DEAD, PPh3, N2, -20 °C, 1 h, then DPPA, room temperature, 16 h. 
Scheme 40: Investigations towards the synthesis of azide (132) 
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Formation of the desired azide (132) using DPPA as a nucleophilic azide source 
proceeds via the mechanism outlined in Scheme 40. 
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Scheme 41: Proposed mechanism of Mitsunobu reaction using DPPA 
With azide (132) in hand, we were in the position to investigate the last set of 
transformations which included reduction of the azide to the amine, oxidative removal 
of the auxiliary and final Fmoc protection of the free amine to furnish Fmoc-Amoa-
OH. 
2.1.12 The synthesis of Fmoc­amoa­OH using a three­step protocol 
Our first approach involved Staudinger aza-Wittig reduction of (132) to (156) 
(mechanism outlined in scheme 41) using PPh3/H2O to furnish the amine in 59% yield 
(scheme 42). Oxidative cleavage of the auxiliary was effected by treating (132) with 
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LiOH/H2O2 and the crude product was N-protected using Fmoc-Cl. This gave (108) in 
disappointing yield (4%) over two steps starting from (132) (Scheme 42). 
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Scheme 42: Mechanism of azide reduction under Staudinger aza­Wittig conditions 
O O N3 O O NH2 
N ii) i) O NO HO 
iii) 
Ph Ph 
O HN 
O 
O 
(132) (156) (59%) (108) (4%) 
Reagents and conditions: i) PPh3, N2, room temperature, 30 min then H2O, 60 °C, 16 h ii) LiOH/ H2O2, 3 h, 0 °C iii) 
dioxane, 10% Na2CO3, Fmoc-Cl, 0 °C, 16 h. 
Scheme 43: The first preparation of Fmoc­Amoa using Fmoc­Cl and the free amine, (156) 
As (108) was isolated in low yield, it was decided to remove the auxiliary first, 
followed by reduction of the azide to the amine and finally, protection of the resulting 
β-amino acid, a protocol analogous to the synthesis of the β-amino acid moiety 
contained within the globomycin analogue described by Kogen.142 Removal of the 
auxiliary was performed by treating (132) with LiOH/H2O2. After work-up of the 
reaction mixture and removal of the solvent, the crude β-azido acid was utilised 
without further purification and was subjected to reduction using PPh3 and H2O. The 
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crude β-amino acid was protected using Fmoc-Cl based on the amount of starting 
azide (132), under basic conditions. The crude Fmoc-β-amino acid was then finally 
purified by column chromatography (silica gel), to give (108) in 4% yield starting 
from (132) over three steps. Ester (157) was also isolated in 8% yield (Scheme 43). 
Ph 
O O N3 
O N i)­iii) HO 
O HN 
O 
O 
(132) (108) 
(4%) 
O 
O HN 
O 
O 
(157) (8%) 
Reagents and conditions: i) LiOH/ H2O2, 3 h, 0 °C ii) PPh3, N2, room temperature, 30 min then H2O, 60 °C, 16 h iii) 
dioxane, 10% Na2CO3, Fmoc-Cl, 0 °C to room temperature, 16 h. 
Scheme 44: The second preparation of Fmoc­Amoa­OH starting from azide (132) using Fmoc­Cl 
Generation of ester (157) could be explained by formation of the mixed anyhydride 
intermediate, in the presence of excess Fmoc-Cl. Reaction of the mixed anhydride 
with fluoren-9-ylmethanol (from the hydrolysis of Fmoc-Cl) would lead to ester (157) 
(Scheme 44). 
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Scheme 45: Mechanism for the formation of ester (157) 
In order to stop in­situ formation of the mixed anhydride, N­protection was effected 
by using Fmoc-OSu which is a less reactive and a more selective acylating reagent. 
Compound (132) was subjected to the same set of transformations as before on using 
1.04 mmol scale, without isolation or purification of the intermediate precursors. The 
unprotected β-amino acid was treated with Fmoc-OSu under basic conditions for 16 h 
at room temperature. Work-up of the reaction (see Experimental) led to two organic 
extracts. Significant amounts of Fmoc- protected β-amino acid were found in both the 
EtOAc and Et2O extracts. It was decided to purify the crude product contained in both 
extracts by preparative RP-HPLC, which led to Fmoc-Amoa-OH (108) in 28% yield 
over three steps from (132) (Scheme 45) in 100% purity by analytical HPLC analysis. 
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(132) (108) (28%) 
Reagents and conditions: i) LiOH/ H2O2, 3 h, 0 °C ii) PPh3, N2, room temperature, 30 min then H2O, 60 °C, 16 h iii) 
Dioxane, 10% Na2CO3, Fmoc-OSu, 0 °C to room temperature, 16 h. 
Scheme 46: Formation of Fmoc­Amoa­OH using FmocOSu 
2.1.13 Scale­up synthesis of Fmoc­Amoa­OH 
Now that the methodology had been established, the stage was now set to scale up the 
preparation of Fmoc-Amoa-OH. 
Scale up of the synthesis was performed on 20 mmol scale starting from (129) as 
shown in Scheme 46. Treatment of (129) with propanoyl chloride afforded acylated 
auxiliary (130) with 88% yield. The oxidation of homoallylic alcohol (118) to (117) 
was achieved in 81% yield and this was subsequently utilised without delay for the 
key aldol reaction step. Acylated auxiliary (130) was treated of with 1.05 eq TiCl4, 
1.10 eq DIPEA, 1.00 eq NMP and 2.0 eq of aldehyde (117). Work-up of the reaction 
mixture, followed by purification of the crude product by column chromatography, 
led to the isolation of (131) in 72% yield, as a single diastereoisomer with no 
indication of formation of the non-Evans-syn product, and recovery of unchanged 
starting material (130) (14%). Formation of azide (132) was achieved by treatment of 
of (131) using previously investigated Mitsunobu conditions and employing DPPA as 
the nucleophilic azide source to furnish the desired azide (132) in 34% yield along 
with eliminated product (155) (Scheme 46) (32% confirmed by 1H NMR). The 
formation of eliminated product (155) compared to (155a) can be rationalised, as the 
activated hydroxy eliminates to form a carbon-carbon double bond in conjugation 
with the C3 double bond within the side chain and not with the carbonyl. This makes 
these transformations particularly challenging. As mentioned previously, Kogen 
reports the reaction of (137) under similar conditions, leading to the formation of the 
desired azide (137) in high yield. Kogen does not reveal isolating any eliminated 
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product. Compound (137) lacks unsaturation within the side chain compared to the 
aldol product (131). Therefore, we can conclude that the presence of alkene 
functionality at the C3 position within the side chain favours elimination of the 
activated hydroxy. The problem of a competing elimination reaction has also been 
reported with activated alcohols when subjected to azidation conditions.191, 192 
Decreasing the temperature in these cases did not make an improvement when 
attempting to lower the propensity of forming undesired elimination side products.191, 
192 
The formation of (155) was confirmed by 1H NMR which shows the appearance of a 
CH3 doublet. If elimination had occurred to give compound (155a), the corresponding 
methyl group should appear as a singlet which was not the case. 
Removal of the auxiliary of azide (132) was perfomed using LiOH/H2O2 followed by 
subsequent reduction and final N-protection using Fmoc-OSu. Work up of the 
reaction led to two organic extracts as before. Both organic extracts contained 
significant amounts of protected β-amino acid and were purified by preparative RP-
HPLC to yield (108) in an overall 21% over three steps (Scheme 46). 
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Reagents and conditions: i) n-BuLi, propanoyl chloride, N2, -78 °C to room temperature, 16 h ii) TiCl4, DIPEA, N-
methylpyrolidin-2-one, N2, 0 °C, 6 h iii) PPh3, DEAD, N2, -20 °C for 1 h, DPPA, -20 °C to room temperature, 16 h iv) 
LiOH/ H2O2, 3 h, 0 °C v) PPh3, N2, room temperature, 30 min then H2O, 60 °C, 16 h vi) Dioxane, 10% Na2CO3, Fmoc-
OSu, 0 to room temperature, 16 h. 
Scheme 47: Scale up towards the preparation Fmoc­Amoa­OH (108) 
With the final Fmoc-protected β-amino acid at hand, we were in the position to 
proceed and complete the first total novel synthesis of banyasin A. 
2.1.14 Fmoc Solid Phase Peptide Synthesis of banyasin A incorporating Fmoc­

Amoa­OH

As mentioned previously, a specific linear sequence was chosen for solid-phase 
peptide synthesis so as to place the potential Arg(MC)-MePhe cis amide bond mid-
way along the chain and also to create a β-turn about the Arg(MC) and MePhe 
residues as seen in the X-ray structure of the Argifin- AfChiB1 complex (see section 
1.9.3). 
Firstly, the loading of 2-chlorotrityl resin was performed using 3 eq of Fmoc-
Asp(OBut)-OH, and 6 eq of DIPEA to furnish (158). Resin loading was quantified by 
91

removal of the Fmoc protecting group. To determine the amount of Asp loaded onto 
the resin, the filtrate was collected (from Fmoc deprotection), diluted to a known 
volume, and the UV absorbance at 301 nm measured. The absorbance correlated to 
71% loading of Asp onto the resin. The presence of free amino groups was confirmed 
by the Kaiser test; this involves the treatment of 1 mg of resin with test reagent and 
heating. The presence of free amino groups causes the resin beads to change colour 
(from yellow to brown/ green/blue) with no colour change indicating a negative 
result. A Kaiser test or chloranil test (in the case for deprotected 2 ° amines such as N-
Me-Phe-OH) was performed at each stage of Fmoc deprotection and coupling of the 
next amino acid derivative throughout the synthesis. Standard Fmoc solid-phase 
peptide synthesis was performed using 3.0 eq of the required amino acid derivative, 
6.0 eq of DIPEA, 1.9 eq of PyBOP and 2.0 eq HOBt.H2O, for 90 min, except for the 
coupling of Fmoc-Arg(Pmc)-OH, where the use of HOBt.H2O was omitted and 3.0 eq 
of PyBrOP (4 times for 90 min) was used, and for the coupling of Fmoc-Amoa-OH, 
where 1.5 eq of the Fmoc-protected β-amino acid and 1.5 eq of HATU for 3 h were 
used. 
The synthesis of banyasin A is outlined in Scheme 47. Cleavage of the final protected 
linear peptide from the resin was affected by treatment of the resin with 
1%TFA/DCM for 10 x 2 min followed by immediate neutralisaion of the resulting 
filtrate with 10% pyridine in MeOH. Precipitation and centrifugation led to isolation 
of the protected linear peptide (164) in 55% overall yield based on initial resin loading 
and was confirmed by HRMS. Analysis of the isolated linear peptide (164) by RP-
HPLC confirmed that the product was 92% pure. 
The cyclisation of the linear peptide was initially investigated on a small scale (0.181 
mmol). Cyclisation of (164) was performed in DCM (0.1 mM) using 1.0 eq of HATU 
and enough DIPEA to render the reaction mixture to pH 9. The use of HATU was 
employed in preference to PyBOP as it is a very effective coupling reagent for 
couplings where there is a risk of epimerisation and rapid coupling is desired.193-195 
The reaction was monitored by analytical RP-HPLC and indicated almost quantitative 
conversion of linear peptide to cyclised product (165) after 16 h. Work-up of the 
reaction mixture indicated formation of the protected cyclised peptide which was 
confirmed by HRMS. The cyclisation step was performed with the remaining linear 
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peptide (164) using the same conditions. In this case, after 16 h, HPLC analysis of the 
reaction mixture showed that the reaction was incomplete. For this reason, another 
equivalent of HATU was added and the reaction mixture was stirred for a further 16 
h. Again, HPLC analysis of the reaction mixture showed that formation of product 
was occurring, but less effectively than that compared to preliminary studies. 
Treatment of the reaction mixture with another equivalent of HATU for 16 h allowed 
almost quantitative conversion of starting linear peptide (164) to cyclised product 
(165) (see HPLC trace in Fig. 33). Work-up of the reaction was performed as before 
leading to formation of (165) in 77% yield. 
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2 
2 
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WVL:214 nm 
164 
165 
7.00 8.00 9.00 10.00 11.00 12.00 13.00 14.00 
min 
Figure 33: HPLC trace of linear peptide (164) (lower trace) and cyclisation reaction after 
extractive work­up to give (165) upper trace). Both HPLC traces were conducted using system 2, 
gradient 1 (see general experimental) 
The deprotection of cyclic peptide (165) was investigated using two sets of

conditions. Initially, deprotection was performed on a small scale, using a solution of
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TFA/TIS/H2O (95:2.5:2.5). The reaction was monitored by analytical RP-HPLC for 1 
h and showed to give rise to multiple components (Fig. 34). 
We speculated that these multiple products could potentially be due to hydrosilylation 
of the double bond contained within the β-amino acid in the presence of TIS and 
TFA196 . 
The process for the hydrosilylation of olefins have been reported to proceed under 
various conditions such as thermally, using radical initiators, basic conditions, and in 
the presence of transition metals.197 The hydrosilylation of tetrasubstituted olefins 
using chlorosilanes has been reported using a catalytic amount of Lewis acid.197 Other 
reports have indicated the hydrosilylation of olefins with silanes such as TDSCl198 
and TES199 in the presence of Lewis acid. 
It was decided to investigate the deprotection of (165) using TFA/DCM (1:1), 
omitting the use of TIS. Analytical RP-HPLC and HRMS revealed exclusive 
formation of deprotected cyclic peptide (166) (Fig 34). It was therefore decided to 
proceed with the deprotection of the remaining protected cyclised precursor using 
these conditions. Precipitation and centrifugation of the reaction mixture, led to the 
isolation of (166) in 76% yield which was confirmed by analytical RP-HPLC and 
HRMS. 
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Figure 34: HPLC profiles of cyclised peptide (165) (lower trace), cyclised peptide (165) treated 
with TFA/TIS/H2O (95:2.5/2.5 v/v/v, middle trace) and TFA/DCM 1:1, v/v, upper trace), 
performed using system 2, gradient 1 (see general experimental) 
With the cyclised, deprotected peptide (166) in hand, the final reaction towards the 
total novel synthesis of banyasin could be attempted. The acylation of (166) was 
performed using the same conditions as that reported for argifin involving the use of 
3.0 eq of the active ester, succinimidyl-N-methylcarbamate, and 6.0 eq of DBU. The 
reaction was monitored for 2 h by analytical RP-HPLC at which point complete 
consumption of starting material was observed, together with the formation of several 
new products. However, the presence of undesired diacylated material was not 
detected. The crude product was purified by semi-preparative RP-HPLC to afford 
(167) as the TFA salt, in 14% yield. 
The preparation of banyasin A by solid-phase peptide synthesis and solution phase 
acylation is summarised in Scheme 47. 
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Reagents and conditions: i) 2-chlorotrityl resin, Fmoc-Asp(OBut)-OH, DIPEA, DCM, N2, room temperaure, 90 min 
ii) piperidine/DMF (v/v, 1:4), 4 x 3 min iii) Fmoc-MePhe -OH, DIPEA, PyBOP, HOBt, DMF, room temperature, 90 
min iv) Fmoc-Arg(Pmc)-OH, DIPEA, PyBrOP, DMF, 4 x 90 min v) Fmoc-Amoa-OH (x), HATU, DIPEA, DMF, 4.5 
h vi) Fmoc-Ala-OH, HATU, DIPEA, DMF, 90 min vii) 1%TFA/DCM (v/v 1:99), 10 x 2 min viii) HATU, 
DIPEA,DCM, room temperature 36 h, ix) TFA/DCM (v/v, 1:1), room temperature, 1 h x) DBU, N-succinimidyl-N-
methylcarbamate, DMF, 40 °C, 3 h. 
Scheme 48: The synthesis of Banyasin A 
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Initially, compound (167) was isolated as a single peak by analysis using RP-HPLC. 
Re-analysis of the isolated material by RP-HPLC showed the appearance of two 
components when varying the composition of the mobile phase. It was decided to 
isolate the two components by semi-preparative HPLC using an isocratic gradient 
(system 1, gradient 10 where A and B contained 0.1% FA, see general experimental). 
Analysis of the combined isolated fractions of the two individual peaks, by analytical 
RP-HPLC, showed an analogous HPLC trace prior to re-purification (Fig 35). 
Analysis of the isolated material by 1H NMR and analytical RP-HPLC showed the 
presence of a mixture of cis and trans isomers that exists around the Arg(MC)-MePhe 
peptide bond. Multiple signals in the α-proton region are consistent with the existence 
of at least two conformations in solution, which slowly interconvert under HPLC 
conditions. 
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Figure 35: HPLC profiles of (167) upon first purification (lower trace). Reanalysis of the first 
component by analytical HPLC (middle trace), and second component (upper trace), all 
performed using system 1, gradient 10 (see general experimental) 
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The proton NMR data from Pluotno and Carmelli128 reveals five distinct α protons 
when the isolated natural product was analysed by 1H NMR using 20% CD3OH and 
CDCl3 suggesting a single conformer in solution. Pluotno and Carmelli also report a 
high-field CH2 proton signal of MePhe and observe a NOE between the α protons of 
Arg(MC) and MePhe. This feature is also observed in the 1H spectrum of argifin, 
therefore the isolated natural product isolated by Pluotno and Carmelli exists as a 
single conformer in solution and has cis configuration about the key Arg(MC)MePhe 
bond as in argifin itself. 
Cis­trans isomerisation has often been observed in peptides containing Pro 200-202 and 
other hindered residues.203 Peptides that include N-methylated amino acid residues 
have also been reported to display cis­trans isomerisaion204-206 and have been 
investigated using 1H NMR and RP-HPLC techniques. Tetra and octapeptides that 
contained N-methylated residues, at various positions within the peptide chain, were 
studied by Sykora and co-workers206 to determine their RP-HPLC profiles. Peptides 
exhibiting cis/trans isomerisation of the R1CO-N(Me)R2 peptide bond showed broad 
peaks. Factors that contributed to peak broadening were found to be nature of the 
surrounding amino acid residues, location of the peptide bond within the chain, 
temperature and mobile phase flow rate. Separation of the two forms of some N-
methylated tetra and octapeptides were attempted in this study by RP-HPLC but each 
form reconverted to the same equilibrium composition prior to purification.206 This is 
analogous to the behaviour of synthetically prepared banyasin A upon RP-HPLC 
analysis. 
To investigate whether we could drive the equilibrium of isomerisation towards a 
single conformer, RP-HPLC experiments were investigated using an increase in 
temperature from 35 °C to 45 °C. This did not lead to any clear change with regards 
to the HPLC profile. Alternatively, cooling to 22 °C did not lead to any change by 
HPLC analysis. It has been noted that nearly complete separation of conformers has 
been achieved by RP-HPLC using fast flow rates and short columns.206 Such methods 
could however not be investigated. 
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2.2 Investigations towards the synthesis of Fmoc­(2R, 3S)­Amoa­OH 
The preparation of both syn diastereoisomers of Amoa would involve development of 
a synthetic strategy that would incorporate a double inversion step from aldol product 
(131) to azide (169), for which techniques have been employed on a similar system.141 
Our initial synthetic strategy involved preparation of bromide (168) which initially 
involved mesylation of aldol (131). The crude mesylate was used without further 
purification and treated with LiBr at 75 °C for 16 h. Work-up and purification of the 
crude reaction mixture furnished bromide (168) in 13% yield (Scheme 48). Two other 
components were also isolated but could not be identified. Neither component 
corresponded to elimination products or recovered starting material. The preparation 
of bromide (168) was achieved in higher yield by treating (131) with CBr4 and PPh3. 
Purification of the crude reaction mixture by column chromatography afforded 
bromide (168) in 34% yield along with eliminated material (155) in 30 % yield 
(Scheme 48). An attempt towards the preparation of azide (169) by the treatment of 
bromide (168) (0.03 mmol scale) with NaN3 and 15-crown-5 was performed in DMF, 
at 60°C for 16 h as described by Kimura et al.141 Purification of the crude reaction 
mixture by column chromatography gave three main fractions. Analysis of the three 
isolated components by HPLC showed that they were however all of high purity. The 
three components were also analysed by HRMS which indicated that all three 
components contained eliminated material and not the desired azide. 
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Reagents and conditions: i) MsCl, Et3N, DCM, 0 °C, N2, 3 h ii) LiBr, acetone, N2, 75 °C, 16 h iii) CBr4, PPh3, N2, 
THF, room temperature, 16 h iv) NaN3, 15-C-5, DMF, N2, 60 °C, 16 h 
Scheme 49: Investigations towards the preparation of the (2R, 3S)­azide (169) using double

inversion strategy
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2.3	 Structure­Based Dissection of the Natural Product 
Cyclopentapeptide Chitinase Inhibitor Argifin. 
As mentioned previously (section 1.9.3), argifin displays inhibition of family 18 
chitinases in the nM range but does not possess “drug-like” properties according to 
Lipinski’s rule of five.88, 207 X-ray structures of argifin bound to a variety of family 18 
chitinases have revealed that the N-methylcarbamoyl-Arg residue (Arg(MC)) and the 
adjacent MePhe unit are essential for biological activity, which decreases significantly 
when this dipeptide motif is modified within the cyclic peptide.103 
For these reasons, we were interested in observing whether linear fragments of argifin 
and banyasin A that contain the key Arg(MC)-MePhe dipeptide unit would still retain 
any biological activity against family 18 chitinases. It was decided to synthesise linear 
peptides containing this motif (Fig. 36). Our choice of peptide sequence and chain 
length again stems from the observation that there is a β-turn about the Arg(MC) and 
MePhe residues of argifin in the X-ray structure of the enzyme-inhibitor complex with 
AfChiB1 (see section 1.9.3). The reason for N-terminal acetylation of all three 
peptides was to maintain the possibility of forming an intramolecular hydrogen bond 
to stabilise a turn-like structure. It was decided to start with the synthesis of tripeptide 
(171). This would be performed by SPPS using 2-chlorotrityl resin and would be 
followed by the synthesis of the tetrapeptide (170) and dipeptide (172) (Fig. 33). 
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Figure 36: The structures of tetrapeptide (170), tripeptide (171) and dipeptide (172) 
2.3.1 Synthesis of of argifin fragments by a combination of SPPS and solution 
phase chemistry. 
We initially attempted to prepare the tripeptide entirely by solid-phase chemistry, 
incorporating the Arg(MC) residue via an Orn residue (Scheme 49) as recently 
reported for the synthesis of argifin analogues103 and the synthesis of argadin.90 The 
first step for the synthesis of the tripeptide was to load Fmoc-Asp(OtBu)-OH on to the 
resin (2.0 eq) using DIPEA (4.0 eq) as base in DMF. Fmoc deprotection using 
piperidine/DMF solution (1:4) followed, which gave 57% loading of Asp onto the 
resin. Following loading of the resin, coupling of Fmoc-MePhe-OH was successfully 
achieved using PyBOP and HOBt activation. Fmoc deprotection, followed by 
coupling of Fmoc-Orn (Dde)-OH was then performed using PyBrOP activation. 
Removal of the Fmoc group followed by acetylation off the N-terminus using acetic 
anhydride then completed the assembly of the tripeptide backbone. At this stage a 
102 
small amount of resin was cleaved using 1% TFA-DCM solution and the filtrate 
neutralised with 10% pyridine/MeOH solution, in order to prevent cleavage of the 
acid-labile tert-butyl ester protection of the Asp residue. The filtrate was analysed by 
mass spectrometry and RP-HPLC, which showed the expected protected tripeptide to 
be present. The rest of the resin was treated with 5% hydrazine-water-DMF solution 
(Dde deprotection). The deprotected ornithine side chain was then guanylated to 
arginine using 1 H-pyrazole-1-carboxamidine hydrochloride (5 eq) and DIPEA (10 
eq) for 2 h. A small amount of compound was cleaved off the resin and analysed by 
mass spectrometry and RP-HPLC to confirm that the reaction was successful. 
Following the Orn guanylation step, the acylation of the newly formed arginine side 
chain was attempted “on resin” using succinimidyl-N-methylcarbamate (3 eq) and 
DBU as base (3 eq). Analysis by HPLC of material cleaved off the resin showed 
formation of a small amount of product. The solid-phase reaction was then repeated 
using further succinimidyl-N-methylcarbamate (6 eq) and DBU (3 eq), and the 
products obtained after resin cleavage analysed by HPLC (Fig. 38) and mass 
spectrometry. This showed the presence of starting material (178), the correct 
acylated product (171) and diacylated product (179) (Fig. 37). 
Due to the difficulty in carrying out the acylation reaction on solid phase it was 
decided to attempt the acylation step of the Arg side chain in solution following 
cleavage from the solid support. The fully deprotected Arg tripeptide was obtained by 
treatment of the resin with TFA/thioanisole/DCM/H2O (16:2:1:1), and reacted with 
succinimidyl-N-methylcarbamate (6 eq) and DBU (3 eq) for 2 h at 40 °C. Work up of 
the reaction and analysis by HPLC showed little conversion to (171). Analysis of the 
reaction mixture by mass spectrometry again indicated the presence of unacylated 
starting material (178), acylated product (171) and diacylated material (179) (Fig. 37). 
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Reagents and conditions: i) 2-Chlorotrityl resin, Fmoc-Asp (OBut)-OH, DIPEA, DCM, 90 min ii) Piperidine/DMF (v/v,1:4), 4 x 
3 min iii) Fmoc-NMePhe-OH, PyBOP, HOBt, DIPEA, DCM/DMF (v/v 3:1), 90 min iv) Fmoc-Orn(Dde)-OH, PyBrOP, 
DIPEA, DCM/DMF (v/v 3:1), 90 min v) Ac2O/pyr/DCM (2:18:1), 35 min vi) H2NNH2/DMF (1:49 v/v), 2 x 15 min then 1H-
pyrazole-1-carboxamide hydrochloride, DIPEA, DMF, 1h vii) DBU, succinimidyl-N-methylcarbamate, DMF, 40 °C, 36 h viii) 
TFA/thioanisole/DCM/H2O (16:2:1:1), 2 h 
Scheme 50: Attempted synthesis of tripeptide (171) 
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Figure 37: Structures of starting material (178), the desired acylated product (171), and 
diacylated product (179) 
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WVL:214 nm 
171 
179 
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4.0 6.0 8.0 10.0 12.0 14.0 16.0 18.0 
min 
Figure 38: HPLC trace of attempted "on­resin" acylation (178) tR = 9.09, (171) tR = 10.00, (179) tR 
= 10.41 
In order to further investigate further the final acylation step, the Arg-containing 
peptide was resynthesised directly following the procedure outlined in Scheme 50 but 
using Fmoc-Arg(Pmc)-OH in place of Fmoc-Orn(Dde)-OH. The resin sample was 
split in half. One half was used to obtain (171) by treatment with 
TFA/thioanisole/DCM/H2O (16:2:1:1), as used for the deprotection of the protected 
cyclic precursor of argifin, which cleaved off both acid-labile protecting groups (tBu 
and Pmc).89 The other sample was used to assemble the desired tetrapeptide 
derivative. In this case, Fmoc deprotection followed by coupling with Fmoc-D-Ala-
OH gave (184) (Scheme 50). Fmoc removal and N-terminal acetylation then gave 
(185), which was cleaved as before (TFA/thioanisole/DCM/H2O) and the products 
analysed by HPLC and MS, which confirmed the successful preparation of 
deprotected tetrapeptide. Modification of the free Arg residues of the deprotected 
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tripeptide and tetrapeptide was attempted in parallel using succinimidyl-N-
methylcarbamate (3 eq) and DBU (6 eq) in DMF at 40 °C for 12 h. HPLC and MS 
showed only unchanged starting materials and did not show any signs of arginine 
acylation under these conditions. Finally, conditions for successful acylation were 
found using succinimidyl-N-methylcarbamate (9 eq) and DBU (6 eq) at 40 °C for 36 
h. The acylation step was relatively more difficult compared to that of argifin and 
banyasin. This could be explained by the fact that the linear fragments are less rigid, 
more flexible molecules that could be extensively internally hydrogen bonded 
compared to the cyclic pentapeptides. This causes the free amine of the arginine side 
chain to be less accessible. The crude products were finally purified by HPLC to gave 
the desired tetrapeptide (170) and tripeptide (171) (TFA salts) as white solids. 
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Reagents and conditions: i) 2-Chlorotrityl resin, Fmoc-Asp(OBut)-OH, DIPEA, DCM, 90 min ii) Piperidine/DMF (1:4 v/v), 4 x 3 min iii) 
Fmoc-MePhe-OH, PyBOP, HOBt, DIPEA, DCM/DMF (3:1 v/v), 90 min iv) Fmoc-Arg(Pmc)-OH, PyBrOP, DIPEA, DCM/DMF (3:1 
v/v), 90 min v) Ac2O/pyr/DCM (2:18:1), 35 min vi) TFA/thioanisole/DCM/H2O (16:2:1:1), 2 h, vii) succinimidyl-N-methylcarbamate, 
DMF, 40 °C, 36 h viii) Fmoc-D-Ala-OH, PyBOP, HOBt, DIPEA, DCM/DMF (3:1 v/v), 90 min 
Scheme 51: Parallel synthesis of (170) and (171) 
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Synthesis of the dipeptide (172) (Scheme 51) was performed in an analogous manner. 
Fmoc-MePhe-OH was successfully loaded onto the resin as before, followed by Fmoc 
deprotection and coupling of Fmoc-Arg(Pmc)-OH. The protected dipeptide (187) was 
N-acetylated using the same conditions used previously. Resin-bound peptide (188) 
was cleaved from the resin and deprotected, as before, and the resulting crude 
material was analysed by HPLC and MS to confirm that deprotection was succesful. 
Acylation of the free arginine side chain in solution was attempted by initially treating 
the crude deprotected dipeptide with succinimidyl-N-methylcarbamate (3 eq) and 
DBU (6 eq) at 40 °C. No reaction was observed by HPLC or MS. Using a larger 
excess of reagents (succinimidyl-N-methylcarbamate (6 eq) and DBU (12 eq)) did 
however lead to disappearance of starting material and the formation of (172). In 
terms of the efficiency of Arg side-chain derivatisation for the three peptides (170), 
(171) and (172), the conditions used for the acylation of the tripeptide and tetrapeptide 
gave only the mono-acylated product with no occurrence of diacylation, compared to 
the dipeptide which also gives diacylated material. The overall yields of (170) and 
(171), after HPLC purification, were respectively 26%, 14% based on 0.21 mmol 
starting resin, and 7% for (172) based on 0.28 mmol starting resin. The lower yield of 
the dipeptide reflects the formation of other products in addition to the desired 
peptide. HPLC traces of all three isolated peptides are shown in Figure 39. 
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Reagents and conditions: i) 2-chlorotrityl resin, Fmoc-NMePhe-OH, DIPEA, DCM, 90 min, ii) piperidine/DMF 
(v/v 1:4), 4 x 3 min iii) Fmoc-Arg(Pmc)-OH, PyBrOP, DIPEA, DCM/DMF (v/v 3:1), 90 min iv) Ac2O/DCM/pyr 
(1:9:0.5), 35 min v) TFA/thioanisole/DCM/H2O (16:2:2:1), 2hrs vi) DBU, succinimidyl-N-methylcarbamate, 
DMF, 40 °C, 36 h. 
Scheme 52: Synthesis of dipeptide (172) 
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Figure 39: HPLC trace of final tetrapeptide (170) (lower trace), tripeptide (171) (middle trace) 
and dipeptide (172) (upper trace), performed using system 1, gradient 1 (see general 
experimental). 
2.3.2 The preparation of Ac­Arg(MC)­NHCH3 
In view of the observation that the di-, tri- and tetra-peptides retain biological activity 
but also bind to family 18 chitinases in a very similar fashion to argifin (see section 
2.7), we were interested to try and find the minimum derivative of this sort which 
would still show some activity. We therefore attempted to prepare a simple derivative 
(192) representing the Arg(MC) itself, and a further compound representing just its 
side chain (see section 2.3.3). 
We initially decided to investigate the synthesis of (192) using the protocol outlined 
in Scheme 52. This involved conversion of Fmoc-Arg(Pmc)-OH (189) to the methyl 
amide (190) using PyBOP activation and methylamine hydrochloride which proved to 
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be unsuccessful. Compound (190) was successfully synthesised in 80% yield using 
HOBt-EDC activation208 (Scheme 52). Attempted acetylation of the N-terminus of 
(190) with acetic anhydride, following Fmoc deprotection with diethylamine failed, 
with no reaction occurring. We speculated that this was due to the steric bulk of the 
protected arginine (Pmc) side chain. For this reason, the reaction was repeated under 
the same conditions, but with the addition of 1.0 eq DMAP. The utilisation of DMAP 
causes generation of an acyl pyridinium intermediate, an activated species prone to 
nucleophilic attack by the free amine.209, 210 This furnished (191) in 43% yield 
(Scheme 52). Cleavage of the Pmc group followed by modification of the Arg side 
chain was then attempted using succinimidyl-N-methylcarbamate (6 eq) and DBU (3 
eq) at 40 °C but no formation of the desired product (192) could be detected by TLC 
or by MS and indicated presence of the unmodified, deprotected Arg derivative. 
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Reagents and conditions: i) EDC.HCl, HOBt, DCM/DMF (v/v 1:1), 0 °C, overnight ii) Et3N, 45 min, 
DMF, room temperature iii) Ac2O, DMAP, DIPEA, DCM, 0 °C iv) TFA/DCM (v/v 1:1), 30 min v) 
succinimidyl-N-methylcarbamate, DBU, DMF, 40 °C, 36 h. 
Scheme 53: Attempted synthesis of compound (192) 
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Synthesis of (192) was attempted by transformation of Fmoc-Orn(Boc)-OH to the 
methyl amide (194) in 89% yield with conditions used for the synthesis of (190). 
Cleavage of the Fmoc group of (194) and acetylation furnished (195) in 73% yield. 
Removal of the Boc group of (195) using 4M HCl in dioxane was followed by an 
attempt to introduce the key Arg(MC) motif, by using a one-step transformation 
directly via the deprotected ornithine side chain, using guanylating reagent (196) 
kindly provided by Dr. Mark Dixon. Analysis of the crude reaction mixture by mass 
spectrometry and RP-HPLC only showed the presence of unchanged starting material 
(Scheme 54). 
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Reagents and conditions: i) HOBt, EDC.HCl, DIPEA, MeNH2.HCl, DCM/DMF, (1:1 v/v), 0 °C to room temperature, 
16 h ii) diethylamine, DCM/DMF (1:1 v/v), room temperature, 45 min iii) DIPEA, DMAP, Ac2O, DCM, 0 °C to 
room temperature, 16 h iv) 4M HCl in dioxane, 20 min v) (196), DBU, DMF, room temperature, 72 h. 
Scheme 54: Attempted synthesis of (192) using guanylating reagent (196) 
Successful preparation of (192) was finally achieved once methyl isocyanate was 
available, a more reactive acylating reagent than succinimidyl-N-methylcarbamate.211 
Methylisocyanate was not available when this work began. Removal of the Pmc 
group of (191) was effected by treatment with TFA:DCM (1:1) to give the 
deprotected peptide as the TFA salt and was used without further purification. The 
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crude deprotected peptide was initially treated with methyl isocyanate (0.5 eq) at 
room temperature for 5 h211 and then heated to 30 °C for 30 min. Work-up of the 
reaction mixture and analysis by analytical RP-HPLC and HRMS revealed the 
presence of deprotected starting material only. The reaction was repeated again using 
the same conditions and stirred at room temperature for 16 h. Work-up of the reaction, 
in the usual manner, followed analytical RP-HPLC and HRMS analysis, showed the 
formation of product (192) and deprotected starting material. Purification of the crude 
product by semi-preparative RP-HPLC furnished analytically pure (192) as the TFA 
salt in 8% yield (Scheme 54). 
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Reagents and conditions: i) TFA/DCM (v/v 1:1), 30 min room temperature ii) Dowex OH 
resin, MeOH, 1 h iii) methyl isocyanate, DMF, N2, room temperature, 16 h. 
Scheme 55: The successful preparation of (192) 
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Figure 40: HPLC trace of “monopeptide” (192) performed using gradient 1, system 1 (see general 
experimental for details) 
2.3.3 The preparation of N­methyl­N­guanyl urea 
In order to truncate the argifin scaffold further and identify the pharmocophore, the 
preparation of (198) was thoroughly investigated. Initially, 1-methylguanidine 
hydrochloride was treated with DBU (3 eq) and succinimidyl-N-methylcarbamate (6 
eq). The reaction was performed at 40 °C, as for the preparation of peptide fragments 
(170­172), and was monitored by HPLC and MS over a period of 4 days. This did not 
indicate any change or formation of the desired product. It was then decided to 
neutralise 1-methylguanidine hydrochloride (197) with Dowex –OH resin, as reported 
by Piskala,211 prior to treatment with DBU (3 eq) and N-succinimidyl-N-methyl 
carbamate (6 eq) at 40 °C (Scheme 55). This also did not indicate formation of the 
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desired product by analysis with MS and HPLC but showed recovery of unchanged 
starting material. 
i) 
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H H HN N N N 
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1) Reagents and conditions: DBU, succinimidyl-N-methylcarbamate, 40 °C, DMF, 4 days 
Scheme 56: Attempted synthesis of (198) 
A one-step procedure for the direct transformation of the Orn side chain to Arg(MC) 
“on-resin” has been achieved using (196) when investigating new methods towards 
the preparation of argifn and related analogues.103 The utilisation of excess (196), for 
extensive periods of time only led approximately 15% conversion for this step.103 For 
this reason a one-step preparation was attempted by guanidination of methylamine 
(199) with (196) which again, was kindly provided by Dr. M. J. Dixon. 
Excess methylamine (10 eq) was treated with (196) for 72 h in DMF at room 
temperature (Scheme 56). The reaction failed and showed the presence of unchanged 
(196) by analysis with TLC, MS, HPLC and 1H NMR. 
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Scheme 57: Attempted synthesis of (198) using guanylating reagent (196) 
Compound (198) was finally obtained uing the same conditions as for the preparation 
of (192) by neutralisation of (197) with Dowex –OH resin, prior to treatment with 
methyl isocyanate.211 Analysis of the crude reaction mixture by HRMS showed the 
presence of desired acylated product as well as diacylated material. Purification of the 
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crude mixture by preparative HPLC led to the isolation of (198) in 25% yield (see 
Figure 41 for HPLC trace of (198). 
WVL:214 nm 
198 
0.0 1.3 2.5 3.8 5.0 6.3 7.5 8.8 10.0 12.1 
Figure 41: HPLC trace of N,N­dimethylguanylurea derivative (198) performed using gradient 6, 
system 2 (see general experimental) 
2.3.4 The preparation of dipeptide (200) and (201) 
The X-ray structure of dipeptide (172) with AfChiB1 reveals that there is a loss of of 
an internal H-bond compared to the tetra and tripeptide derivative (see section 2.7.1.3) 
and that the bioactive conformation of dipeptide (172) shows a trans amide bond 
about the Arg(MC)-MePhe motif. We envisaged that dipeptide derivative (200) and 
(201) (Fig. 42), incorporating a C-terminal methyl amide, may possibly re-establish 
this internal hydrogen bond and could potentially contribute to cis conformation about 
the Arg(MC)-MePhe amide bond (Fig. 43). 
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The key difference of dipeptide (172) to (200) and (201) is replacement of the MePhe 
residue for Phe. The reason for this modification was to investigate whether removal 
of an N-methylated residue (previously seen to be essential for activity)103 and still 
potentially restoring an internal H-bond, leads to an effect in activity towards family 
18 chitinases. 
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Figure 42: The structure of demethylated dipeptide (200) and methylated dipeptide (201) 
containing MePhe residue 
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Figure 43: Possible β­turn conformations of dipeptide derivatives (200) and (201), internal 
hydrogen bond depicted with dashed line. 
2.3.4.1 The preparation of (200) 
The first step towards preparing (200) involved formation of methyl amide (204) 
(Scheme 57). Boc-Phe-OH was treated with HOBt, EDC.HCl, DIPEA and 
methylamine hydrochloride followed by work-up and purification of the crude 
product by column chromatography to furnish (204) in 63% yield. Formation of 
dipeptide (205) was achieved by removal of the Boc group followed by the coupling 
of Fmoc-Arg(Pmc)-OH using PyBrOP activation. Isolation of (205) was achieved in 
43 % yield. Removal of the Fmoc blocking group of (205) under basic conditions, 
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followed by subsequent N­acetylation and purification of the crude product furnished 
the acetylated protected dipeptide (206) in 39% yield. Finally, removal of the Pmc 
group under acidic conditions was subsequently followed by neutralisation of the 
resulting TFA salt using Dowex –OH resin. Acylation of the crude precursor was 
achieved by treatment with succinimidyl-N-methylcarbamate (6 eq) and DBU (3 eq) 
in DMF at 40 °C for 3 h. Purification of the crude product by preparative RP-HPLC 
led to the the isolation of (200) as the TFA salt with 77% yield. 
The preparation of (201) involved the same set of transformations and using the same 
conditions starting from Boc-MePhe-OH (207) (Scheme 57). Purification of the final 
crude product by preparative RP-HPLC resulted in the isolation of (201) as the TFA 
salt with 42% yield from (210). 
Analysis of (201) by high resolution 1H NMR revealed the presence of geometrical 
isomers resulting from cis and trans isomerisation about the Arg(MC)-MePhe peptide 
bond. Analysis of dipeptide derivative (200) by analytical RP-HPLC revealed a single 
species (Fig. 44). Analysis of the 1H NMR spectrum of (200) reveals the presence of a 
single isomer. Removal of the methyl group of NMePhe causes isomerisation to the 
more energetically favoured rotamer compared to (201). The more stable rotamer 
causes a trans amide bond to exist in dipeptide (200) about the Arg(MC)-MePhe 
motif. 
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Reagents and conditions: i) HOBt, EDC.HCl, H2NMe.HCl, DIPEA, 1:1 DCM/DMF, 0 °C 1 hr, room temperature, 16 h 
ii) 4M HCl/dioxane, room temperaure, 1h iii) DIPEA, PyBrOP, Fmoc-Arg(Pmc)-OH, DCM, 0 °C to room temperature, 
16 h iv) Et2NH,1:1 DCM/DMF, room temperature, 1 h v) DIPEA, DMAP, Ac2O, DCM, 0 °C to room temperature, 16 h 
vi) 1:1 TFA/DCM, 30 °C, 3h, Dowex OH resin vi) succinimidyl-N-methylcarbamate, DBU, DMF, 40 °C, 3h. 
Scheme 58: The synthesis of dipeptide (201) (R = Me) and dipeptide (200) (R = H) 
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Figure 44: HPLC trace of dipeptide (200) (lower trace) and dipeptide (201) (upper trace) 
performed using gradient 1, system 1 (see general experimental) 
2.4 The preparation of α­argifin 
We speculated that reducing the ring size of argifin would enable it to bind deeper 
into the active site of family 18 chitinases as seen in the X-ray crystal structure of the 
argadin-AfChiB1 complex which also has a smaller peptide-backbone ring size than 
argifin. This was investigated through the preparation of α-argifn. Whereas argifin 
contains a β-linkage between the two terminal Asp residues, α-argifin would be α-
linked, which would reduce the overall backbone, ring size and could potentially lead 
to deeper binding and affinity for the active site, in-turn resulting in an increase in 
inhibitory activity towards family 18 chitinases. 
The preparation of α-argifin (Scheme 59) followed a similar protocol as for the 
literature procedure of argifin itself.89 The synthetic approach to (219) involved 
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Fmoc-based solid-phase peptide synthesis of the orthogonally protected linear 
pentapeptide. The assembly of peptide (215) on 2-chlorotrityl polystyrene resin was 
performed using 3 eq of Fmoc-protected amino acids and PyBOP activation, except 
for the coupling of Fmoc-Arg(Pmc)-OH to the hindered MePhe residue which 
required the use of PyBrOP. Cleavage from the resin with 1% TFA/DCM gave (216) 
in 44% yield based on the original resin loading. The cyclisation of (216) to the fully 
protected cyclic pentapeptide (217) proceeded efficiently in DCM using HATU 
activation and DIPEA as base. Peptide (217) was isolated in 79% yield after simple 
extractive work-up. Analytical RP-HPLC and HRMS indicated formation of (217) 
with no evidence of oligomeric side products. The choice of linear sequence and point 
of cyclisation was decided so as to place potential turn-inducing residues (MePhe, D-
Ala) in the second and fourth positions of the sequence, respectively (see section 
1.9.3). 
The synthesis was completed by removal of the Pmc and tBu protecting groups of 
(217) by treatment with TFA/TIS/H2O (95:2.5:2.5) for 1 h. RP-HPLC analysis 
revealed full conversion to (218). Isolation of (218) by precipitation and 
centrifugation gave (218) as the TFA salt in 98% yield. Introduction of the N-methyl 
carbomyl group onto the Nω position of the Arg side chain was achieved by treating 
(218) with 3 eq of succinimidyl-N-methylcarbamate in DMF at 40 °C with DBU as 
base. Purification of the crude product by preparative RP-HPLC furnished (219) in 
15% yield. Diacylated material was also isolated in 4% yield. 
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Reagents and conditions: i) 2-Chlorotrityl resin, Fmoc-Asp (OBut)-OH, DIPEA, DCM, 90 min ii) Piperidine/DMF (v/v,1:4), 4 x 3 min iii) 
Fmoc-NMePhe-OH, PyBOP, HOBt, DIPEA, DMF (v/v 3:1), 90 min iv) Fmoc-Arg(Pmc)-OH, PyBrOP, DIPEA, DMF (v/v 3:1), 4 x 90 
min v) Fmoc-D-Ala-OH, PyBOP, HOBt, DIPEA, DMF (v/v 3:1), 90 min vi) Fmoc-Asp (OBut)-OH, PyBOP, HOBt, DIPEA, DMF (v/v 
3:1), 90 min vii) TFA/DCM (1:99 v/v) 10 x 2 min viii) HATU, DIPEA, DCM, 14 h, 79% ix) TFA/TIS/H2O (v/v/v 95:2.5:2.5), 1 h x) 
DBU, succinimidyl-N-methylcarbamate, DMF, 40 °C, 3 h. 
Scheme 59: The synthesis of α­argifin 
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2.5 Investigating aspartimide formation in argifin 
Initial studies towards the synthesis of argifin encountered quantitative formation of 
aspartimide when preparing the linear sequence H-D-Ala-Arg(Pmc)-MePhe-β-
Asp(OBn)-β-Asp(OBn)-OH on 2-chlorotrityl resin.89 Aspartimide formation occurred 
on exposure to a single cycle of Fmoc deprotection using a solution of 
piperidine/DMF (1:4 v/v). This observation demonstrated the sensitivity of benzyl 
ester protection of aspartic acid to basic conditions. Utilisation of tert­butyl protection 
has been shown to reduce the formation of aspartimide products compared to peptide 
sequences containing benzyl ester protection groups. 104 The assembly of H-β-
Asp(OBut)-D-Ala-Arg-(Pmc)-MePhe-β-Asp(OBut)-OH eliminated base-induced 
aspartimide formation using 2-chlorotrityl resin as solid support. There have been 
reports for the formation of aspartimides212-214 under strongly acidic or basic 
conditions (Scheme 60). Formation of aspartimides is highly sequence dependant 
when using But or benzyl protected aspartic acid and asparagine derivatives.215 
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Scheme 60: Formation of aspartimide (220) and subsequent ring opening to possibly furnish α or 
β­peptides 
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Dolling et al215 investigated the formation of aspartimide by synthesising certain 
analogues of the corticotrophin-releasing hormone CRH with D-amino acid 
replacements. For the analogue of CRH containing D-Leu186 and D-Ala,187 next to 
Asp(OBut)-Gln(Trt), aspartimide and β-piperidide formation was indicated by 
analysis of the crude product by HPLC/ES-MS. Treatment of the crude peptide with 
aqueous NaOH also led to formation of both α and β-peptides through ring-opening of 
the aspartimide at the α and β positions of the succinimide.215 The formation of 
aspartimide is more favourable in Asp-Gly sequences.216 The analysis of aspartyl 
peptide degradation products by HPLC and HPLC-ESMS was investigated by De 
Boni et al.216 Degradation products of the model aspartyl tripeptides Phe-Asp-Gly-
NH2 and Gly-Asp-Phe-NH2 were incubated at acidic and basic pH and the resulting 
peptides were isolated by HPLC to reveal formation of L-Phe-α-L-Asp-Gly-NH2/L-
Phe-β-L-Asp-Gly-NH2 and L-Phe-α-D-Asp-Gly-OH/ L-Phe-β-D-Asp-Gly-OH, caused 
by enantiomerisation of the acidic α-succinimidyl carbon to the D and L forms. Under 
acidic conditions, the major compound formed was the succinimidyl peptide. At 
alkaline pH, both deamination of the C-terminal amide was observed in addition to 
isomerization and enantiomerisation. 
Gypsophin, interestingly a novel α-glucosidase inhibitory cyclic peptide from the 
roots of Gypsophila oldhamiana, is an example of a natural product that contains an 
aspartimide residue217 (Fig. 45). 
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Figure 45: Structure of Gypsophin, aspartimide residue depicted in green 
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New methodology towards the preparation of argifin and argifin scaffolds for SAR 
studies was developed by Dixon et al103 to circumvent the problem of aspartimide 
formation upon cleavage of the Arg(Pmc) protecting group. The synthesis involved 
loading of Fmoc-Asp OAll (221) to 2-chlorotrityl resin incorporating Orn(Dde) in 
replacement of Arg(Pmc) and is summarised in Scheme 60. The final step involved 
removal of the tert-butyl protection group and release from the solid support. Despite 
varying acid concentration and contact time using TFA/DCM, formation of 
aspartimide products sill resulted. A two-step deprotection procedure was therefore 
used. Initially, cleavage of peptide (227) from the resin was performed by treatment 
with TFA/DCM (1:99 v/v) which kept the non-terminal aspartic acid derivative 
protected as the tert-butyl ester. The tert-butyl group of (228) was removed under 
mild acidic conditions using 1M HCl at 60 °C for 90 min to give quantitative and 
exclusive formation of (229) (Scheme 60). Therefore, the synthesis of argifin using 
this protocol was achieved with an overall yield of 18% over 17 steps with the need of 
only a final HPLC purification. 
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Reagents and conditions: i) 2-Chlorotrityl chloride polystyrene resin, DIPEA, DCM, 60 min ii) Fmoc SPPS iii) Pd(Ph3P)4, PhSiH3, DCM, 
3 x 20 min iv) piperidine/DMF (1:4 v/v), 4 x 3 min v) PyBOP, DIPEA, DCM, 2 x 60 min vi) H2HNH2/DMF (1:49 v/v), 2 x 15 min vii) 
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TFA/DCM (1:99), 10 x 2 min x) 1 M HCl, 60 °C, 90 min. 
Scheme 61: The preparation of argifin using a final novel acidolysis procedure 
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Although this synthetic route apparently eliminates the problem of aspartimide 
formation in the final deprotection, via the novel acidolysis procedure, we decided to 
investigate in more detail the stability of argifin itself under acidic conditions. 
An authentic sample of argifin was split into two parts and treated separately with a 
solution of 1M HCl at 60 °C for 90 min and 1M HCl for over 4 days (Scheme 61). In 
both experiments, the reaction concentration was 2.9 mM. 
Analytical RP-HPLC and HRMS indicated the formation of aspartimide when argifin 
was treated with 1M HCl for 90 min at 60 °C, which were the conditions used for the 
removal of the final tert-butyl ester group in the recent synthesis of argifin.103 The 
conversion of substrate to aspartimide was 25% by HPLC analysis (Fig. 46). To 
investigate the ring opening of the resulting succinimide to form either α and/or β-
cyclic peptide, the sample was first dried. Analysis of the dried material by RP-HPLC 
indicated the same reaction mixture composition as before. The sample was dried 
again and subsequently treated with 1H HCl (2.9 mM solution). The sample was then 
concentrated in vacuo at 40 °C. Analysis of the reaction mixture by RP-HPLC (Fig. 
46) showed only starting substrate and aspartimide with the same ratio as before (75% 
substrate, 25% aspartimide). Analysis of both reactions by HRMS also confirmed the 
presence of unchanged starting material and aspartimide product. After the treatment 
of argifin with 1M HCl at room temperature for 4 days, RP-HPLC indicated 8% 
conversion of substrate to aspartimide (Scheme 61) as determined by RP-HPLC 
analysis of the reaction mixture (Fig. 46). 
We therefore concluded that exposure of the cyclic pentapeptide, argifin, to mild 
acidic conditions (1M HCl) can lead to aspartimide formation. The rate of aspartimide 
formation increases at higher temperatures (60 °C). However, when the aspartimide is 
treated with 1M HCl at 60 °C, ring opening at either the α or β position did not occur 
demonstrating the stability of the aspartimide. 
Aspartimide formation was not detected during the novel acidolysis procedure by 
Dixon et al.103 Aspartimide formation may have been possible to a small extent but 
was undetectable under HPLC conditions used and was removed upon preparative 
HPLC purification. The formation of aspartimide, if it occurred at the final 
deprotection stage, must have occurred after side chain deprotection as opposed to 
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initial formation of the aspartimide, followed by regioselective ring opening, as the 
aspartimide is stable once formed. 
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1M HCl, 60 °C 75 : 25 
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Scheme 62: Investigation of aspartimide formation using 1M HCl 
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Figure 46: HPLC trace of argifin treated with 1M HCl for 90 minutes at 60 °C, argifin at tR= 4.64 
and aspartimide at tR= 4.92 (Left). HPLC trace of argifin treated with 1M HCl at room 
temperature for 4 days (Right) 
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2.6	 New synthesis of argifin and elimination of aspartimide 
formation 
Although the recent synthetic route towards argifin greatly reduces the propensity 
towards aspartimide formation via a novel acidolysis procedure, there was still the 
need for developing methodology towards the preparation of argifin eliminate to 
allow the potential to scale up the synthesis of argifin for further studies. 
Protecting groups that are not susceptible to base-induced aspartimide formation in 
the linear assembly by Fmoc SPPS were necessary. Furthermore, the protecting 
groups employed should be removable under neutral or very mild acidic conditions at 
room temperature to avoid aspartimide formation. 
The new synthesis of argifin is shown in scheme 62. Our approach involved 
employing Wang resin instead of 2-chlorotrityl resin used in initial investigations for 
the synthesis of argifin. With the linear precursor chosen, the first (C-terminal) 
residue (Asp-OBn) is not susceptible to aspartimide formation as it is attached to the 
solid support. The utilisation of O-benzyl (for β-Asp protection) and 
benzyloxycarbonyl (Arg(Z)2) protection groups was used to allow for a one-step, 
global deprotection218 procedure unlike previous methods, which requires two-steps 
involving aqueous acidolysis, that could lead to aspartimide formation. Boc-Asp-OBn 
was chosen as the N-terminal residue. This way, the N-terminal protection group is 
removed upon cleavage from the solid support with 95% TFA. This avoids the risk of 
aspartimide formation which would occur if Fmoc-Asp-OBn was used, where 
exposure to basic conditions would be required at the N-terminal deprotection step. In 
principle, this methodology would only require a single HPLC purification step 
following acylation of the free arginine side chain. 
Loading of the resin was achieved in 62% yield followed by automated SPPS. 
Cleavage of the linear peptide was effected by treatment with TFA/DCM (1:1 v/v), 
followed by precipitation and centrifugation to give the crude peptide. Analysis of the 
crude material by HPLC and HRMS indicated formation of (232) and linear 
tetrapeptide (233) which was formed due to incomplete coupling of Fmoc-Arg(Z)2-
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OH to MePhe using PyBrOP. This particular coupling could be further investigated 
by employing a more efficient coupling reagent such as HATU. 
The crude product was taken on further without purification. Cyclisation of the linear 
precursor (232) was performed using HATU activation and DIPEA as with the 
preparation of α-argifin and banyasin A. Work-up of the reaction mixture, followed 
by preparative HPLC purification to furnished (234) in 26% yield based on the 
original loading of the resin. 
In principle, the HPLC purification step after cyclisation could be omitted, allowing 
the global deprotection of the cyclised material. 
The stage was now set to deprotect (234) by hydrogenolysis.218 After investigation of 
this step on a small scale, it was decided to treat (234) with 80% Pd(OH)2/C in acetic 
acid, under H2, for 16 h to afford (235) as the acetate salt in 89% yield. Mild acidic 
conditions of the reaction mixture did not lead to the formation of aspartamide whilst 
following the course of the reaction by RP-HPLC and HRMS. 
Acylation of (235) to (236) was initially performed using 3 eq of succinimidyl-N-
methylcarbamate and 6 eq of DBU at 40 °C. After monitoring the reaction for 2 h by 
HPLC, only 50% of the substrate was converted to product. It was decided to treat the 
reaction mixture with a further 6 eq of DBU for 0.5 h. Analysis of the reaction 
mixture by RP-HPLC indicated 70% conversion at which point, the reaction mixture 
was treated with a further 3 eq of ester for 16 h. As this did not enhance the formation 
of product, the reaction mixture was treated with another 3 eq ester and 6 eq DBU for 
5 h. RP-HPLC analysis indicated 82% conversion of starting material to product. 
Purification of the crude product furnished (236) as the TFA salt in 14% yield. 
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Reagents and conditions: i) Wang resin, Fmoc-Asp-OBn, DIC, DMAP, DCM, 0 °C, 25 min ii) Piperidine/DMF (v/v,1:4), 4 x 3 min iii) 
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Scheme 63: The alternative preparation of Argifin 
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We can therefore conclude that the new synthesis of argifin, which incorporates 
protection groups that can be removed upon hydrogenolysis, furnishes argifin without 
the occurrence of aspartimide products. Together with the utilisation of automated 
SPPS, scaling up the synthesis of argifin is feasible. 
After these investigations were conducted, a report by Sunazuka et al describes an 
alternative synthetic pathway for the preparation of argifin involves incorporation the 
essential N­methylcarbamoyl unit by “on-resin” guanidination of an ornithine 
residue.219 Like our approach, this involves a single final HPLC purification step, but 
the choice of protecting groups involve exposure of the cyclic peptide to an acidic 
final deprotection, thereby risking aspartimide formation. As this approach is also a 
completely on-resin strategy, the scale of synthesis achievable will also be ultimately 
limited. 
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2.7	 Biological evaluation of argifin fragments, α­argifin and 
banyasin 
2.7.1 Biological evaluation of argifin fragments 
As mentioned previously, argifin is a potent inhibitor of several family 18 chitinases, 
acting through extensive (peptide) mimicry of the enzyme-catalysed reaction 
intermediate.54, 93 The design of peptide fragments was based on the X-ray structure, 
of argifin, in complex with AfChiB1 and therefore, all fragments contain the 
dimethylguanylurea group, previously shown to deeply penetrate the active site 
pocket. To compare the linear peptides synthesised against argifin, inhibition was 
tested against the fungal chitinase, AfChiB1, HCHT, and total chitinase activity from 
a lung homogenate (LH) froma mouse model of chronic asthma. This lung 
homogenate has previously been shown to mainly contain AMCase, that has been 
proposed as an antiasthma drug target.36, 37 AfChiB1 crystals were soaked, in parallel, 
in solutions containing the five compounds (170­172), (192) and (198) and the 
resulting crystal structures were investigated. The five structures were solved to a 
maximum resolution of 1.90 – 2.2 Å (Table 7), similar to the published (2.0 Å) 
AfChiB1-argifin comples, and hence, the structures possess a comparable amount of 
solvent detail. The data gave electron density maps showing clear positions for the 
ligand, confirming the structure and stereochemistry of the synthesised linear peptides 
(Fig 47-51). 
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2.7.1.1 Biological evaluation of Tetrapeptide (170) 
Linearisation and removal of one of the Asp residues of argifin leads to tetrapeptide 
(170) which retains significant inhibitory activity (IC50 = 4.3 µM against AfChiB1, 
Table 7). X-ray structure of (170) in complex with AfChiB1 (Fig. 47) reveals that it 
binds to the chitinase with the Arg(MC) side chain in an identical position to that 
observed in the AfChiB1-argifin complex, with a similar conformation of the peptide 
backbone. The tetrapeptide fills the -1, +1, and +2 subsites, and all direct and 
intramolecular hydrogen bonds observed in the argifin complex are conserved. The 
only significant differences are the loss of water-mediated hydrogen bonds to 
Glu322/Asn323 and a cis amide bond in the N-terminal N-acetyl group, allowing an 
additional internal hydrogen bond between the C-terminal carboxylate and the 
backbone nitrogen of D-Ala. The total surface area occupied by argifin and (170) are 
identical (141 Å2). Therefore, removal of the second isoAsp and linearization of 
argifin lowers the affinity of binding to the chitinase due to loss in entropic energy by 
complexation of the more flexible, acyclic structure of (170) and /or loss of several 
water-mediated hydrogen bonds. The methylcarbamoyl unit retains five direct 
hydrogen bond interactions to Asp175, Glu177, Tyr245 and Asp246 and a stacking 
interaction with Trp384 as found with argifin itself. 
Figure 47: X­ray structure of tetrapeptide (170)­AfChiB1 complex 
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2.7.1.2 The Active Tripeptide (171) 
From inspection of the AfChiB1-argifin/tetrapeptide complexes, the D-Ala side chain 
does not make significant interactions with the enzyme active site. The tripeptide 
(171), lacking the D-Ala residue, inhibits chitinase activity of AfChiB1, HCHT and 
LH with IC50 values similar to those of the tetrapeptide (170). Crystallographic 
analysis of the bound conformation of (171) with AfChiB1 (Fig. 48) shows that the 
Arg(MC) side chain binds in the usual position and that the tripeptide backbone 
adopts a conformation almost identical to that observed in the AfChiB1-argifin 
complex. The major differences between the tetrapeptide and tripeptide are loss of an 
isoAsp at the C-terminus, the loss of the extra internal hydrogen-bond and an extra 
water-mediated hydrogen-bond with Ser250. Once again, inspection of the X-ray 
structure clearly reveals conserved direct hydrogen-bond interections of the 
methylcarbomoyl unit to Asp175, Glu177, Tyr245 and Asp246 and a stacking 
interaction with Trp384 as found with argifin itself and the tetrapeptide. 
Figure 48: X­ray structure of tripeptide (171)­AfChiB1 complex 
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2.7.1.3 The active dipeptide (172) 
Evaluation of the tripeptide-protein interactions of (171) led to the design of the 
dipeptide (172). Both the derivatised argifin and the N-methylated phenylalanine 
make tight interactions with the active site and truncation of these amino acids was 
expected to lower binding affinity to the active site. The only interaction the 
remaining isoAsp side chain makes with the protein is to accept a hydrogen bond 
from Trp137 indole, although this interaction is fully conserved in argifin, 
tetrapeptide and tripeptide complexes. It has also been shown that mutation of Trp137 
completely abolishes argifin inhibition. 
Nevertheless, to truncate argifin further into smaller scaffolds for completing the 
series and identification of the pharmacophore, dipeptide (172) was prepared and 
evaluated. Dipeptide (172) inhibits the chitinases with IC50 values of up to an order of 
magnitude less than that obtained against (170) and (171) (Table 7). The AfChiB1-
dipeptide complex (Fig. 49) reveals that the terminal Arg(MC) moiety generates the 
same five hydrogen bonds with Asp175, Glu177, Tyr245, and Asp246 as seen in the 
AfChiB1 complexes with argifin, the tetrapeptide and the tripeptide. The bound 
conformation also reveals the loss of an internal hydrogen bond and the hydrogen 
bond with the side chain of Trp137. The loss of these hydrogen bonds appears to 
contribute to the induction of significant conformational changes in the backbone 
(shifts of up to 3.4 Å for equivalent argifin backbone atoms), with the L-Arg-L-
MePhe peptide bond adopting a trans configuration. This is attributed to replacement 
of the Arg301 to L-Arg carbonyl hydrogen bond with a hydrogen bond from Arg301 
to the MePhe carboxylate. The MePhe side chain only occupies the +2 subsite 
through a reduced interaction with Phe251. The shift of the inhibitor backbone causes 
Trp137 to settle in a dual conformation, with the additional conformation pointing 
toward the indole group of Trp384, which itself is also displaced. However, these 
conformational changes also result in the generation of three new water-mediated 
hydrogen bonds that may attribute to inhibitory activity though there is a loss of direct 
hydrogen-bond interactions. The considerably smaller dipeptide generates a protein 
contact surface of equivalent size to that observed in the AfChiB1-tripeptide complex. 
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Figure 49: X­ray structure of Dipeptide (172)­AfChiB1 complex 
2.7.1.4 N­Methylated carbamoylated arginine (192) still retains activity. 
The dipeptide unit alone still retains significant inhibitory activity towards chitinases. 
Because of this, the preparation of (192) was designed, prepared and evaluated as we 
envisaged that the pharmacophore was likely to be a smaller fragment. Investigation 
of the inhibitory effects of the “monopeptide” (192) shows that it still retains 
significant activity against the chitinases. With an IC50 value of 81 µM, (192) is 3 
orders of magnitude higher than that of the intact cyclopentapeptide argifin and 40-
fold higher than the linear tetrapeptide (170). The crystal structure of AfChiB1-(192) 
(Fig. 50) complex reveals that despite the removal of the MePhe residue and 
concominent loss of the hydrophobic interactions with Trp137/Phe251, the modified 
arginine side chain still establishes the same five hydrogen bonds as observed in the 
argifin, tetrapeptide, tripeptide, and dipeptide complexes. Similar to the dipeptide 
complex, Trp137 is flipped with a 120° rotation around the Cα-Cβ bond, allowing 
stacking interactions with the L-Arg backbone and the N-terminal acetyl group. 
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Figure 50: X­ray structure of "monopeptide" (198)­AfChiB1 complex 
2.7.1.5 Dimethylguanyl urea derivative (198) 
All linear fragments, as well as the “monopeptide” (192), display the majority of 
interactions with the key catalytic residues of the active site, via the modified arginine 
side chain. For this reason, we investigated the biological properties that (198) would 
display against family 18 chitinases. 
The small fragment only consists of 9 heavy atoms and has a molecular weight of 130 
Da. Compound (198) also proves to be an inhibitor of AfChiB1 (IC50 = 500 µM) and 
other chitinases. The X-ray crystal structure of (198) in complex with AfChiB1 (Fig. 
51) shows that the ligand is well ordered, occupies the same position as observed in 
the argifin and linear peptide complexes, and is able to make the same five hydrogen 
bonds to the small fragment via Asp175, Glu177, Tyr245 and Asp246 and a stacking 
interaction with Trp384 as found with argifin itself and all truncated peptides 
discusses above. 
The reduction in potency can be explained by the loss of the L-Arg carbonyl to 
Arg301 hydrogen bond as well as a considerably smaller buried surface area due to 
loss of interactions with Trp137. 
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In terms of binding efficiency, the dimethylguanyl urea unit alone is the most efficient 
when taking into account its binding efficiency index (BEI) value (27.7), it is a much 
more efficient at binding to the active site of AfChiB1 compared to argifin and linear 
fragments (see table 7 for BEI values). 
The dimethylguanyl urea unit alone makes less interactions to the protein than argifin 
itself, (198) may have the potential to bind to a number of other active sites. 
Compound (198) is also a much smaller molecule than argifin itself. Compound (198) 
contains 4 hydrogen bond donors, 1 hydrogen bond acceptor, a molecular weight of 
130 Da, and with a clogP = -0.48, meets the criteria set by the Lipinski rule of five.88, 
Figure 51: X­ray structure of (198)­AfChiB1 complex 
Interestingly, evaluation of (198) against A. fumigatus Chitinase A (AfChiA), a plant-
type chitinase, indicates that this compound is a comparatively good inhibitor (IC50 = 
79 µM). This is significant, as very few inhibitors of this sub-family are known, in 
contrast to those of bacterial-type enzymes. 
140 
AfChiB1 
IC50 
HCHT 
IC50 
LH 
IC50 
AfChiB1 
BEI 
Argifin 0.027 4.5 0.030 11.7 
Tetrapeptide (170) 4.3 28 2.9 9.1 
Tripeptide (171) 5.1 68 8.2 10.2 
Dipeptide (172) 12 190 27 12.0 
Monopeptide (192) 81 1000 180 15.3 
Dimethylguanylurea 
(198) 
500 5800 1030 27.7 
Table 7: Chitinase inhibition of Argifin­derived peptides: IC50 values of argifin and the peptide 
derivatives against AfChiB1, HCHT and mouse lung homogenate (LH) are given in micromolar. 
For AfChiB1, ligand efficiency is expressed as the Binding Efficiency Index (BEI) 
2.7.2 Biological evaluation of α­argifin (219) 
The inhibitory activity of α-argifin was investigated against AfChiB1 and the human 
enzyme, AMCase with IC50 values of 148 µM and 681 µM respectively. 
Argifin itself contains 17 backbone atoms. The preparation of α-argifin results in 
reduction of the peptide backbone ring size to 15 atoms. Reduction of the overall ring 
size results to constrain of the cyclic peptide and contributes to a decrease in 
biological activity towards AfChiB1, compared to argifin. 
An analogue of argifin that has been prepared involves the replacement of MePhe for 
Phe (Fig. 50). This represents a further analogue of argifin where only the peptide 
backbone has been manipulated. Inspection of the X-ray structure with AfChiB1 
reveals a trans amide bond existing about the Arg(MC)MePhe dipeptide motif. An 
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IC50 value of 60 µM against AfChiB1 has been reported for (237) (Fig. 52), 
comparable to α-argifin103 . 
N 
H 
NH 
NH 
HN 
H 
N 
O 
N 
H 
NH 
N 
H
O 
O 
OHO 
O 
O 
HO 
O O 
N 
H 
(237) 
Figure 52: The structure of argifin MePhe to Phe analogue 
Analysis of α-argifin in solution by 1H NMR reveals that the molecule exists as a 
mixture of isomers about the MePhe-Arg(MC) dipeptide motif. Isomerisation between 
cis and trans isomers could potentially disfavour the binding of α-argifin to the active 
site of AfChiB1 in the conformation observed with argifin and truncated fragments 
thus resulting to a decrease in biological activity towards AfChiB1 compared to 
argifin. As mentioned previously, it has been noted that the cyclopentapeptide argadin 
is capable of binding deeper into the active site of AfChiB1 due to it contining a more 
compact peptide backbone but interacts with key residues of AfChiB1 in the -1 subsite 
via the histidine side chain. 
Through the preparation and evaluation of α-argifin, we have demonstrated that 
constraining the peptide backbone of argifin clearly leads to a reduction in biological 
activity towards AfChiB1. This provides further evidence for the requirement of the 
cis amide dipeptide motif in argifin. Manipulating the cyclic peptide backbone of 
argifin disfavours the cis configuration and leads to reduced activity. 
142 
2.7.3 Biological evaluation of dipeptides (200) and (201) 
Biological evaluation of peptides (200) and (201) were performed against AfChiB1. 
The methylated dipeptide derivative (201) displayed an IC50 of 86 µM. Dipeptide 
(200) however, did not show any inhibition against AfChiB1. 
As mentioned previously, our design and of dipeptides (200) and (201) as both C-
terminal methylamides was inspired by analysis of the AfChiB1-dipeptide (172) X-ray 
structure. It was thought that installing a C-terminal methyl amide would potentially 
reinforce a “β-like turn” by creating an internal hydrogen bond between the N-
terminal N­acetyl carbonyl and the NH of the C-terminal methylamide. The 
demethylated dipeptide derivative (200) was prepared as a control. We have already 
observed that a mutation of MePhe for Phe in argifin diminishes biological activity 
from 0.027 µM to 60 µM highlighting the importance of the Arg(MC)-MePhe 
dipeptide motif. It is therefore not surprising that the potency of dipeptide (200) is 
lower than that of (201). 
As discussed previously, analysis of the X-ray structure of dipeptide (172) with 
AfChiB1 reveals that dipeptide (172) binds with the trans conformation about the 
Arg(MC)-MePhe motif and forms three water-mediated hydrogen bonds. 
Replacement of the C-terminal acid to a methyl amide may lead to loss of water-
mediated hydrogen bonds which causes a reduction in potency of the two dipeptide 
derivatives (200) and (201). 
As previously mentioned, 1H NMR studies on dipeptide (200) reveals that the 
molecule exists exclusively as the trans conformer. Presumably this relative lack of 
conformational flexability compared to (201) prevents it from adopting a suitable 
cioactive conformation and thus leads to reduction in potency towards AfChiB1. 
In comparison, analysis of dipeptide (201) reveals that the molecule displays both the 
cis and trans forms which perturbs binding of (201) in the desired bioactive 
conformation. Dipeptide (200) displays lower potency than dipeptide (201) which 
could be due to loss of water-mediated hydrogen bond interactions upon modifying 
the C-terminal acid to a methylamide. 
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2.7.4 Biological evaluation of Banyasin A 
Banyasin shows improved activity against AfChiB1 (IC50 = 105 µM) compared to α-
argifin. In comparison to argifin itself, banyasin still retains the essential Arg(MC)-
MePhe dipeptide motif but contains two alternative residues, the β amino acid Amoa, 
and L-Ala. Furthermore, the backbone ring size of banyasin contains 16 atoms, 
leading to the molecule being more constrained than argifin. This again demonstrates 
that modification of the argifin backbone can lead to a significant decrease in potency 
towards family 18 chitinases and any such change that might potentially increase 
stability must be carefully judged. Additionally, the X-ray structure of the AfChiB1-
argifin complex reveals a hydrogen-bond interaction between the N­terminal β-Asp 
and the indole ring of Trp137. Banyasin contains L-Asp instead of a β-Asp residue 
and this may cause loss the hydrogen-bond interaction to Trp137. 
As mentioned, HPLC analysis of banyasin reveals slow interconversion between 
conformers of the isolated peptide. In this case, it is likely that the diastereoisomer of 
banyasin prepared does not exist exclusively in the desired bioactive conformation 
with respect to the Arg(MC)MePhe dipeptide motif, which is relected in the activity 
observed relative to argifin. 
Attempts to obtain X-ray data of banyasin bound to various Family 18 chitinases is in 
progress. 
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3 Conclusions 
3.1 Structural dissection of argifin 
We have been able successfully to linearise and truncate sequentially the family 18 
chitinase inhibitor argifin, to identify the pharmacophore required to retain some 
biological activity. The series of compounds were inspired by the original argifin-
chitinase X-ray structure.54, 102 
Potency of the linear peptide fragments towards family 18 chitinases decreases as we 
further truncate the linear peptide sequence of argifin and is likely to be caused by 
loss of protein-inhibitor interactions as the the linear sequence is shortened, which is 
confirmed by high resolution X-ray crystallographic data of all five structures bound 
to AfChiB1. Furthermore, linearization of a constrained cyclic pentapeptide causes a 
gain in entropy. 
X-ray crystallographic evidence has revealed that all peptide fragments bind to the 
active site of AfChiB1 in almost an identical way to each other and of the natural 
product itself. All peptide fragments demonstrate the importance of the modified 
arginine moiety (Arg(MC)) as this unit makes five direct interactions in the -1 subsite 
to Asp175, Glu177, Tyr245 and Asp246 and is conserved in argifin and all five 
fragments. 
Guided by X-ray crystallography, we have demonstrated that the minimum 
pharmocophore of argifin is the dimethylguanyl derivative (198). Compound (198) 
serves as a lead compound, and a starting point towards the design and creation of 
related derivatives. Progression towards a more drug-like molecule could potentially 
be achieved now that the pharmacophore has been identified. 
Very recently, derivitised linear fragments of argifin, bearing the key N-
methylcarbamoyl-L-Arg motif but containing azido, phenyl, benzyl and triazole 
functional groups, using in situ click chemistry, have been reported by Sunazuka et al. 
They report that a derivatised linear fragment inhibits SmChiB with an IC50 value of 
0.022 µM. 
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3.2 Dipeptides (200) and (201) 
Two major factors may attribute to the fact that dipeptide (200) does not exhibit any 
significant biological activity towards AfChiB1, the first being due to installation of a 
C-terminal methylamide which may potentially have the consequence of a loss in 
water-mediated hydrogen bond interactions with the active site and the second reason 
stems from 1H NMR analysis revealing that dipeptide (200) exists exclusively as the 
trans isomer due to the presence of a trans amide bond about the Arg(MC)-MePhe 
dipeptide motif. This reduces the capacity of the molecule to adopt the desired 
bioactive conformation towards the active site of AfChiB1. 
Dipeptide (201) however does show biological activity towards AfChiB1. Analysis of 
(201) by 1H NMR revals that it exists as both the cis and trans isomeric form in 
solution which, as a consequence, does not allow the molecule to fully adopt the 
desired bioactive conformation towards the active site of AfChiB1. 
3.3 Banyasin and α­argifin 
Manipulating and constraining the argifin peptide backbone leads to a decrease in 
potency towards AfChiB1 demonstrating, that the argifin backbone scaffold is an 
important factor towards biological activity. Changing the peptide backbone of argifin 
has been achieved through the preparation of banyasin and α-argifin both of which are 
more constrained than argifin itself. 
The complete, novel, diasteroselective preparation of banyasin has been achieved 
through the utilisation of diastereoselective aldol chemistry for the synthesis of the 
rare β-amino acid, Amoa. We can conclude that the R,R configuration at the C3 and 
C5 position of banyasin leads to slow interconversion between the cis and trans 
Arg(MC)-MePhe amide bond. We are confident that the natural product reported by 
Pluotno and Carmelli exists exclusively as the cis isomer in solution for reasons 
discussed previously. It is therefore necessary to prepare the next three 
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diasteroisomers of banyasin in order to establish the configuration at both the C3 and 
C5 positions contained within the Amoa residue of the cyclic pentapeptide natural 
product. 
3.4 Future work 
The preparation of the three diastereoisomers of banyasin is necessary in order to 
determine the correct configuration at the C3 and C5 positions of the natural product 
isolated by Pluotno and Carmelli. 
To control further cis and trans isomerisation shown by dipeptides (172), (200) and 
(201), we could artificially control isomerisation towards the cis form by insertion of 
an isostere,208 replacing the Arg(MC)-MePhe dipeptide motif. 
Futher manipulation of the dimethylguanyl urea derivative (198) could be produced to 
increase the potency of the resulting compound towards family 18 chitinases, which is 
currently under investigation. 
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4 Experimental 
4.1 General 
Chemical reagents were purchased from Sigma, Aldrich, Fluka, Acros, Lancaster and 
Novabiochem. Anhydrous DCM was obtained by distillation over calcium hydride, 
anhydrous THF and Et2O over sodium/benzophenone. All other solvents were 
purchased from Fisher Scientific. Analytical TLC was performed using silica gel 60 
F254 pre-coated on aluminium sheets (0.25 mm thickness) and reverse phase analytical 
TLC was performed with RP-18 F254s pre-coated on aluminium sheets (0.27 mm 
thickness). Column chromatography was performed on silica gel 60 (35-70 micron) 
from Fisher Scientific. Melting points were recorded on a Reichert-Jung Kofler block 
apparatus and are uncorrected. Optical rotations were measured at ambient 
temperature using an Optical Activity Ltd AA-10 polarimeter in a cell volume of 1 
mL or 5 mL and specific rotations are given in 10-1 deg. mL g-1 . IR spectra were 
recorded on a Perkin-Elmer 782 infra-red spectrometer using NaCl discs and values 
are given in cm-1 . 1H and 13C NMR were recorded using a Bruker Advance DPX 
500MHz FT, JEOL JMN GX-270MHz or EX-400MHz spectrometers. J values are 
given in Hz. Analytical RP-HPLC was performed on a Dionex HPLC system (system 
1) equipped with a Dionex Acclain 3 µm C-18 (150 x 4.6mm) column with a flow 
rate of 1 mL min-1 or a Dionex UltiMate 3000 HPLC system (system 2) equipped 
with a Phenomenex Gemini 5µm C-18 (150 x 4.6 mm) column with a flow rate of 1 
mL min-1 . Semi-preparative RP-HPLC was performed on a Dionex HPLC system 
equipped with a Phenomenex Gemini 5µm C-18 (250 x 10 mm) column with a flow 
rate of 2.5 mL min-1 . Preparative RP-HPLC was performed on a Dionex HPLC 
system equipped with a Phenomenex Gemini 5µm C-18 (250 x 30 mm) with a flow 
rate of 22.5 mL min-1. Mobile phase A was 0.1% TFA in water, mobile phase B was 
0.1% TFA in acetonitrile, mobile phase C was 0.1% FA in water, mobile phase D was 
0.1% FA in acetonitrile unless specified. 
Gradient 1 was T = 0 min, B = 5%; T = 10 min, B = 95%; T = 15 min, B = 95%; T = 
15.1 min, B = 5%; T = 18.1 min, B = 5%. 
148 
Gradient 2 was T = 0 min, B = 5%; T = 20 min, B = 40%; T = 22 min, B = 95%; T = 
27 min, B = 95%; T = 27.1% B= 5%; T = 32 min, B = 5%. 
Gradient 3 was T = 0 min, B = 5%; T = 20 min, B = 30%; T = 30 min, B = 95%; T = 
30.1 min, B = 95%; T = 35.1 min, B = 5%, T = 40 min, B = 5%. 
Gradient 4 was T = 0 min, B = 5%; T = 15 min, B = 32.5%; T = 17 min, B = 95%; T = 
22 min, B = 95%; T = 23 min, B = 5%; T = 30 min, B = 5%. 
Gradient 5 was T = 0 min, B = 5%; T = 12 min, B = 7.8%; T = 14 min, B = 95%; T = 
19 min, B = 95%; T = 21 min, B = 5%; T = 29 min, B = 5%; T = 29.1, B = 5%. 
Gradient 6 was T = 0 min, B = 5%; T = 30 min, B = 12%; T = 32 min, B = 95%; T = 
37 min, B = 95%; T = 38 min, B = 5%; T = 42 min, B = 5%; T = 42.1, B = 5%. 
Gradient 7 was T = 0 min, B = 5%; T = 30 min, B = 23.75%; T = 32 min, B = 95%; T 
= 37 min, B = 95%; T = 39 min, B = 5%; T = 48 min, B = 5%; T = 48.1, B = 5%. 
Gradient 8 was T = 0 min, B = 5%; T = 35 min, B = 26.8%; T = 37 min, B = 95%; T = 
42 min, B = 95%; T = 44 min, B = 5%; T = 53 min, B = 5%; T = 53.1, B = 5%. 
Gradient 9 was T = 0 min, B = 5%; T = 30 min, B = 60%; T = 35 min, B = 95%; T = 
40.1 min, B = 95%; T = 45 min, B = 5%; T = 45.1 min, B = 5%. 
Gradient 10 was T = 0 min, B = 5%; T = 20 min, B = 95%; T = 25 min, B = 95%; T = 
25.1 min, B = 5%; T = 30 min, B = 5%; T = 30.1 min, B = 5%. 
Gradient 11 was T = 0 min, B = 35%, C = 0%, D = 35% T = 28.1 min, B = 35%%, C 
= 0%, D = 35%. 
Low resolution mass spectrometry was performed on an ABI Mariner TOF electro 
spray ionisation mass spectrometer. High resolution mass spectrometry was 
performed using a Bruker MicroTOF autospec electrospray ionisation mass 
spectrometer. 
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4.2 E­N­Methoxy­N­methylhex­3­enamide (114)

N 
O 
OCH3 
4.2.1 Method A 
A stirred solution of (E)-3-hexanoic acid (5.00 g, 43.81 mmol) in anhydrous DCM (40 
mL) was cooled to –20 °C and treated with DIPEA (7.63 mL, 43.81 mmol) and 
isobutyl chloroformate (5.68 mL, 43.81 mmol) for 8 minutes after which N,O-
dimethylhydroxylamine hydrochloride (4.27 g, 43.81 mmol) and DIPEA (7.63 mL, 
43.81 mmol) were added. The reaction mixture was allowed to warm to room 
temperature and stirred for 16 h. The reaction was washed with 1M aq. HCl (2 x 15 
mL), sat. aq. NaHCO3 (2 x 15 mL) and brine (15 mL). The combined organic extracts 
were dried (MgSO4), and concentrated in vacuo. The crude material was purified by 
column chromatography (EtOAc/petrol ether 2:3) to give the isobutyl ester (155) 
(4.28 g, 57% yield) and the desired product (114) as a yellow oil (1.37g, 20% yield), 
Rf 0.35 (EtOAc/Petrol, 2:3). 
4.2.2 Method B 
A stirred solution of (E)-3-hexanoic acid (0.50 g, 4.38 mmol) in anhydrous DCM (5.0 
mL) under Ar was treated with DIPEA (0.76 mL, 4.38 mmol) and PyBOP (2.23 g, 
4.38 mmol) for 7 minutes after which N,O-dimethylhydroxylamine hydrochloride 
(0.43 g, 4.38 mmol) and DIPEA (0.76 mL, 4.38 mmol) were added. The reaction 
mixture was stirred at room temperature for 8 h. The reaction was diluted with DCM 
(13.0 mL), washed with 2M aq. HCl (2 x 7 mL), sat. aq. NaHCO3 (2 x 13 mL) and 
brine (2 x 13 mL), dried (MgSO4) and concentrated in vacuo. The crude product was 
purified by column chromatography (EtOAc/Petrol (3:7) to give (114) as a yellow oil 
(0.41 g, 60 % yield); Rf 0.60 (DCM 100%); IR (DCM) br 2950, 1713, 1650, 1386, 
1177; δH (500 MHz, CDCl3): 0.93 (3H, t, J = 7.4, CH3CH2), 1.95 (2H, m, 
CH3CH2CH), 3.10 (5H, s, N-CH3 + CH2CO), 3.63 (3H, s, N-OCH3), 5.50, (2H, m, 
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CH=CH); δC (125 MHz, CDCl3): 13.79 (CH3CH2), 25.46 (CH3CH2), 32.07 (NCH3), 
36.00 (CH2CO), 61.26 (NOCH3), 121.34 (CH=CH), 135.85 (CH=CH), 173.08 (C=O); 
[Found: (ES+) 158.1182 [M+H]+, C8H16NO2 requires 158.1176]. 
4.3 (E)­3­hexenal (117) 
H 
O 
4.3.1 Method A146 
A stirred solution of (114) (0.50 g, 3.16 mmol) in anhydrous THF (20 mL) at 0 °C 
under Ar was treated drop-wise, with LiAlH4 solution (1.14 mL, 3.98 mmol, 3.50 M 
in THF). The reaction was stirred for 1 h after which, the reaction was quenched by 
slow addition of 5% aq. citric acid (20 mL) and diluted with Et2O (40 mL). The 
organic and aqueous phases were separated and the aqueous phase was extracted with 
Et2O (2 x 20 mL). The combined organic extracts were washed with 10% aq. citric 
acid (2 x 20 mL), sat. aq. NaHCO3 (2 x 20 mL) and brine (2 x 20 mL), dried (MgSO4) 
and concentrated in vacuo. 1H NMR and MS analysis of the crude material indicated 
the presence of unchanged (114) was present (0.44 g). 
4.3.2 Method B147 
A stirred suspension of pyridinium chlorochromate (4.30 g, 19.96 mmol) and sodium 
acetate (0.60 g, 7.31 mmol) in anhydrous DCM (25 mL) under Ar was rapidly treated 
with a solution of (E)-3-hexen-1-ol (1.00 g, 9.98 mmol) in anhydrous DCM (2 mL) 
and stirred for 1 h after which the reaction mixture was diluted with Et2O (15 mL) and 
passed through a short column of florisil. Hydroquinone (15 mg) was added to the 
filtrate and concentrated in vacuo. Analysis of the crude material by TLC, 1H NMR 
and MS did not show consumption of the alcohol and did not indicate formation of 
the desired product with almost full recovery of unchanged starting material (0.89 g). 
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4.3.3 Method C148 
A stirred solution of (E)-3-hexen-1-ol (1.00 g, 9.98 mmol) in anhydrous DCM (10 
mL) at 0 °C was treated with trichloroisocyanuric acid (2.44 g, 10.51 mmol) followed 
by TEMPO (16.4 mg, 0.1 mmol). The reaction was allowed to warm to room 
temperature and stirred for 40 minutes. The reaction mixture was filtered through 
celite, washed with sat. aq. NaHCO3 (20 mL), 1M aq. HCl (20 mL), brine (20 mL), 
dried (MgSO4) and concentrated in vacuo. 
1H NMR and MS analysis of the crude 
material showed mainly the presence of starting alcohol (0.98 g) and did not indicate 
formation of the desired product. 
4.3.4 Method D149 
A stirred suspension of (E)-3-hexene-1-ol (0.50 g, 4.99 mmol), N-methylmorpholine 
N-oxide (1.01 g, 7.48 mmol) and 4Å molecular sieves in anhydrous DCM (18 mL), 
under Ar at room temperature, was treated with TPAP (35.1 mg, 0.1 mmol). After 5 h 
the reaction mixture was filtered through silica and celite and washed with DCM (10 
mL). The organic filtrate was distilled to remove DCM. 1H NMR and MS analysis of 
the crude material did not indicate formation of the desired product with recovery of 
unchanged starting material (0.39g). 
4.3.5 Method E150, 151 
A stirred solution of (E)-3-hexen-1-ol (0.19 g, 1.95 mmol) in anhydrous DCM (14 
mL) at room temperature under Ar, was treated with Dess-Martin periodinane (0.90 g, 
2.12 mmol). The reaction was stirred for 3 h after which, TLC analysis of the 
reaction mixture (EtOAc/ Petrol, 1:5) showed full consumption of starting alcohol. 
The reaction mixture was filtered, washed with sat. aq. NaHCO3 (20 mL) containing 
Na2S2O3 (7.6 g). The organic extract was re-filtered and washed with sat NaHCO3 (20 
mL) containing Na2S2O3 (7.6 g). Filtration and washing of the organic extract was 
repeated a further three times. The organic phase was dried (MgSO4) and 
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concentrated by distillation at atmospheric pressure under Ar to give (117) as a yellow 
tinted oil (0.78 g, 85% by 1H NMR); Rf 0.68 (EtOAc/ Petrol, 1:5); δH (500 MHz, 
CDCl3): 0.9 (3H, t, J = 7.4, CH3CH2), 2.05 (2H, m, CH3CH2), 3.10 (2H, d, J = 6.8, 
CH2), 5.47 (1H, m, CH=CH), 5.63 (1H, m, CH=CH), 9.65, (1H, s, CHO). 
4.4 R­4­benzyl­3­propanoyloxazolidin­2­one (103)174 
O O 
O N

Ph 
A solution of (4S)-4-benzyl-oxazolidin-2-one (2.5 g, 14.01 mmol) in anhydrous THF 
(43 mL) under Ar at –78 °C was treated with a solution of n-BuLi (9.0 mL, 1.6 M in 
THF, 14.2 mmol) dropwise over 10 minutes. The reaction was maintained at -78 °C 
and stirred for 0.5 h after which propanoyl chloride (1.36 mL, 15.50 mmol) was 
added. The reaction was allowed to warm to room temperature and stirred for 3.5 h, 
followed by addition of sat. aq. NaCl (7.5 mL). Concentration of the reaction mixture 
in vacuo resulted to formation of a slurry which was extracted with DCM (3 x 15 
mL). The organic extracts were washed with 1M aq. NaOH (25 mL) and brine 
(25mL). The organic extracts were combined, dried (MgSO4) and the solvent 
evaporated to give (103) as white crystals (3.16 g, 97%), Rf 0.48 (EtOAc/ Petrol, 3:7); 
m. p. 45-47 °C (lit. 44-46 °C173); IR (DCM) 3422, 2972, 1782, 1705, 1454, 1387, 
1212, 1080; [α]D + 96 (c 1.0 in EtOH, lit. = + 99)
173; δH (500 MHz, CDCl3): 1.18 
(3H, t, J = 7.3, CH3CH2), 2.75 (1H, dd, J = 13.3, 9.5, CH2Ph), 2.89 (2H, m, CH2CH3), 
3.27 (1H, dd, J = 13.3, 3.2, CH2Ph) 4.14 (2H, m, CHCH2O), 4.64 (1H, m, NCH), 
7.20-7.34 (5H, m, Ar H); δC (125 MHz, CDCl3): 8.32 (CH3CH2), 29.21 (CH3CH2), 
37.89 (NCH2), 55.15 (CH2Ph), 66.23 (CHCH2Ph), 128.75 (ArCH), 129.07 (2x 
ArCH), 129.19 (2x ArCH), 135.38 (ArC), 153.54 (OC=O), 174.05 (NC=O); m/z 
(ES+) 234.12 (100%, [M+H]+). 
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4.5 R­4­Benzyl­3­(2R, 3R)­3­hydroxy­2­methylpropanoyl­3­
phenyl)oxazolidin­2­one (126) 
O O OH

O N Ph 
Ph 
A stirred solution of (103) (0.10 g, 0.43 mmol) in anhydrous DCM (5 mL) at 0 °C, 
under Ar was treated with a solution of dibutylboron triflate (0.50 mL, 1 M in DCM, 
0.50 mmol) and anhydrous Et3N (80 µL, 0.56 mmol) for 15 minutes, after which the 
reaction mixture was cooled to -78 °C and treated with benzaldehyde (48 µL, 0.48 
mmol). The reaction mixture was allowed to warm to room temperature and stirred 
for an additional 3 h after which, the reaction was quenched by the addition of pH 7 
aqueous phosphate buffer (0.5 mL) and stirred for a further 10 minutes. The reaction 
mixture was then cooled to 0 °C and treated drop-wise with a solution of 27% 
H2O2/MeOH (1:2 v/v, 1.5 mL,) and stirred for an additional 1 h. The reaction mixture 
was concentrated in vacuo. The resulting slurry was extracted with Et2O (3 x 7 mL). 
The organic extract was washed with 5 % aq. NaHCO3 (7 mL) and brine (7 mL), 
dried (MgSO4) and concentrated in vacuo. The crude product was purified by column 
chromatography (1:5 - 1:1 EtOAc: Petrol) to give (126) as a white solid (0.10g, 71%); 
Rf 0.45 (EtOAc/Petrol, 1:1); m. p. 91-94 °C (lit. 92-93 °C)
174; IR 3436 (br), 1782, 
1667, 1455, 1365, 1269, 1196; [α]D + 72 (c 1.0 in DCM, lit. = + 76
174); δH (500 
MHz, CDCl3): 1.21 (3H, d, J = 6.9 CH3), 2.73 (1H, dd, J = 9.5, 13.4 CHHPh) 3.20 
(1H dd, J = 3.2, 13.3 CHHPh), 3.99 (1H, t, J = 8.5 CH3CH) 4.06-4.15 (2H, m, CH2 
oxazolidinone) 4.53-4.60 (1H, m, CH-N oxazolidinone) 5.06 (1H, d, J = 4.1 CH-OH) 
7.17-7.39 (10H, m, aromatic H); δC (125 MHz, CDCl3): 11.09 (CH3CH), 37.92 (CH2 
Ph), 44.69 (CH3CH), 53.39 (CHCH2Ph), 66.26 (CH2-O), 77.97 (CH-OH), 126.23 (CH 
Ph ox), 127.52 (2 x CH Ph ox), 127.74 (2 x CH Ph ox), 128.35 (CH Ar), 129.09 (2 x 
CH Ar), 129.54 (2 x CH Ar), 135.17 (C Ph ox), 141.46 (C Ar), 153.03 (C=O ox), 
176.72 (C=O); m/z (ES+) 340.15 (100%, [M+H]+), 362.16 (12%, [M+Na]+). Reaction 
repeated on 0.86 mmol scale to give product (0.21 g, 72%). 
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4.6 (R)­4­Benzyl­3­((2R, 3S)­E­3­hydroxy­2­methyloct­5­enoyl)­
oxazolidin­2­one (104) 
O N 
O O OH 
Ph 
4.6.1 Method A174 
A stirred solution of (103) (0.25 g, 0.11 mmol) in anhydrous DCM (5 mL) at 0 °C, 
under Ar was treated with dibutylboron triflate solution (1.30 mL, 1 M in THF, 0.13 
mmol) and anhydrous Et3N (80 µL, 0.57 mmol) for 15 minutes after which, the 
reaction mixture was cooled to –78 °C and treated with (E)-3-hexenal (0.20 mL, 1.42 
mmol). The reaction was warmed to 0 °C and stirred for 3 h. The reaction was 
quenched with pH7 aqueous phosphate buffer solution (3.75 mL) and stirred for 10 
minutes. A solution of 27% H2O2/MeOH (1:2 v/v, 3.75 mL) was added drop wise and 
stirred for 1 hour at 0 °C. The reaction mixture was evaporated to give a pale white 
slurry which was extracted with diethyl ether (3 x 7mL). The organic extract was 
washed with 5% aq. NaHCO3 (7 mL) and brine (7 mL), dried (MgSO4) and 
concentrated in vacuo. An attempt to purify the crude by column chromatography 
(EtOAc/Petrol, (1:1)) was performed. This gave R-4-benzyl-3-propanoyloxazolidin-2-
one (103) (0.12g) and R-4-benzyloxazolidin-2-one (0.13g). 
4.6.2 Method B 
The reaction was performed as described in section 4.6.1 method A using (103) (0.11 
g, 0.48 mmol), dibutylboron triflate (0.60 mL, 1 M in THF, 0.56 mmol), anhydrous 
Et3N (87 µL, 0.63 mmol), (E)-3-hexenal (0.26 g, 2.67 mmol), pH 7 aqueous 
phosphate buffer (0.5 mL) and 27% H2O2/MeOH (1:2 v/v, 1.5 mL). The crude 
product was purified by column chromatography (EtOAc /Petrol 1:1) to give the 
starting acylated oxazolidinone (103) (65 mg, 58%) and (104) as a yellow oil (18 mg, 
12% yield), Rf 0.25 (EtOAc:Petrol, 1:1); IR (DCM) 3447, 2967, 1765, 1699, 1455, 
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1384, 1269; [α]D + 83 (c 1.0 in DCM); δH (500 MHz, CDCl3): 0.98 (3H, t, J = 7.4, 
CH3), 1.28 (3H, d, J = 7.0 CH3) 2.03 (2H, quin, J = 7.4, CH2CH3), 2.22-2.49 (2H, m, 
CH2CH(OH)), 2.78 (2H, dd, CH2 oxazolidinone, J = 3.8, 9.5), 3.26 (1H. dd, J = 3.3, 
10.1, OH), 3.81 (1H, m, CHCH3), 3.96 (1H, m, CH(OH)), 4.15 – 4.25 (1H, m, 
CH2Ph), 5.36-5.44 (1H, m, CH=CH) 5.56-5.63 (1H, m, CH=CH), 7.15-7.36 (5H, m, 
ArH); δC (125MHz, CDCl3): 10.72 (CH3CH), 13.75 (CH3CH2), 25.67 (CH3CH2), 
37.25 (CH2Ph), 37.81 (CHCH3), 41.51 (CHCH2), 55.17 (CH2O), 66.16 (CHOH), 
71.21 (CH2OH), 124.44 (Ar CH), 127.46 (CH=CH), 129.00 (2 x Ar CH), 129.46 (2 x 
Ar CH), 135.07 (CH=CH), 135.98 (Ar C), 152.98 (C=O oxazolidinone), 177.24 
(C=O); [Found: (ES+) 332.1874 [M+H]+, C19H26NO4 requires 332.1862]. 
4.6.3 Method C220 
A stirred solution of (103) (0.24 g, 1.02 mmol) in anhydrous THF (5 mL) at -78 °C 
under Ar was treated with a solution of LDA (0.75 mL, 1.50 M in THF, 1.12 mmol) 
drop-wise and stirred for 45 minutes. The reaction mixture was then treated with (E)-
3-hexenal (0.10 g, 1.02 mmol) via cannula and stirred for 4 h. TLC (EtOAc/Petrol, 
1:1) showed no consumption of acylated oxazolidinone. The reaction was quenched 
with sat. aq. NaCl (20 mL) and allowed to –20 °C and stirred for 1 h. The reaction 
mixture was extracted with diethyl ether (3 x 20 mL). The organic extract was dried 
(MgSO4) and the solvent evaporated. An attempt to purify the crude material (silica 
gel eluted using EtOAc/Petrol (1:5 - 1:1)) was performed. 1H NMR and MS analysis 
did not indicate formation of the desired product with full recovery of (103). 
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4.7 (R)­4­benzyl­3­((2R, 3S)­E­3­hydroxy­2­methyloct­5­
enoyl)oxazolidin­2­one (127) 
O N 
O O OH 
Ph 
4.7.1 Method A175 
A stirred solution of (103) (0.37 g, 1.57 mmol) in anhydrous DCM (6 mL) at 0 °C 
under Ar was treated with TiCl4 (3.15 mL, 1.00 M in DCM, 3.15 mmol) dropwise and 
stirred for 10 minutes. The reaction mixture was treated with DIPEA (0.30 mL, 1.73 
mmol) and stirred for 20 minutes. The reaction mixture was cooled to -78 °C followed 
by drop-wise addition of (E)-3-hexenal (0.17 g, 1.73 mmol) via cannula. The reaction 
was warmed to 0 °C, stirred for 3 h and quenched with half sat. aq. NaCl (6 mL). The 
organic and aqueous phases were separated. The aqueous phase was extracted with 
DCM (3 x 7mL), dried (NaSO4) and the solvent evaporated. The crude product was 
purified by column chromatography (100 % DCM) which gave (103) (0.15 g, 41% 
yield) and (127) as a yellow oil (66 mg, 13% yield). 
4.7.2 Method B 
The reaction was performed as described in 4.7.1 method A using (103) (0.37 g, 1.57 
mmol), TiCl4 (3.15 mL, 1.00 M in DCM, 3.15 mmol), (-)-sparteine (0.40 mL, 1.73 
mmol) and (E)-3-hexenal (0.17 mg, 1.73 mmol). The crude product was purified by 
column chromatography (EtOAc/Petrol 3:2) to give (103) (0.21 g, 57% yield) and the 
product as a yellow oil (91 mg, 18%). 
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4.7.3 Method C 
The reaction was performed as described in 4.7.1 Method A using (103) (0.64 g, 2.73 
mmol), TiCl4 (5.46 mL, 1.00 M in DCM, 5.46 mmol), DIPEA (0.52 mL, 3.00 mmol) 
and (E)-3-hexenal (0.54 g, 5.46 mmol) in anhydrous DCM (6 mL). The crude product 
was purified by column chromatography (DCM/Petrol, 1:1 to MeOH/DCM, 1:9) 
containing 0.1% pyridine to give (127) as a yellow oil (0.46 g, 51% yield) Rf 0.25 
(EtOAc/Petrol, 1:1); IR (DCM) 3447, 2967, 1781, 1699, 1480, 1455, 1384, 1211; [α]D 
- 65.8 (c 1.0 in DCM). δH (500 MHz, CDCl3): 0.87 (3H, t, J = 7.4, CH3), 1.11 (3H, d, 
J = 6.9 CH3) 1.94 (2H, m, CH2CH3), 2.07-2.14 (1H, m, CHH-CH=CH), 2.25-2.30 
(1H, m, CHH-CH=CH), 2.64-2.69 (2H, m, CH3CH +PhCHH), 3.19 (1H, t, J = 13.5, 
PhCHH), 3.78-3.81 (1H, m, CH-CH2Ph), 4.04-4.15 (2H, m, CH2O), 4.57-4.62 (1H, 
m, OH), 5.34-5.42 (1H, m, CH=CH) 5.49-5.55 (1H, m, CH=CH), 7.11-7.25 (5H, m, 
Ar H); δC (125MHz, CDCl3): 9.45 (CH3CH), 13.19 (CH3CH2), 24.63 (CH3CH2), 
36.64 (CH2Ph), 40.72 (CHCH3), 41.48 (CHCH2), 54.13 (CH2O), 65.91 (CHOH), 
71.38 (CH2OH), 123.64 (Ar CH), 126.28 (CH=CH), 127.82 (2 x Ar CH), 128.43 (2 x 
Ar CH), 134.27 (CH=CH), 134.87 (Ar C), 152.39 (C=O oxazolidinone), 175.50 
(C=O); [Found: (ES+) 354.1714 [M+Na]+, C19H25NO4Na requires 354.1701]. 
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4.8 (R)­4­benzyl­3­((2S, 3S)­3­hydroxy­2­methyl­3­
phenylpropanoyl)oxazolidin­2­one (128)175 
O N 
O O 
Ph 
OH 
Ph 
The reaction was performed as described in 4.7.1 method A using (103) (0.25 g, 1.07 
mmol), TiCl4 (2.14 mL, 1.00 M in DCM, 2.14 mmol), DIPEA (0.31 mL, 1.76 mmol) 
and benzaldehyde (0.12 mL, 1.18 mmol). The product was purified by column 
chromatography (1:5 to 1:1 EtOAc: Petrol) containing 0.1% pyridine to give (128) as 
a white solid (0.26g, 72%); Rf 0.83 (EtOAc/ Petrol, 1:1); m. p. 93-95 °C; IR (DCM) 
3511, 1781, 1688, 1454, 1384, 1211; [α]D - 67 (c 1.0 in DCM); δH (270 MHz, 
CDCl3): 1.14 (3H, d, J = 6.8, CH3), 2.57 (1H, dd, J = 9.6, 3.8, CHHPh), 3.07 (1H, dd, 
J = 9.5, 3.3, CHHPh), 4.08-4.21 (3H, m, CH3CH + CH2O), 4.62-4.68 (1H, m, CH 
oxazolidinone), 5.13 (1H, d, J = 4.4, CHOH), 7.10-7.44 (10H, m, ArCH); δC (100 
MHz, CDCl3): 10.91 (CH3), 37.78 (CH2Ph), 44.45 (CHCH3), 55.12 (CHCH2Ph), 
66.11 (CH2O), 73.91 (CH-OH), 126.32 (Ar CH), 126.63 (Ar CH), 126.92 (Ar CH), 
127.39 (Ar CH), 127.63 (Ar CH), 127.92 (Ar CH), 128.13 (Ar CH), 128.29 (Ar CH), 
128.96 (Ar CH), 129.36(Ar CH), 135.10 (Ar C), 141.32 (Ar C), 153.07 (C=O 
oxazolidinone), 176.24 (C=O). Reaction was repeated on 0.86 mmol scale to give 
(128) (0.23 g, 80%). 
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4.9 (R)­3­((2S, 3S)­E­3­azido­2­methyloct­5­enoyl)­4 
benzyloxazolidin­2­one (105) 
O N 
O O 
Ph 
N3 
4.9.1 Method A185 
A stirred solution of (127) (0.10 g, 0.30 mmol) in anhydrous DCM (2 mL) at 0 °C 
under Ar, was treated with anhydrous Et3N (84 µL, 0.60 mmol) and drop-wise 
addition of methanesulfonyl chloride (23.40 µL, 0.30 mmol) and stirred for 3 h. The 
reaction mixture was quenched with sat. aq. NaCl (2 mL). The reaction mixture was 
extracted with DCM (2 x 2 mL). The organic extract was dried (MgSO4) and 
concentrated in vacuo. Analysis of the resulting residue by MS confirmed the 
presence of the expected mesylate. A stirred solution of the crude mesylate in 
anhydrous DMF (1.5 mL) under Ar was treated with NaN3 (58.6 mg, 0.9 mmol) and 
stirred for 3 days after which, the reaction was heated to 60 °C and stirred for a further 
24 h. The reaction was then refluxed for an additional 24 h. Analysis of the reaction 
mixture by TLC (EtOAc/petrol, 1:1) showed no consumption of the mesylate and the 
reaction mixture was quenched with sat. aq. NaCl (2 mL), extracted with DCM (2 x 2 
mL), dried (MgSO4) and concentrated in vacuo to give a yellow oil. 
1H NMR and MS 
analysis of the crude material did not indicate formation of the desired azide with full 
recovery of (127) (0.89 g). 
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4.9.2 Method B186 
A stirred solution of (127) (0.11 g, 0.33 mmol) in anhydrous DCM (5 mL) at 0 °C 
under N2 was treated with anhydrous pyridine (32 µL, 0.39 mmol) and dropwise 
addition of trifluoromethanesulfonic anhydride (61 µL, 0.36 mmol) and stirred for 3 h 
until TLC (EtOAc/Petrol, 1:1, Rf 0.32) indicated full consumption of starting alcohol. 
The reaction mixture was diluted with DCM (5 mL) extracted with cold 0.1M aq. HCl 
(2 x 5 mL) and cold sat. NaHCO3 (2 x 5 mL), dried (MgSO4) and the solvent 
evaporated. A stirred solution of crude triflate in anhydrous DMF (10 mL) at room 
temperature under N2 was treated with NaN3 (0.42 g, 6.53 mmol). The reaction 
mixture was heated to 60 °C and stirred for 36 h. Analysis of the reaction mixture by 
TLC (EtOAc/Petrol, 1:1) revealed the appearance of a new component and starting 
triflate. The reaction mixture was cooled to room temperature, concentrated in vacuo 
and the resulting residue was partitioned between DCM and water. The organic 
extract was dried (NaSO4) and concentrated by evaporation of the solvent. 
1H NMR 
and MS analysis of the crude material showed a small amount of dehydrated-
elimination product and unchanged starting alcohol (127) and did not indicate the 
formation of the desired azide. 
4.9.3 Method C 
The reaction was performed as described in 4.9.2 method B using using (127) (50.0 
mg, 0.2 mmol), anhydrous pyridine (16 µL, 0.18 mmol), trifluoromethanesulfonic 
anhydride (28 µL, 0.17 mmol) and NaN3 (0.20 g, 3.02 mmol). The reaction was 
performed under N2 at room temperature. 
1H NMR and MS analysis of the crude 
material did not show the formation of the desired azide with full recovery of (127). 
4.9.4 Method D142 
A solution of (127) (50.0 mg, 0.2 mmol) in anhydrous THF (1 mL) at room 
temperature under Ar was treated with DEAD (26 µL, 0.17 mmol) and PPh3 (44.0 
mg, 0.2 mmol). The reaction was stirred for 10 minutes after which, DPPA (36 µl, 0.2 
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mmol) was added. The reaction mixture was stirred for 16 h and then concentrated in 
vacuo to give 0.19 g of yellow oil. An attempt to purify the crude material 
(EtOAc/Petrol, (1:9 - 1:0) was performed to give recovered (127) and potential 
dehydrated-elimination product as determined by 1H NMR and MS analysis of the 
isolated products. The desired azide was not detected. 
4.10 Methyl­2S, 3R­E­ 3­hydroxy­2­methyloct­5­enoate (142)

O 
O OH 
A stirred solution of (127) (0.10 g, 0.30 mmol) in 4:1 THF:H2O (2 mL) at 0 °C under 
N2 was treated with 27% aqueous H2O2 (37 µL, 1.21 mmol) over a 3 minute period 
after which a solution of LiOH (12.0 mg, 0.5 mmol) in H2O (0.24 mL) was added. 
The reaction was stirred for 1.5 h and a solution of Na2SO3 (0.15 g, 1.21 mmol) in 
H2O (1 mL) was added. The reaction mixture was concentrated in vacuo to remove 
organic solvent. The remainig aqueous residue (pH 12-13) was extracted with DCM 
(3 x 25 mL). The aqueous extract was acidified (pH 1) using 6M aq. HCl. The 
acidified aqueous solution was extracted with EtOAc (5 x 25 mL), dried (MgSO4) and 
concentrated in vacuo. The resulting residue was dissolved in 5% aq. NaHCO3 and 
extracted with DCM (3 x 15 mL). The aqueous layer was acidified with 6M aq. HCl 
and extracted with EtOAc (5 x 15 mL), dried (MgSO4) and concentrated in vacuo to 
give crude carboxylic acid (142a) (50 mg) ((2S, 3R)-E-3-hydroxy-3-methyloct-5-
enoic acid). The DCM extracts were dried (MgSO4) and the solvent evaporated to 
give oxazolidinone ((4R)-4-benzyloxazolidin-2-one) (50 mg). 
A solution of crude carboxylic acid (142a) (50.0 mg, 0.3 mmol) in anhydrous ether 
(1.5 mL), at room temperature, under N2, was treated drop wise, with a solution of 
trimethylsilyldiazomethane (0.22 mL, 2.00 M in Et2O, 0.44 mmol) and stirred for 1 h. 
The reaction mixture was diluted with ether (3 mL), washed with 5% aq. NaHCO3 (2 
mL) and sat. aq. NaCl (2 mL). The organic extracts were combined, dried (MgSO4) 
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and concentrated in vacuo. The crude product was purified by column 
chromatography (DCM/MeOH, 100:0 to 98:2) to give (142) as a clear oil (12 mg, 
22%); Rf 0.62 (MeOH/DCM, 1:9); δH (270 MHz, CDCl3): 0.97 (3H, t, J = 8.3 
CH3CH2) 1.19 (3H, d, J = 7.9 CHCH3) 1.99-2.05 (2H, m, CH2CH3) 2.16-2.21 (1H, m, 
CH(OH)CHH) 2.51-2.64 (1H, m, CH(OH)CHH, 3.70 (3H, s, O-CH3) 3.85-3.96 (1H, 
m, CH-OH) 5.29-5.53 (1H, m, CH=CH) 5.55-5.61(1H, m, CH=CH); δC (101MHz, 
CDCl3): 10.89 (CHCH3), 13.75 (CH2CH3), 25.68 (CH2CH3), 37.82 (CH2CH(OH)), 
44.49 (CHCH3), 51.85 (O-CH3), 72.76 (CH-OH), 124.31 (CH=CH), 136.47 
(CH=CH), 176.42 (C=O) [Found: (ES+) 209.1141 [M+Na]+, C10H18O3Na requires 
209.1148]. 
4.11 4R, 5S­4­Methyl­5­phenyl­3­propanoyloxazolidin­2­one (130)174 
O N 
O O 
Ph 
A stirred solution of (4R, 5S)-4-methyl-5-phenyl-2-oxazolidinone (1.00 g, 5.65 mmol) 
in anhydrous THF (20 mL) at -78 °C under N2, was treated with a solution of n-BuLi 
(5.69 mmol, 1.90 M in THF, 3.00 mL) added drop-wise and stirred for 0.5 h after 
which, propanoyl chloride was added (6.20 mmol, 0.49 mL). The reaction was 
warmed to room temperature and stirred for 4 h. The reaction was then quenched by 
the addition of sat. aq. ammonium chloride solution (4 mL). The aqueous and organic 
phases were separated. The organic phase was washed with 1M aq. NaOH (2 x 10 
mL), brine (2 x 10 mL), dried (MgSO4) and concentrated in vacuo. The crude product 
was purified by column chromatography (EtOAc/ Petrol, 1:5) to give (130) as a clear 
oil (0.84 g, 64%); Rf 0.88 (EtOAc/ Petrol, 2:3); IR (DCM) 3435, 2986, 1781, 1704, 
1505, 1455, 1369, 1348, 1200; [α]D - 145 (c 1.0 in CHCl3); δH (270 MHz, CDCl3): 
0.85 (3H, d, J = 6.6, CH3 oxazolidinone), 1.13 (3H, t, J = 7.2, CH3), 2.87-2.99 (2H, m, 
CH2), 4.71-4.79 (1H, m, CH oxazolidinone), 5.62 (1H, d, J = 7.2, CHPh), 7.23-7.43 
(5H, m, Ar H); δC (67.5 MHz, CDCl3): 8.37 (CH3), 14.67 (CH3 oxazolidinone), 29.38 
(CH2), 54.83 (CHCH3 oxazolidinone), 79.10 (CHPh), 125.72 (Ar CH), 128.83 (Ar 
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CH), 133.43 (Ar C), 153.21 (C=O oxazolidinone), 173.92 (C=O). Reaction was 
repeated on 28.9 mmol scale to give (130) in 96 % yield. 
4.12 (4R, 5S)­3­((2S, 3R)­E­3­hydroxy­2­methyloct­5­enoyl)­4­methyl­
5­phenyloxazolidin­2­one (135) 
O N 
O O OH 
Ph 
A stirred solution of (130) (2.97 mmol, 0.69g) in anhydrous DCM (20 mL) at 0 °C, 
under nitrogen was treated with drop-wise addition of TiCl4 (5.95 mmol, 0.65 mL) 
and stirred for 20 minutes after which DIPEA (3.27 mmol, 0.57 mL) was added and 
the reaction mixture was stirred for a further 15 min. The reaction was cooled to -78 
°C and treated with dropwise addition of (E)-3-hexenal (5.94 mmol, 0.58 g) via 
cannula. The reaction was warmed to room temperature and stirred for 7 h. The 
reaction was quenched by the addition of half-sat. aq. NaCl solution (20 mL). The 
organic and aqueous layers were separated. The organic phase was dried (MgSO4) 
and the solvent evaporated. The product was purified by column chromatography 
(EtOAc/Petrol, 5:95 containing 0.1% pyridine) to give a mixture of two 
diastereoisomers (0.27 g). The desired diastereoisomer (135) was isolated as a clear 
oil (0.25 g, 27%); Rf 0.27 (EtOAc/ Petrol, 1:5); IR (DCM); 3440, 2908, 1781, 1701, 
1456, 1340, 1232; [α]D - 84 (c 1.0 in DCM); δH (270 MHz, CDCl3): 0.88 (3H, d, J= 
6.6, CH3 oxazolidinone), 0.94 (3H, t, J = 7.4, CH3CH2), 1.21 (3H, d, J = 7.2, CH3CH), 
1.97 (2H, quin, J = 7.2, CH2CH3), 2.17-2.26 (2H, m, CH2COH), 2.68 (1H, br, OH), 
3.86-3.89 (1H, m, CHOH)), 3.90-3.96 (1H, m, CHCH3), 4.73 (1H, quin, J = 6.9, CH 
oxazolidinone), 5.25-5.44 (1H, m, CH=CH), 5.53-5.58 (1H, m, CH=CH), 5.65 (1H, d, 
J = 7.2, CHPh), 7.24-7.44 (5H, m, Ar H); δC (67.5 MHz, CDCl3): 10.87 (CH3CH), 
13.84 (CH3CH2), 14.68 (CH3 oxazolidinone), 25.75 (CH2CH3), 37.34 (CH2CHOH), 
41.72 (CHCH3), 54.98 (CCH3 oxazolidinone), 71.35 (CHOH), 78.95 (CPh), 124.58 
(CH=CH), 125.71 (Ar CH), 128.84 (Ar CH), 133.20 (Ar C), 136.00 (CH=CH), 
152.80 (C=O oxazolidinone), 176.89 (C=O); [Found: (ES+) 332.1838 [M+H]+, 
C19H26NO4 requires 332.1856]. 
164 
4.13 Preparation of (4R,5S)­3­((2R,3R)­3­hydroxy­2­methyl­3­
phenylpropanoyl)­4­methyl­5­phenyloxazolidin­2­one (136) 
O N 
O O OH 
Ph 
4.13.1 Method A174 
The reaction was performed as described in 4.6.1 method A using (130) (0.12 g, 0.53 
mmol), dibutylboron triflate solution (0.62 mL, 1.00 M in anhydrous DCM, 0.62 
mmol), Et3N (98 µL, 0.69 mmol) and benzaldehyde (60 µL, 0.58 mmol) in 1.1 mL 
anhydrous DCM. The crude product was purified by column chromatography (silica 
gel eluted with 1:5 to 2:5 EtOAc/Petrol) to give (136) as a white solid (0.10 g, 60%). 
4.13.2 Method B175 
The reaction was performed as described in 4.7.1 method A using (130) (0.10 g, 0.43 
mmol) anhydrous DCM (4 mL), TiCl4 (94 µL, 0.86 mmol), DIPEA (82 µL, 0.47 
mmol), benzaldehyde (48 µL, 0.47 mmol) and stirred for 5 h at -78 °C and allowed to 
-40 °C for 16 h. Analysis by TLC and 1NMR showed the presence of two distinct 
diastereoisomers. 
4.13.3 Method C184 
A stirred solution of (103) (0.23 g, 1.00 mmol) in anhydrous DCM (10 mL) was 
cooled to 0 °C under nitrogen and treated with TiCl4 (0.16 mL, 1.05 mmol) and stirred 
for 15 minutes after which, DIPEA (0.19 mL, 1.10 mmol) was added and stirred for a 
further 40 minutes. The reaction mixture was treated with NMP (96 µL, 1.00 mmol) 
and stirred for 10 minutes after which, benzaldehyde (0.11 mL, 1.10 mmol) was 
added and stirred for 3 h. The reaction was quenched by the addition of half saturated 
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aqueous NH4Cl. The organic and aqueous phase was separated. The aqueous phase 
was extracted with DCM (2 x 10 mL). The combined organic extracts were dried 
(MgSO4) and the solvent was evaporated. The crude product was purified by column 
chromatography (1:9 to 1:5 EtOAc/Petrol) to give (136) as a white solid (0.16 g, 
47%); Rf 0.42 (EtOAc/Petrol 1:5); m. p. 102–105 °C; IR 3074, 1782, 1689, 1455, 
1365, 1345, 1196; [α]D + 24 (c 1.0 in CHCl3); δH (270 MHz, CDCl3): 0.85 (3H, d, J 
= 6.6, CHCH3), 1.19 (3H, d, J= 6.8 CH3 oxazolidinone), 3.09 (1H, d, J = 2.7, 
CH(OH)), 4.07-4.12 (1H, m, CHCH3), 4.62-4.70 (1H, m, CHCH3 oxazolidinone), 
5.06-5.07 (1H, br, s, OH), 5.43 (1H, d, J =7.2, CHPh oxazolidinone), 7.24-7.38 (10H, 
m, ArH); δC (67.5 MHz, CDCl3): 11.03 (CHCH3), 14.45 (CH3 oxazolidinone), 44.81 
(CHCH3), 54.99 (CHCH3 oxazolidinone), 74.19 (CH(OH)), 79.05 (CHPh), 125.67 
(CHAr), 126.27 (CHAr), 127.70 (2 x CHAr), 128.37 (2 x CHAr), 128.83 (2 x CHAr), 
128.92 (2 xCHAr), 133.12 (2 x CAr), 152.62 (C=O oxazolidinone), 176.52 (C=O). 
4.14 (4R, 5S)­3­((2R, 3S)­E­3­hydroxy­2­methyloct­5­enoyl)­4­methyl­
5­phenyloxazolidin­2­one (131) 
O N 
O O OH 
Ph 
A stirred solution of (103) (0.55 g, 2.35 mmol) in anhydrous DCM (23 mL) was 
cooled to 0 °C under nitrogen and treated with TiCl4 (0.27 mL, 2.47 mmol) and 
stirred for 15 minutes after which DIPEA (0.45 mL, 2.58 mmol) was added and 
stirred for 40 minutes. The reaction mixture was treated with NMP (0.22 mL, 2.35 
mmol) and stirred for 10 minutes after which (E)­3-hexenal (0.46 g, 4.70 mmol) was 
added via cannula and stirred for 6 h. The reaction was quenched by the addition of 
half-saturated aqueous NH4Cl (20 mL). The organic and aqueous phase was 
separated. The aqueous phase was extracted with DCM (2 x 20 mL). The combined 
organic extracts were dried (MgSO4) and concentrated in vacuo. The crude product 
was purified by column chromatography (1:9 to 1:5 EtOAc/Petrol) to give (131) as a 
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yellow oil (0.47 g, 61%); Rf 0.54 (1:5 EtOAc/Petrol), IR 3461, 2969, 1781, 1701, 
1457, 1346, 1197; [α]D + 29 (c 1.0 in CHCl3); δH (270 MHz, CDCl3): 0.86 (3H, d, J 
= 6.6, CH3 oxazolidinone), 0.94 (3H, t, J = 7.4, CH3CH2), 1.22 (3H, d, J = 7.2 
CHCH3), 1.97 (2H, quin, J = 7.2, CH2), 2.12-2.30 (2H, m, CH2CH3), 2.79 (1H, s, 
OH), 3.76-3.85 (1H, m, CHCH3), 3.93-3.99 (1H, m, CH(OH)), 4.72 (1H, quin, J = 
6.6, CHCH3 oxazolidinone), 5.35-5.46 (1H, m, CH=CH), 5.54-5.62 (1H, m, CH=CH), 
5.65 (2H, d, J = 7.4, CHPh), 7.30-7.38 (5H, m, ArH); δC (67.5 MHz, CDCl3): 10.60 
(CHCH3), 13.83 (CH2CH3), 14.46 (CH3 oxazolidinone), 25.74 (CH2CH3), 37.37 
(CH2CH(OH), 41.68 (CHCH3), 54.86 (CHCH3), 71.36 (CH-OH), 78.98 (CHPh), 
124.55 (ArCH), 125.68 (4 x ArCH), 128.84 (C=C), 128.91 (C=C), 136.01 (ArC), 
152.65 (C=O oxazolidinone), 177.09 (C=O). [Found: (ES+) 332.1860 [M+H]+,

C19H26NO4 requires 332.1861].

Reaction was repeated on 19.8 mmol scale which gave (131) in 72 % yield.

4.15 (4R,5S)­3­((2S,3S,)­E­3­azido­2­methyloct­5­enoyl)­4­methyl­5­
phenyloxazolidin­2­one (132a) 
O N 
O O 
Ph 
N3 
4.15.1 Method A185 
A stirred solution of alcohol (135) (50.0 mg, 0.2 mmol) in anhydrous DCM (0.5 mL) 
at 0 °C under Ar was treated with anhydrous Et3N (42 µL, 0.30 mmol) for 3 minutes 
after which methansulfonylchloride (17.3 mg, 0.2 mmol) was added dropwise and 
stirred for 6 h at which point the reaction mixture was quenched with sat. aq. NaCl 
(0.5 mL) and extracted with DCM (2 x 0.5 mL). The organic extract was dried 
(MgSO4) and concentrated in vacuo. A stirred solution of the resulting residue in 
DMF (1.5 mL) at room temperature was treated with NaN3 (29.5 mg, 0.5 mmol) for 
16 h after which sat. aq. NaCl (1.5 mL) was added and the reaction mixture was 
extracted with DCM (2 x 1.5 mL). The organic extract was dried (MgSO4), and 
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concentrated in vacuo. Analysis of the resulting residue by TLC, MS and 1H NMR 
showed the presence of eliminated material and unchanged mesylate. 
4.15.2 Method B142 
A stirred solution of (135) (0.13 g, 0.37 mmol) in anhydrous THF (10 mL) at room 
temperature under Ar was treated with DEAD (65 µL, 0.42 mmol) and PPh3 (0.11 g, 
0.42 mmol) and stirred for 10 minutes after which DPPA (90 µL, 0.42 mmol) was 
added and stirred for 18 h. The reaction mixture was concentrated in vacuo and the 
crude product was purified by column chromatography (EtOAc/ Petrol, 5:95) to give 
(132a) as an orange oil (8 mg, 7%), Rf 0.61 (EtOAc/Petrol 1:5); δH (270 MHz, 
CDCl3): 0.85 (3H, d, J = 6.6, CH3 oxazolidinone), 0.95 (3H, t, J = 7.4, CH3CH2), 1.16 
(3H, t, J = 6.9, CH3CH), 1.98 (2H, quin, J = 7.2, CH2CH3), 2.13-2.24 (1H, m, 
CHHCHN3), 2.42-2.49 (1H, m, CHHCHN3) 3.68-3.87 (2H, m, CHCN3 and CHCH3), 
4.74 (1H, quin, J = 6.6, CH oxazolidinone), 5.37-5.48 (1H, m, CH=CH), 5.59-5.64 
(1H, m, CH=CH), 5.66 (1H, d, J = 7.4, CHPh), 7.24-7.53 (5H, m, ArH); δC(101 
MHz, CDCl3): 12.98 (CHCH3), 14.12 (CH2CH3), 14.35 (CH3 oxazolidinone), 40.87 
(CH), 50.51 (CHN3), 60.48 (CHMe oxazolidonone), 70.85 (CHPh), 120.28 (ArCH), 
120.60 (CH=CH), 120.85 (2 x ArCH), 120.89 (2 x ArCH), 130.64 (CH=CH), 150.23 
(C=O), 170.43 (C=O); [Found: (ES+) 357.1927 [M+H]+, C19H25N4O3 requires 
357.1921. 
Reaction was repeated on 0.15 mmol scale at 0 °C for 10 min, then after the addition 
of DPPA, the reaction was allowed to warm to room temperature and stirred for 16 h 
which gave (132a) (6 mg, 11%). 
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4.16 (2R, 3S)­E­2­methyl­1­((4R, 5S)­4­methyl­2­oxo­5­
phenyloxazolidin­3­yl)­1­oxooct­5­en­3­yl 4­
methylbenzenesulfonate (154) 
O 
S 
O O O 
O 
O N 
Ph 
A stirred solution of (131) (50.0 mg, 0.2 mmol) in anhydrous pyridine (0.3 mL) under 
N2 at 0 °C was treated with p-toluenesulfonyl chloride (32.0 mg, 0.2 mmol) and the 
reaction mixture was allowed to warm to room temperature and stirred for 18 h. The 
reaction was warmed to 40 °C and stirred for 6 h and then warmed to 70 °C and 
stirred for a further 16 h. The reaction mixture was poured over ice-cold 1M aq. HCl 
(1 mL) and extracted with DCM (3 x 5mL). The organic extract was washed with 
brine (2 x 5mL), dried (MgSO4) and concentrated by evaporation of the solvent. 
Analysis of the resulting residue by 1H NMR indicated the presence of unchanged 
starting material (131). 
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4.17 (4R, 5S)­3­((2R, 3R)­E­3­azido­2­methyloct­5­enoyl)­4­methyl­5­
phenyloxazolidin­2­one (132) 
O N 
O O 
Ph 
N3 
4.17.1 Method A (using HN3)
221 
Hydrazoic acid was prepared as follows221: 
A solution of NaN3 (1.63 g, 0.03 mmol) in water (29 mL) was cooled to 0 °C at which 
point CHCl3 (10 mL) was added. The reaction mixture was treated with H2SO4 (0.68 
mL, 0.01 mmol), added drop-wise. The organic layer was decanted and dried 
(MgSO4) to give a solution of HN3. 
A stirred solution of (131) (50.0 mg, 0.2 mmol) in anhydrous toluene (1 mL) under 
nitrogen at 0 °C was treated with PPh3 (44.0 mg, 0.2 mmol) and DEAD (26 µL, 0.2 
mmol) and stirred for 15 minutes after which, hydrazoic acid (92 µL, 0.17 mmol) was 
added. The reaction was allowed to warm to room temperature and stirred for 16 h. 
The reaction was concentrated by evaporation of the solvent and the crude mixture 
was purified by column chromatography (5:95 to 1:5 EtOAc/Petrol) to give 
eliminated product (155) (29 %) and unchanged starting material (131) (60%). 
4.17.2 Method B (Mitsunobu method)142 
A stirred solution of (131) (0.34 g, 1.03 mmol) in anhydrous THF (6 mL) under N2 at 
-20 °C was treated with PPh3 (0.29 g, 1.13 mmol) and DEAD (0.18 mL, 1.13 mmol) 
and stirred for 15 minutes after which DPPA (0.25 mL, 1.13 mmol) was added and 
stirred at -20 °C for 1 h. The reaction was allowed to warm to room temperature and 
stirred for 16 h. The reaction was concentrated in vacuo and the crude product was 
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purified by column chromatography (EtOAc/Petrol 5:95 to 1:5) containing 0.1% 
pyridine to give (132) as a yellow oil (0.199 g, 50%); Rf 0.64 (1:5 EtOAc/Petrol); IR 
(DCM) 3420, 2967, 2105, 1781, 1669, 1456, 1345, 1196; [α]D + 49 (c 1.0 in CHCl3). 
δH (270 MHz, CDCl3): 0.85 (3H, d, J = 6.6, CH3 oxazolidinone), 0.95 (3H, t, J = 7.4, 
CH2CH3), 1.16 (3H, d, J = 6.9, CHCH3), 1.98 (2H, quin, J = 7.2, CH2CH3), 2.13-2.24 
(1H, m, CHHCHN3), 2.42-2.49 (1H, m, CHHCHN3), 3.68-3.87 (2H, m, CHN3 and 
CHCH3), 4.74 (1H, quin, J = 6.6, CHCH3 oxazolidinone), 5.37-5.48 (1H, m, 
CH=CH), 5.59-5.64 (1H, m, CH=CH), 5.66 (1H, d, J = 7.4, CHPh), 7.20-7.37 (5H, 
m, ArCH); δC (67.5 MHz, CDCl3): 13.63 (CHCH3), 14.12 (CH2CH3), 14.62 (CH3 
oxazolidinone), 25.77 (CH2CH3), 34.74 (CH2CHN3), 41.85 (CHCH3), 55.09 (CHN3), 
64.55 (CHCH3 oxazolidinone), 79.08 (CHPh), 123.19 (CH=CH), 125.67 (CHAr), 
125.70 (2 x CHAr),128.83 (2 x CHAr), 133.25 (CAr), 136.85 (CH=CH), 152.67 
(C=O oxazolidinone), 174.67 (C=O). [Found (ES+) 379.1747 [M+Na]+, 
C19H24N4O3Na requires 379.1746]. 
Reaction was repeated using 0.15 and 3.02 mmol scale to give the desired azide (132) 
and elimination product (155) (0.19 mg, 35% and 0.37 g, 34% respectively). 
4.18 (4R, 5S)­3­((2R, 3R)­E­3­amino­2­methyloct­5­enoyl)­4­methyl­
5­phenyloxazolidin­2­one (156) 
O N 
O O NH2 
A stirred solution of (132) (50.0 mg, 0.1 mmol) in anhydrous THF (0.40 mL) was 
treated with PPh3 (45.0 mg, 0.2 mmol) at room temperature for 30 minutes after 
which H2O (14 µL) was added. The reaction was heated to 60 °C and stirred for 16 h. 
The reaction was concentrated in vacuo and the crude product was purified by column 
chromatography (EtOAc/Petrol, 5:95 to 2:3) containing 0.1% pyridine to give (156) 
as a yellow oil (27 mg, 59%); Rf 0.42 (EtOAc/Petrol 2:3); δH (270 MHz, CDCl3): 
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0.94 (3H, t, J = 7.5, CH2CH3), 1.12 (3H, d, J = 7.2, CHCH3), 1.35 (3H, d, J = 6.6, 
CH oxazolidinone), 1.83-2.05 (2H, m, CH2CH3), 2.15-2.23 (1H, m, CHHCHNH2), 
2.33 (1H, quin, J = 7.1, CHHCHNH2), 2.89-2.93 (1H, m, CH(NH2)), 3.94-4.04 (1H, 
m, CH3CH), 4.95-5.02 (1H, m, CHCH3 oxazolidinone), 5.05 (1H, d, J = 4.9, CHPh), 
5.15-5.26 (1H, m, CH=CH), 5.43 (2H, br, s, NH2), 5.51-5.65 (1H, m, CH=CH), 7.25-
7.41 (5H, m, ArH); δC (100 MHz, CDCl3): 12.40 (CH3CH2), 13.48 (CH3), 13.68 
(CH3 oxazolidinone), 25.59 (CH2CH3), 37.16 (CH2CHNH2), 40.75 (CHCH3), 52.05 
(CH(NH2)), 78.87 (CHPh), 122.09 (ArCH), 126.43 (2 x ArCH), 127.54 (2 x ArCH), 
128.72 (CH=CH), 128.70 (CH=CH), 133.17 (ArC), 154.22 (C=O oxazolidinone), 
172.80 (C=O); [Found: (ES+) 331.2006 [M+H]+, C19H27N2O3 requires 331.2016]. 
4.19 (2R, 3R)­E­3­(((9H­fluoren­9­yl)methoxycarbonylamino)­2­
methyloct­5­enoic acid (108) and ester (157) 
HO O 
O HN 
O 
O O HN 
O 
O 
(108) (157) 
4.19.1 Method A 
A stirred solution of (156) (27.0 mg, 0.1 mmol) in H2O/THF (1:4 v/v, 0.4 mL) at 0 °C 
was treated with 30 % H2O2 (10 µL, 0.3 mmol) and LiOH (3.1 mg, 0.1 mmol) and 
stirred for 3 h after which, Na2SO3 (41.2 mg, 0.3 mmol) was added. The reaction 
mixture was concentrated in vacuo. The resulting residue was dissolved in H2O (5 
mL) and extracted with DCM (3 x 5 mL). The organic extract was dried (MgSO4) and 
the solvent evaporated to give 8.2 mg of oxazolidinone (129). The aqueous phase was 
neutralised by addition of 6M HCl and concentrated in vacuo. A stirred solution of the 
resulting residue in 10% aq. Na2CO3 (21.6 mg, 0.2 mmol) and dioxane (0.15 mL) at 0 
°C, was treated with Fmoc-Cl (21.1 mg, 0.1 mmol) after which the reaction mixture 
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was allowed to warm to room temperature and stirred for 16 h. The reaction mixture 
was diluted with H2O (5 mL) and extracted with Et2O (2 x 5 mL). The aqueous 
extract was acidified to pH 2 and extracted with DCM (3 x 5 mL). The organic extract 
was dried (MgSO4) and the solvent evaporated. The crude product was purified by 
column chromatography (MeOH/DCM, 0:1 to 5:95) to give (108) as a clear oil (1.2 
mg, 4%); Rf 0.53 (15:85 MeOH/DCM). 
4.19.2 Method B 
A stirred solution of azide (132) (92.0 mg, 0.3 mmol) in 1:4 H2O/THF (1.4 mL) at 0 
°C was treated with 30 % H2O2 (32 µL, 1.0 mmol) and LiOH (10.0 mg, 0.4 mmol) 
and stirred for 3 h after which Na2SO3 (0.13 g, 1.03 mmol) was added. The reaction 
mixture was evaporated and the resulting residue was dissolved in H2O and extracted 
with DCM (3 x 5 mL). The organic extract was dried (MgSO4) and evaporated to give 
of oxazolidinone (129) (52 mg). The aqueous extract was acidified to pH 1 and 
extracted with EtOAc (6 x 5 mL). The combined organic extracts were dried (MgSO4) 
and the solvent evaporated. The resulting residue was dissolved in anhydrous THF 
(1.5 mL) and treated with PPh3 (73.0 mg, 0.3 mmol) and stirred at room temperature 
for 30 minutes under N2 after which, water (45 µL) was added and the reaction 
mixture was heated at 60 °C for 16 h. The reaction mixture was evaporated, dissolved 
in water (5 mL) and extracted with DCM (3 x 5 mL). The aqueous extract was 
concentrated in vacuo and dissolved in a solution of 10% aq. NaHCO3 (8.3 mmol, 
0.70 mL) and dioxane (0.45 mL) then treated with Fmoc-Cl (67.0 mg, 0.3 mmol) and 
stirred for 16 h at room temperature after which, the reaction mixture was diluted with 
water (5 mL) and extracted with Et2O (3 x 5 mL). The aqueous extract was acidified 
to pH 2 and extracted with EtOAc (6 x 5 mL). The organic extract was washed with 
sat. aq. NaCl (2 x 5 mL), dried (MgSO4) and concentrated in vacuo. The crude 
product was purified by column chromatography (MeOH/DCM 0:1 to 5:95) to give 
the acylated Fmoc ester (157) as a clear oil (12 mg, 8%); Rf 0.65 (DCM 100%) and 
the product as a clear oil (4 mg, 4%); Rf (0.54), (MeOH/DCM 15:85). Data for Fmoc 
ester (157): δH (270 MHz, CDCl3): 0.89 (3H, t, J = 7.4, CH2CH3), 1.23 (3H, d, J = 
7.1, CHCH3), 1.92-2.04 (2H, m, CH3CH2), 2.21 (2H, t, J = 6.6, CH2CH(NHFmoc), 
2.71-2.77 (1H, m, CHCH3), 3.77-3.87 (1H, m, CH(NH-Fmoc), 4.19 (1H, t, J = 6.6, 
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CH­Fmoc), 4.34 (2H, d, J = 7.2, CH2-Fmoc), 5.28-5.41 (1H, m, CH=CH), 5.48-5.58 
(1H, m, CH=CH), 7.26 (4H, t, J = 7.2, 4 x ArCH), 7.35 (4H, t, J = 7.4, 4 x ArCH), 
7.57 (4H, d, J = 7.2, 4 x ArCH), 7.73 (4H, d, J = 7.2, 4 x ArCH); δC (67.5 MHz, 
CDCl3): 13.81 (CH3), 15.06 (CH3CH2), 25.67 (CH3CH2), 36.53 (CH2CH(NHFmco)), 
41.77 (CHCH3), 47.35 (CH(NHFmoc)), 53.24 (Fmoc amide CH), 53.55 (Fmoc ester 
CH), 66.68 (Fmoc amide CH2), 66.86 (Fmoc ester CH2), 120.06 (2 x ArCH), 124.21 
(C=C), 125.22 (2 x ArCH), 127.05 (2 x ArCH), 127.75 (2 x ArCH), 128.64 (ArC), 
128.84 (ArC), 132.13 (ArC), 132.25 (ArC), 136.15 (C=C), 144.06 (Fmoc amide 
C=O), 156.43 (Fmoc ester C=O). [Found (ES+) 572.2793 [M+H]+, C38H38NO4 
requires 572.2795]. 
4.19.3 Method C 
A stirred solution of (132) (0.37 g, 1.04 mmol) in 1:4 H2O/THF (6 mL) at 0 °C under 
N2, was treated with 30 % H2O2 (0.13 µL, 4.15 mmol) and LiOH (40.0 mg, 1.7 mmol) 
and stirred for 3 h after which Na2SO3 (0.5 mg, 4.2 mmol) was added. The solvent 
was evaporated and the resulting residue was dissolved in H2O (15 ml) and extracted 
with DCM (3 x 20 mL). The aqueous extract was acidified to pH 1 and extracted with 
EtOAc (6 x 20 mL). The combined organic extracts were dried (MgSO4) and the 
solvent evaporated. The resulting residue was dissolved in 5% aq. NaHCO3 (15 mL) 
and extracted with DCM (2 x 20 mL). The organic extracts were dried (MgSO4) and 
the solvent evaporated to give oxazolidinone (129) (188 mg). The aqueous extract 
was acidified and extracted with EtOAc (6 x 20 mL). The organic extract was dried 
and the solvent was evaporated. A stirred solution of the resulting residue in 
anhydrous THF (2.0 mL) under N2, at room temperature, was treated with PPh3 (0.33 
g, 1.25 mmol) and stirred at room temperature for 30 minutes after which, H2O (0.18 
mL) was added and the reaction mixture was heated at 60 °C for 16 h. The solvent 
was evaporated and the resulting residue was dissolved in water (8 mL) and extracted 
with DCM (2 x 10 mL). The aqueous extract was concentrated by evaporation, re-
dissolved in 10% aq. NaHCO3 (2.75 mL) and treated with FmocOSu (0.35 g, 1.04 
mmol) and dioxane (0.45 mL) then stirred at room temperature for 16 h. The reaction 
mixture was diluted with water (10 mL) and extracted with Et2O (10 mL). The solvent 
of the organic extract was evaporated. The aqueous extract was acidified to pH 1 and 
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extracted with EtOAc (6 x 10 mL). The organic extract was washed with sat. aq. NaCl 
(2 x 5 mL), dried (MgSO4) and the solvent evaporated. The resulting residue was 
dissolved in EtOAc (10 mL) and washed with 10% aq. NaHCO3 (10 mL). The 
aqueous extract was acidified to pH 1 and extracted with EtOAc (6 x 10 mL). The 
organic extract was dried (MgSO4) and the solvent was evaporated. The residue from 
the EtOAc extract was purified by preparative RP-HPLC (gradient 1, λ = 214 nm, tR = 
14.7 - 15.0), RP-HPLC (analytical, system 2, gradient 1, λ = 214 nm, tR = 10.9). The 
residue from the Et2O extract was purified by preparative RP-HPLC (gradient 9, tR = 
28.8) RP-HPLC ((analytical, system 2, gradient 1, tR = 10.8) which gave (108) as a 
white solid (37 mg, 9%), m. p. 146–148 °C; IR (DCM) 3428, 2964, 1717, 1509, 1451, 
1232; [α]D + 15 (c 1.0 in CHCl3); δH (250 MHz, CDCl3): 0.90 (3H, t, J = 7.4, 
CH2CH3), 1.24 (3H, d, J = 6.6, CHCH3), 1.93-2.02 (2H, m, CH3CH2), 2.22 (2H, t, J = 
6.6, CH2CH(NHFmoc), 2.72-2.81 (1H, m, CHCH3), 3.79-3.89 (1H, m, CH(NH-
Fmoc), 4.19 (1H, t, J = 6.8, CH­Fmoc), 4.35 (2H, d, J = 7.2, CH2-Fmoc), 5.28-5.41 
(1H, m, CH=CH), 5.49-5.59 (1H, m, CH=CH), 7.26 (2H, t, J = 7.2, 2 x ArCH), 7.35 
(2H, t, J = 7.4, 2 x ArCH), 7.57 (2H, d, J = 7.2, 2 x ArCH), 7.73 (2H, d, J = 7.4, 2 x 
ArCH); δC (100 MHz, CDCl3): 13.68 (CH3CH), 14.79 (CH2CH3), 25.56 (CH2CH3), 
41.69 (CHCH3), 47.23 (CH(NH-Fmoc)), 53.02 (CH-Fmoc), 66.74 (CH2-Fmoc), 
119.95 (2 x ArCH), 123.93 (CH=CH), 125.06 (2 x ArCH), 127.00 (2 x ArCH), 127.65 
(2 x ArCH), 136.18 (CH=CH), 141.28 (2 x ArC), 143.92 (2 x ArC), 156.35 (Fmoc 
C=O), 180.07 (C=O). [Found (ES+) 394.2023 [M+H]+, C24H28NO4 requires 
394.2018]. 
Reaction was repeated using 0.51 and 3.51 to give (108) (55 mg, 28% and 0.25 g, 
21% respectively). 
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4.20 H­L­Ala­Amoa­L­Arg(Pmc)­L­MePhe­L­Asp(OBut)­OH (164) 
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Synthesis was performed manually using 2-chlorotrityl polystyrene resin (0.30 g, 0.39 
mmol). Loading of the resin was achieved by treating the resin with a solution of 
Fmoc-L-Asp(OBut)-OH (0.48 g, 1.17 mmol) and DIPEA (0.41 mL, 2.34 mmol) in dry 
DCM (7 mL) for 90 min at room temperature. Fmoc deprotection was achieved by 
treatment of the resin with piperidine/DMF (v/v 1:4) for 4 x 4 min. Peptide couplings 
were performed using Fmoc-amino acid (3.0 equiv.), PyBOP (1.9 equiv.), HOBt (2.0 
equiv) and DIPEA (6.0 equiv) in DMF (7 mL) for 90 min, except for the coupling to 
MePhe, where Fmoc-Arg(Pmc)-OH (3.0 equiv), PyBrOP (1.9 equiv) and DIPEA (6.0 
equiv) for 4 x 90 min were used and for the coupling to Arg(Pmc), where Fmoc-
amoa-OH (108) (1.5 equiv), HATU (1.5 equiv) and DIPEA (4.5 equiv) for 4.5 h were 
used. Solid-phase reactions were monitored by use of a qualitative Kaiser test for the 
detection of primary amines and the chloranil test for the detection of secondary 
amines. Cleavage from the resin was achieved by treatment with TFA/DCM (v/v, 
1:99, 4 mL) for 10 x 2 min. The cleavage solutions were immediately neutralised by 
addition to pyridine/MeOH (v/v 1:9, 10 mL).The cleavage solution was concentrated 
in vacuo. The crude peptide was dissolved in the minimum amount of MeOH (2.5 
mL) and added to cold water (45 mL). The precipitate was collected by 
centrifugation, dissolved in DCM (20 mL) and washed with water (15 mL). The 
organic extract was dried (MgSO4) and concentrated in vacuo to give (164) as a white 
solid (0.21 g, 55% yield, based on 0.39 mmol starting resin), m. p. 120–123 °C RP-
HPLC (analytical, system 2, gradient 1, tR = 8.8 min). [Found: (ES+) 997.5373 
[M+H]+, C50H77N8O11S requires 997.5354]. 
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4.21 Cyclo­[L­Ala­Amoa­L­Arg(Pmc)­L­MePhe­L­Asp(OBut)] (165) 
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A stirred solution of linear peptide (164) (0.18 g, 0.18 mmol) in DCM (181 mL), was 
treated with HATU (0.21 g, 0.54 mmol) and adjusted to pH 9 by the addition of 
DIPEA (1.75 mL) and stirred for 36 h at room temperature. The reaction mixture was 
concentrated in vacuo, dissolved in EtOAc (25 mL) and washed with 5% citric acid 
(20 mL), and sat. NaHCO3 (20 mL). The organic extract was dried (MgSO4) and 
concentrated in vacuo, to give (165) as a white solid (77%, 0.14 g), m. p. 132–136 °C 
RP-HPLC (analytical, system 2, gradient 1, tR = 10.9 min). [Found (ES+) 1001.5125 
[M+Na]+, C50H74N8O10SNa requires 1001.5146]. 
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4.22 Cyclo­[L­Ala­Amoa­L­Arg­L­MePhe­L­Asp] (166)
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A stirred solution of peptide (165) (0.10 g, 0.10 mmol) was treated with a solution of 
TFA/DCM (v/v, 1:1, 10 mL) and stirred at room temperature for 3 h. The reaction 
mixture was concentrated in vacuo, dissolved in TFA (1.6 mL) and precipitated by the 
addition to ice-cold Et2O. The precipitate was collected by centrifugation to give 
(166) as the trifluoroacetate salt (76 %, 50 mg). RP-HPLC (analytical, system 2, 
gradient 1, tR = 6.1 min). [Found: (ES+) 657.3682 [M+H]
+, C32H49N8O7 requires 
657.3724]. 
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4.23 Banyasin A (167)
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A stirred solution of peptide (166) (50.0 mg, 0.1 mmol) in DMF (1.3 mL) was treated 
with DBU (54 µL, 0.4 mmol), heated to 40 °C and stirred for 2 min, after which a 
solution of succinimidyl N-methylcarbamate (36.0 mg, 0.2 mmol) in DMF (0.25 mL) 
was added and stirred for 2 h at 40 °C. The reaction mixture was concentrated in 
vacuo and the crude product was purified by semi-preparative RP-HPLC (gradient 10, 
λ = 214 nm, tR = 15.1 min) to give (167) as the trifluoroacetate salt (6.7 mg, 13 %). 
RP-HPLC (analytical, system 2, A = H2O, B = MeCN, C = H2O with 0.1% FA, D = 
MeOH, gradient 11, tR = 3.2 min). δH (600 MHz, 20% MeOD, 80% CDCl3, 2:1 
mixture of rotamers); 0.61-0.72 (1H, m, β-Arg CH), 0.72-0.78 (3H, m, CH2CH3), 
0.92 (1H, d, J = 4.4, CH3 amoa minor), 1.01 (2H, d, J = 4.4, CH3 amoa major), 1.07-
1.17 (1H, m, β-Arg CH), 1.22 (1.5H, d, J = 4.2, CH3 D-Ala minor), 1.31 (1.5H, d, J = 
4.2, CH3 D-Ala major), 1.38-1.61 (2H, m, γ-Arg CH2), 1.73-1.84 (2H, m, amoa 
CH2CH3), 1.85-1.94 (1H, m, amoa CHHCH), 2.02-2.08 (1H, m, amoa CHHCH), 
2.37-2.46 (1H, m, amoa CHCH3), 2.55 (2H, s, N-CH3 major), 2.61-2.65 (4H, m, MC-
NHCH3 + β-Asp CHH), 2.66 (1H, s, N-CH3 minor), 2.79-2.88 (2H, m, δ-Arg CH2), 
2.98-3.15 (2H, m, β-MePhe CH2), 3.55-3.64 (1H, m, amoa CHCH2), 3.76-3.84 (1H, 
m, α-Arg CH), 4.61-4.21 (0.5H, m, α-D-Ala CH), 4.26-4.35 (1H, m, α-Asp CH), 4.49-
4.52 (0.5H, m, α-D-Ala CH), 4.60-4.66 (1H, br, s, NH), 4.91-4.98 (0.5H, m, α-MePhe 
CH), 5.05-5.14 (0.5H, m, α-MePhe CH), 5.23-5.31 (1H, m, CH=CH), 5.38-5.43 (1H, 
m, CH=CH), 7.09-7.37 (5H, m, MePhe ArCH); δC (101MHz, 20% CD3OD in 
CDCl3): 13.84 (CH3), 15.46 (CH3 D-Ala minor), 15.69 (CH3 D-Ala major), 16.64 
(CH3 amoa major), 17.97 (CH3 amoa minor), 25.47 (γ-Arg CH2), 26.27 (CH2CH3), 
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26.31 (NHCH3), 28.62 (β-Arg CH2), 30.24 (N-CH3 major), 34.48 (β-MePh CH2), 
34.72 (β-Asp CH2), 37.50 ( Amoa CH2CH), 38.39 (δ-Arg CH2), 40.17 (N-CH3), 40.37 
(Amoa CHCH3), 48.57 (α-Arg CH minor), 49.43 (α-Ala CH), 49.79 (α-Arg CH 
major), 52.75 (Amoa CHCH2 minor), 53.35 (CHCH2 major), 64.31 (α-MePHe CH 
minor), 68.55 (α-MePhe CH major), 125.35 (ArCH), 127.73 (ArCH), 127.76 (ArCH), 
129.54 (ArCH), 129.79 (ArCH), 130.28 (ArC), 154.24 (MC C=O), 155.36 (N=C), 
172.81 (MePhe C=O), 173.26 (Asp C=O), 174.38 (Arg C=O), 175.31 (D-Ala C=O), 
175.42 (Amoa C=O). [Found: (ES+) 714.3917 [M+H]+, C34H52N9O8 requires 
714.3938]. 
4.24 (4R, 5S)­3­((2S, 3R)­E­3­bromo­2­methyloct­5­enoyl)­4­methyl­
5­phenyloxazolidin­2­one (168) 
O N 
O O Br 
4.24.1 Method A 
A stirred solution of (131) (0.30 mmol, 0.10 g) in anhydrous DCM (1 mL) under N2 at 
0 °C was treated with Et3N (0.60 mmol, 85 µL) and methansulfonyl chloride (0.30 
mmol, 24 µL) and stirred for 3 h after which, the reaction was quenched by the 
addition of sat. aq. NaCl (1 mL) and extracted with DCM (3 x 1 mL). The organic 
extract was dried (MgSO4) and concentrated in vacuo to give 111 mg of crude 
mesylate which was used further without purification. A stirred solution of crude 
mesylate (0.27 mmol, 0.11 g) in Ac2O (1 mL) at room temperature under N2 was 
treated with LiBr (1.28 mmol, 0.11 g) and stirred for 4 h after which water (5 mL) 
was added. The reaction mixture was extracted with EtOAc (5 x 10 mL) and DCM 
(10 mL). The organic extract was dried (MgSO4) and concentrated in vacuo. The 
crude mixture was purified by column chromatography (EtOAc/Petrol 5:95) to give 
(131) (50 mg). 
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4.24.2 Method B141 
The reaction was performed as described in 4.24.1 method A using (131) (0.39 mmol, 
0.13 g), Et3N (0.79 mmol, 0.11 mL), MsCl (0.39 mmol, 31 µL). Treatment of the 
crude mesylate with LiBr (0.11 g, 1.26 mmol) under N2 was performed at reflux for 
16 h. The crude bromide was purified by column chromatography (5:95 EtOAc/Petol) 
to give (168) as a clear oil (13%, 14 mg). 
4.24.3 Method C 
A stirred solution of (131) (88.0 mg, 0.3 mmol) in dry DCM (15 mL) was treated with 
CBr4 (0.19 g 0.56 mmol) and PPh3 (0.22 g, 0.85 mmol) at room temperature under N2 
for 16 h after which, the reaction was concentrated in vacuo. The crude product was 
purified by column chromatography (5:95 EtOAc/Petrol) to give bromide (168) as a 
yellow oil (35 mg, 34 %) as well as eliminated material (155) (25 mg, 30%). Rf 0.64 
(1:9 EtOAc/Petrol); IR (DCM) 4213, 3681, 3025, 2400, 1780, 1699, 1519, 1334, 
1220; [α]D + 35 (c 1.0 in CHCl3) δH (270 MHz, CDCl3): 0.87 (3H, d, J = 6.6, 
CHCH3), 0.97 (3H, t, J = 7.4 CH2CH3), 1.24 (3H, d, J = 6.3, CH3 oxazolidinone), 2.01 
(2H, quin, J = 6.3, CH2CH3), 2.44 – 2.55 (1H, m, CHHCHBr), 2.67 – 2.75 (1H, m, 
CHHCHBr), 4.27 – 4.36 (2H, m, α, β CH), 4.74 (1H, quin, J = 7.2, CHCH3 
oxazolidinone), 5.45 – 5.62 (2H, m, CH=CH), 5.67 (1H, d, J = 6.9, CHPh), 7.28 – 
7.43 (5H, m, ArCH); δC (101 MHz, CDCl3): 13.67 (CHCH3), 14.31 (CH2CH3), 15.86 
(CH3 oxazolidinone), 25.63 (CH2CH3), 37.69 (CHBr), 44.80 (CH), 55.11 (CH2), 
56.27 (CH oxazolidinone), 79.11 (CHPh), 109.95 (ArCH), 123.90 (CH=CH), 125.58 
(2 x ArCH), 128.72 (2 x ArCH), 133.12 (ArC), 136.40 (CH=CH), 152.16 (C=O 
oxazolidinone), 174.33 (C=O). [Found: (ES+) 394.1009 [M+H]+, C19H25BrNO3 
requires 394.1017, 416.0823 [M+Na]+, C19H24BrNO3Na requires 416.0837]. 
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4.25 (4R, 5S)­3­((2R, 3S)­E­3­azido­2­methyloct­5­enoyl)­4­methyl­5­
phenyloxazolidin­2­one (169) 
O N 
O O N3 
A stirred solution of bromide (168) (34.0 mg, 0.1 mmol,) in DMF (0.43 mL) was 
treated with NaN3 (17.0 mg 0.3 mmol,) and 15-crown 5 ether (8.6 x 10
-3 mmol, 2 mg) 
at 60 °C, under N2 for 16 h. The reaction mixture was quenched with water (5 mL) 
and extracted with EtOAc (4 x 6 mL). The organic extract was dried (MgSO4) and 
concentrated in vacuo. The crude product was purified by column chromatography 
(5:95 EtOAc/Petrol). Analysis of the isolated components by 1H NMR and HRMS did 
not correspond to the desired azide (see section 2.2). 
4.26 Attempted preparation of Ac­L­Arg(MC)­L­MePhe­iso­L­Asp­
OH (171) 
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4.26.1 Method A 
Synthesis was attempted manually on 2-chlorotrityl polystyrene resin (0.11 g, 0.15 
mmol). Loading of the resin was achieved by treating the resin with a solution of 
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Fmoc-Asp(OBut)-OH (0.12 g, 0.30 mmol) and DIPEA (0.10 mL, 0.60 mmol) in dry 
DCM (2 mL) for 90 min. Fmoc deprotection was performed by treatment of the resin 
with piperidine/DMF (v/v, 1:4, 2.5 mL) for 4 x 3 min. Peptide couplings were 
performed using Fmoc-amino acid (2 equiv), PyBOP (1.9 equiv), HOBt (2 equiv) and 
DIPEA (4 equiv) in DCM/DMF (v/v 3:1, 2.5 mL) for 90 min, except for the coupling 
to MePhe where Fmoc-Orn(Dde)-OH (2 equiv), PyBrOP (2 equiv), and DIPEA (4 
equiv) DCM/DMF (v/v 3:1, 2.5 mL) 2 x for 90 min were used. Solid phase reactions 
were monitored by use of a qualitative Kaiser test for the detection of primary amines 
and the chloranil test for the detection of secondary amines. After the coupling of 
Fmoc-Orn(Dde)-OH , N(α) Fmoc deprotection and acetylation by treatment of the 
resin with a solution of acetic anhydride/pyridine (v/v 1:4, 0.14 mL) in DCM (0.90 
mL) for 30 min, the resin was treated with a solution of 5% hydrazine/DMF (2 mL) 
for 30 min. Guanidination of the ornithine side chain to arginine was performed by 
treatment of the resin with a solution of 1H-pyrazole-1-carboxamide hydrochloride 
(63.0 mg, 0.4 mmol) and DIPEA (0.15 mL, 0.86 mmol) in DMF (2.0 mL) for 1 h. A 
small amount of resin was treated with 1% TFA/DCM (2.5 mL) (2 x 10 min) and 
immediate neutralisation of the filtrate with 10% pyr/MeOH (5 mL). The combined 
filtrates were concentrated in vacuo, and analysed by ESMS which indicated the 
presence of guanidinated product (178) only. 
4.26.2 Method B: (Attempted acylation on resin) 
The resin was treated with a solution of DBU (39 µL, 0.26 mmol) and succinimidyl-
N-methylcarbamate (44.0 mg, 0.3 mmol) in DMF (2.5 mL) for 2 h. A small amount 
of resin was treated with 1% TFA/DCM (10 x 2 min, 2 mL) and immediate 
neutralisation with 10% Pyr/MeOH. The filtrate was concentrated in vacuo. Analysis 
of the resulting residue by RP-HPLC indicated the presence of unchanged starting 
material and a small amount of the desired product. The reaction was repeated again. 
Cleavage of a small amount of resin and analysis of the resulting residue as before 
indicated the presence of mainly unchanged starting material, desired acylated 
tripeptide, and diacylated tripeptide by RP-HPLC and MS analysis. Cleavage from the 
resin was then effected by treatment with TFA/Thioanisole/DCM/H2O (16:2:1:1, 3 
mL). The cleavage solution was concentrated in vacuo, and the residue was dissolved 
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in H2O (5 mL) and washed with DCM (5 x 6 mL). The aqueous extract was 
concentrated in vacuo by freeze dying to give the crude guanidinated tripeptide (178) 
as the TFA salt (36 mg). 
4.26.3 Method C (Attempted acylation in solution)89 
A stirred solution of tripeptide (36.0 mg, 0.1 mmol) in DMF (0.90 mL) was heated to 
40 °C and treated with DBU (70 µL, 0.45 mmol) and a solution of succinimidyl-N-
methylcarbamate (42.0 mg, 0.2 mmol) in DMF (0.15 mL) for 2 h. Analysis of the 
reaction mixture by RP-HPLC and MS indicated the presence of mainly unchanged 
starting material and multiple by products. 
4.27 Ac­D­Ala­L­Arg(MC)­L­MePhe­iso­L­Asp­OH (170) 
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Synthesis was performed manually on 2-chlorotrityl polystyrene resin (0.30 g, 0.42 
mmol). Loading of the resin was achieved by treating the resin with a solution of 
Fmoc-Asp(OBut)-OH (0.35 g, 0.84 mmol) and DIPEA (0.29 mL, 1.68 mmol) in DCM 
for 90 min. Fmoc deprotection was achieved by treatment with piperidine/DMF (v/v, 
1:4) for 4 x 3 min. Peptide couplings were performed using Fmoc-amino acid (2 
equiv), PyBOP (1.9 equiv), HOBt (2 equiv) and DIPEA (4 equiv) in DCM/DMF (v/v 
3:1) for 90 min, except for the coupling to MePhe, where Fmoc-Arg(Pmc)-OH (2 
equiv), PyBrOP (2 equiv) and DIPEA (4 equiv) in DCM/DMF (v/v 3:1) for 3 x 90min 
were used. Solid-phase reactions were monitored by use of a qualitative Kaiser test 
for the detection of primary amines and the chloranil test for detection of secondary 
amines. After coupling of Fmoc-Arg(Pmc)-OH, the resin was divided into two equal 
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portions, which were then used for the preparation of (170) and (171) respectively. 
For (170), after coupling of Fmoc-D-Ala-OH, the resin-bound tetrapeptide was N-(α)-
deprotected and acetylated by treatment with acetic anhydride/DCM/pyridine (v/v/v 
0.5:1:8.5) for 35 min. Cleavage from the resin was then effected by treatment with 
TFA/thioanisole/DCM/H2O (16:2:1:1, 5mL). The cleavage solution was concentrated 
in vacuo, and the residue was dissolved in H2O (7mL) and washed with DCM (6 x 
7mL). The aqueous extract was freeze-dried to give the fully deprotected Arg-
containing tetrapeptide intermediate as the trifluoroacetate salt as a white solid (12.3 
mg, 0.02 mmol). 
Acylation: 
A stirred solution of the crude peptide from above in DMF (2 mL) was treated with 
succinimidyl-N-methylcarbamate (24.9 mg, 0.2 mmol ) and DBU (14 µL, 0.1 mmol) 
at 40 °C for 36h. The reaction mixture was concentrated in vacuo and the crude 
product was purified by RP semi-preparative HPLC (gradient 2, λ = 214 nm, tR = 18.9 
min) to give (170) as the trifluoroacetate salt a white solid (4.0 mg, 26% yield, based 
on 0.21 mmol starting resin). RP-HPLC (analytical, system 1, gradient 1, λ = 214 
nm): tR = 9.4 min. δH (400MHz, D2O, 1:2 mixture of rotamers); 1.19 (3H, d, J = 
6.8, Ala CH3), 1.45-1.49 (4H, m, Arg β-CH2 + γ-CH2), 1.88 (1H, s, AcCH3 minor), 
1.93 (2H, s AcCH3 major), 2.65 (2H, s, MC-CH3 major), 2.74 (1H, s, MC-CH3 
minor), 2.89 (1H, s, N-CH3, major), 2.90 (2H, s, N-CH3, minor), 2.94-2.99 (4H, m, 
Asp β-CH2 + δ-CH2), 3.17-3.21 (2H, m, CH2Ph), 4.06-4.16 (1H, m, α CH Ala), 4.59-
4.69 (1H, m, α CH Arg), 4.72-4.78 (1H, m, NH), 4.96-4.98 (1H, m, α CH Asp), 5.11-
5.14 (1H, m, α CH Phe), 7.15-7.31 (5H, m, ArH); δC (101MHz, D2O): 17.09 (Ala 
CH3), 21.77 (AcCH3 major), 23.85 (AcCH3 minor), 26.10 (γ-CH2), 27.26 (MC-CH3 
minor), 28.01 (MC-CH3 major), 30.24 (β-CH2), 33.58 (N-CH3 minor), 35.62 (N-CH3 
major), 40.62 (CH2Ph), 45.49 (δ-CH2), 48.79 (Asp β-CH2), 49.37 (α CH Ala), 49.74 
(α CH Arg), 59.81 (α CH Phe), 127.05 (ArCH), 127.35 (ArCH), 128.77 (ArCH), 
129.20 (ArCH), 129.66 (ArCH), 136.78 (ArC), 162.97 (C=NH), 163.33 (MC C=O), 
171.66 (Arg C=O), 173.20 (Ac C=O), 173.94 (Ala C=O), 174.07 (Phe C=O), 174.12 
(Asp C=O), 174.48 (Asp C=O). [Found: (ES+) 621.3008 [M+H]+, C27H41N8O9 
requires 621.2991]. 
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4.28 Ac­L­Arg(MC)­L­MePhe­iso­L­Asp­OH (171)
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The resin-bound tripeptide (see 4.27) was N(α)-deprotected and acetylated as for 
(170). Following cleavage from the resin and isolation as before, the crude, fully 
deprotected Arg-containing tripeptide intermediate was obtained as the 
trifluoroacetate salt as a white solid (10.9 mg). 
Acylation: 
A stirred solution of the crude peptide from above in DMF (2 mL) was treated with 
succinimidyl-N-methylcarbamate (23.2 mg, 0.1 mmol) and DBU (13 µL, 0.1 mmol) 
at 40 °C for 36 h. The reaction mixture was concentrated in vacuo and the crude 
product was purified by RP semi-preparative HPLC (gradient 2, λ = 214 nm, tR = 18.8 
min) to give (171) as the trifluoroacetate salt a white solid (1.9 mg, 14% yield, based 
on 0.21 mmol starting resin). RP-HPLC (analytical, gradient 1, λ = 214 nm): tR = 
9.4min. δH (400MHz, D2O, 2:1 mixture of rotamers): 1.36-1.50 (4H, m, Arg β-CH2 
+ γ-CH2), 1.72 (2H, s, AcCH3 major), 1.76 (1H, s, AcCH3 minor), 2.56 (2H, s, MC-
CH3 major), 2.59 (1H, s, MC-CH3 minor), 2.71 (1H, s, N-CH3 minor), 2.81 (2H, s, N-
CH3 major), 2.82-2.91 (4H, m, Asp β-CH2 + δ-CH2), 3.08-3.14 (2H, m, CH2Ph), 3.32-
3.38 (1H, m, NH), 4.08-4.10 (1H, m, α CH Arg), 4.46-4.47 (1H, m, NH), 4.51-4.52 
(1H, m, NH), 4.86 (1H, dd, J = 11.2, 2.8, α CH Asp), 5.10-5.14 (1H, m, α CH Phe), 
7.05-7.21 (5H, m, ArH); δC (101MHz, D2O): 21.62 (AcCH3 major), 23.38 (AcCH3 
minor), 26.01 (γ-CH2), 27.25 (MC-CH3 minor), 27.89 (MC-CH3 major), 30.27 (Arg 
β-CH2), 35.92 (N-CH3 major), 36.22 (N-CH3 minor), 40.57 (CH2Ph), 49.25 (δ-CH2), 
50.05 (Asp β-CH2), 54.23 (α CH Asp), 59.36 (α CH Arg), 62.71 (α CH Phe), 126.98 
(ArCH), 127.23 (ArCH), 128.66 (ArCH), 129.13 (ArCH), 129.56 (ArCH), 136.69 
(ArC), 137.33 (C=NH), 170.70 (MC C=O), 171.42 (Arg C=O), 173.38 (Ac C=O), 
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173.75 (Phe C=O), 174.36 (Asp C=O), 175.06 (Asp C=O). [Found: (ES+) 550.2608 
[M+H]+, C24H36N7O8 requires 550.2620]. 
4.29 Ac­L­Arg(MC)­L­MePhe (172)
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Solid-phase peptide synthesis was performed as for (170), using 2-chlorotrityl 
polystyrene resin (0.20 g, 0.28 mmol). After cleavage from the resin and isolation as 
before, the crude, fully deprotected Arg-containing dipeptide intermediate was 
obtained as the trifluoroacetate salt as a white solid (28.2 mg,) 
Acylation: 
A stirred solution of the crude peptide from above in DMF (2 mL) was treated with 
succinimidyl-N-methylcarbamate (88.3 mg, 0.5 mmol) and DBU (0.10 mL, 0.68 
mmol) at 40 °C for 36 h. The reaction mixture was concentrated in vacuo and the 
crude product was purified by RP semi-preparative HPLC (gradient 2, λ = 214 nm, tR 
= 19.5 min) to give (172) as the trifluoroacetate salt as a white solid (4.5 mg, 7% 
yield). RP-HPLC (analytical, system 1, gradient 1, λ = 214 nm): tR = 9.7 min; δH 
(400MHz, D2O, 2:1 mixture of rotamers): 0.82-0.91 (2H, m, γ-CH2), 1.42-1.52 (2H, 
m, β-CH2), 1.76 (2H, s, AcCH3 major), 1.79 (1H, s, AcCH3 minor), 2.61 (2H, s, MC-
CH3 major), 2.64 (1H, s, MC-CH3 minor), 2.79 (1H, s, N-CH3, minor), 2.81 (2H, s, 
N-CH3, major), 2.86 -2.97 (2H, m, δ-CH2), 3.12-3.17 (1H, m, CHHPh), 3.20-3.24 
(1H, m, CHHPh), 4.01 (1H, t, J = 4.4, α CH Arg), 4.50 (1H, t, J = 5.2, α CH Phe), 
4.94 (1H, m, NH), 7.13-7.26 (5H, m, ArH): δC (101MHz, D2O): 21.55 (AcCH3 
major), 21.66 (AcCH3 minor), 23.75 (γ CH2), 26.02 (β-CH2), 27.83 (MCCH3), 33.88 
(N-CH3 major), 33.96 (N-CH3 minor), 34.79 (CH2Ph), 40.62 (δ-CH2), 48.30 (α CH 
Arg), 49.12 (α CH Phe), 126.86 (ArCH), 128.60 (2 x ArCH), 129.10 (2 x ArCH), 
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129.34 (ArC), 137.45 (MC C=O), 137.97 (C=NH), 173.33 (Arg C=O), 173.39 (Ac 
C=O), 174.10 (Phe C=O). [Found: (ES+) 435.2334 [M+H]+, C20H31N6O5 requires 
435.2350. The diacylated dipeptide was also isolated (1.7 mg, 4%), RP semi-
preparative HPLC (gradient 2, λ = 214 nm, tR = 20.6 min); (analytical, system 1, 
gradient 1, λ = 214 nm): tR = 6.1 min; 
4.30 Fmoc­L­Arg(Pmc)­NHMe (190) 
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4.30.1 Method A 
A stirred solution of Fmoc-Arg (Pmc)-OH (1.00 g, 1.51 mmol) and PyBOP (0.79 g, 
1.51 mmol) in DCM (10 mL) was treated with DIPEA (0.26 mL, 1.51 mmol). The 
reaction was stirred for 15 minutes at room temperature and then treated with 
methylamine hydrochloride (0.10 g, 1.51 mmol) and DIPEA (0.26ml, 1.51mmol). The 
reaction mixture was stirred for 5 h and then concentrated in vacuo. The resulting 
residue was dissolved in DCM (15 mL), washed with 5% aq. citric acid (2 x 7 mL), 
5% aq. NaHCO3 (2 x 7 mL) and brine (7 mL). The organic extract was dried (MgSO4) 
and concentrated in vacuo. Analysis of the crude mixture by MS and RP-HPLC only 
showed the presence of starting material. 
188 
4.30.2 Method B208 
A stirred solution of Fmoc-Arg (Pmc)-OH (0.50 g, 0.75 mmol) in 1:1 DCM/DMF (6 
mL) at 0 °C, was treated with HOBt (0.14 g, 1.06 mmol) and EDC.HCl (0.15 g, 0.75 
mmol). The reaction was stirred for 1 h after which methylamine hydrochloride (51.0 
mg, 0.8 mmol) and DIPEA (0.29 mL, 1.66 mmol) were added. The reaction was 
allowed to warm to room temperature and stirred for 16 h. The reaction mixture was 
concentrated in vacuo and the residue dissolved in EtOAc (15 mL), washed with 5% 
aq. citric acid (2 x 8 mL), 5% aq. NaHCO3 (2 x 8 mL), water (2 x 8 mL) and brine (8 
mL). The organic extract was dried (MgSO4) and concentrated in vacuo. The crude 
product was purified by column chromatography (MeOH/DCM 0:1 to 1:9) to give 
(190) as a colourless oil (0.41g, 80%); Rf 0.31 (MeOH/DCM, 1:9); IR (DCM) 3428, 
3353, 2945, 1718, 1673, 1618, 1552, 1249, 1111; [α]D + 42 (c 1.0 in MeOH); δH (270 
MHz, CDCl3): 1.24 (6H, s, 2 x CH3) 1.47-1.84 (6H, m, β-CH2 + γ-CH2 + 
CH2C(CH3)2) 2.05 (3H, s, ArCH3) 2.43-2.61 (8H, m, 2 x CH3, ArCH2) 2.69, 2.71 
(1.5H each, s, NHCH3 rotamers) 3.10-3.39 (2H, m, δ-CH2) 4.03 (1H, t, J = 7.1 α CH) 
4.18-4.37 (3H, m, (Fmoc CH + CH2) 6.19-6.37 (3H, m, (NH2 + NHCH3) 7.15 -7.24 
(3H, m, CO2NH + 2 x Ar CH) 7.29 (2H, t, J = 7.3, 2 x ArCH) 7.49 (2H, d, J = 7.4, 2 x 
ArCH) 7.67 (2H, d, J = 7.5, 2 x ArCH); δC (101 MHz, CDCl3): 12.26 (ArCH3), 17.64 
(ArCH3), 18.69 (ArCH3), 21.50 (CH2), 25.75 (CH2), 26.35 (CH3)2), 26.82 ((CH3)2), 
30.02 (CH2), 32.80 ((CH3)2CCH2CH2), 40.04 (δ-CH2), 47.01 (NHCH3), 53.57 (CH) 
54.57 (CH), 67.05 (CH2O), 73.79 (C=N), 118.15 (C(CH3), 120.01 (C-CH2 Pmc), 
124.29 (2 x ArCH), 125.23 (2 x ArCH), 127.13 (2 x ArCH), 127.78 (2 x ArCH), 
133.00 (C-S), 134.91 (C(CH3), 135.50 (C(CH3), 141.27 (2 x ArC), 143.52 (2 x ArC), 
153.40 (CO2NH), 156.29 (Fmoc CO), 173.21 (CONH(CH3). [Found: (ES+) 676.3128 
[M+H]+, C36H46N5O6S requires 676.3168]. 
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4.31 Ac­L­Arg(Pmc)­NHMe (191)
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4.31.1 Method A 
A stirred solution of (190) (0.31 g, 0.46 mmol) in DMF (6 mL) was treated with 
diethylamine (0.47 mL, 4.56 mmol) for 45 minutes. The reaction was concentrated in 
vacuo. A stirred solution of the resulting residue in DCM (6 mL) was cooled to 0 °C 
and treated with DIPEA (95 µL, 0.55 mmol) and acetic anhydride (86 µL, 0.91 
mmol). The reaction was allowed to warm to room temperature and stirred for 16 h. 
The reaction mixture was diluted with DCM (10 mL), washed with 5% aq. citric acid 
(2 x 8 mL), 5% aq. NaHCO3 (2 x 8 mL), water (2 x 8 mL) and brine (8 mL). The 
organic extracts were dried (MgSO4) and the solvent was evaporated to give 79 mg of 
a white solid. 1H NMR and MS analysis did not show formation of the desired 
product and mainly presence of Ac-Arg-NHCH3. 
4.31.2 Method B 
Reaction was performed as described in 4.33.1 method A using (190) (0.20 g, 0.29 
mmol), diethylamine (0.22 g, 2.95 mmol), DIPEA (52 µL), acetic anhydride (56 µL, 
0.59 mmol) and DMAP (36.0 mg, 0.3 mmol). The product was purified by column 
chromatography (0:1-1:9 MeOH/DCM) to give (191) as a yellow gum (61 mg, 42%); 
Rf 0.32 (MeOH/DCM, 1:9); IR (DCM) 3336, 2934, 1662, 1550, 1451, 1203, 1109; 
[α]D + 37 (c 1.0 in MeOH); δH (270 MHz, CDCl3, 1:1 mixture of rotamers): 1.27 
(6H, s, C(CH3)2) 1.50-1.79 (6H, m, (CH3)2CCH2 + γ-CH2 + β-CH2)1.95 (3H, s, 
CH3O) 2.06 (3H, S, ArCH3) 2.49-2.72 (8H, m, 2 x ArCH3, CH2) 2.85, 2.93 (1.5H 
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each, s, NHCH3 rotamers) 3.09-3.29 (NH) 4.37-4.48 (1H, m, αCH) 6.36 (2H, br, NH2) 
7.25 (1H, m, NAcNH) 7.37 (1H, m, CONHCH3); δC (101 MHz, CDCl3): 12.23 
(ArCH3), 17.58 (ArCH3), 18.64 (ArCH3), 21.50 (CH2), 23.07 (NAcCH3), 25.50 
((CH3)2CCH2CH2), 26.26 (CH3)2), 26.83 ((CH3)2), 29.81 (β-CH2), 32.90 
((CH3)2CCH2), 40.40 (δ­CH2), 53.55 (αCH), 73.80 (C=N), 118.15 (C-CH3), 124.25 
(C(CH2CH2C(CH3)2), 133.04 (C-S), 134.86 (C-CH3), 135.42 (C-CH3), 153.78 (C-
OC(CH3)2), 156.59 (C-NH2), 171.24 (NAcC=O), 172.95 (C=O(NHCH3); [Found: 
(ES+) 518.2367 [M+Na]+, C23H37N5SNa requires 518.2350]. 
4.32 Fmoc­L­Orn(Boc)­NHMe (194)208 
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A stirred solution of Fmoc-L-Orn (Boc)-OH (193) (0.50 g, 1.10 mmol) in DCM/DMF 
(1:1 v/v, 6 mL) was cooled to 0 °C and treated with HOBt (1.54 mmol, 0.21 g), 
EDC.HCl (1.10 mmol, 0.21 g) and stirred for 1 h after which, DIPEA (2.42 mmol, 
0.42 mL) and methylamine hydrochloride (74.0 mg, 1.1 mmol) was added. The 
reaction mixture was stirred for a further 16 h. The reaction mixture was concentrated 
in vacuo, re-dissolved in EtOAc (20 mL) and washed with 5% aq. citric acid (20 mL), 
5% aq. NaHCO3 (20 mL), water (15 mL) and brine (20 mL). The organic extract was 
dried (MgSO4) and concentrated in vacuo. The crude product was purified by column 
chromatography (5:95 MeOH/DCM) to give (194) as a white solid (0.46g, 89%); Rf 
0.35 (MeOH: DCM, 1:9); m. p. 101-102 °C (lit. 101-102 °C 222); δH (270 MHz, 
CDCl3): 1.43 (9H, s, 3 x CH3) 1.53-1.58 (2H, m, γ-CH2) 1.74-1.79 (2H, m, β-CH2) 
2.77, 2.78 (3H, d, J = 7.9, NHCH3) 2.95-3.10 (2H, m, δ CH2) 3.17-3.25 (1H, m, αCH) 
4.06 (1H, t, J = 7.7, CHCH2-O) 4.27 (2H, d, J = 7.7, CH2OC=O) 4.72 (1H, br, α NH) 
191 
5.76 (1H, br, δ­CH2NH) 6.59 (1H, br, NH) 7.21-7.42 (4H, m, 4 x ArCH) 7.53 (2H, d, 
J = 8.1, 2 x ArCH) 7.72 (2H, d, J = 8.1, 2 x ArCH); δC (101 MHz, CDCl3): 26.29 (γ 
CH2), 26.70 (CH3NH), 28.51 (3 x CH3), 30.45 (β-CH2), 38.87 (δ­CH2), 47.25 (αCH), 
53.39 (CH Fmoc), 67.01 (CH2-O), 79.54 (C(CH3)), 120.06 (2 x ArCH), 125.21 (2 x 
ArCH), 127.15 (4 x ArCH), 141.40 (2 x ArC), 143.85 (2 x ArC), 156.50 (NHC=O-O), 
172.65 (NHC=OCH3). 
4.33 Ac­L­Orn(Boc)­NHMe (195)222 
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Reaction was performed as described in 4.31.2 method B using Fmoc-Orn-(Boc)-

NHCH3 (0.25 g, 0.54 mmol), diethylamine (0.55 mL, 5.35 mmol), DIPEA (93 µL,

0.54 mmol), DMAP (7.0 mg, 0.5 mmol) and acetic anhydride (0.10 mL, 1.07 mmol). 
The crude product was purified by column chromatography (1:9 MeOH/DCM) to 
give (195) as white solid (0.11 g, 73%); Rf 0.36 (MeOH/DCM, 1:9); m. p. 110-114 °C 
(lit. 108-111 °C)222; IR (DCM) 3447, 3345, 3054, 2981, 1665, 1512, 1368, 1251, 
1168; [α]D + 3 (c 0.5 in CHCl3, lit. 1.7)
222 δH (270 MHz, CDCl3): 1.37 (9H, s, 3 x 
CH3), 1.40-1.83, (4H, m, β-CH2, γ-CH2). 1.93, (3H, s, (COCH3), 2.68, 2.71 (3H, d, J 
= 7.8, NHCH3), 2.96-3.20, (2H, m, δ­CH2), 4.44-4.53, (1H, m, αCH), 5.05 (1H, br, δ­
NH), 7.49 (2H, s, 2 x amide NH); δC (101 MHz, CDCl3): 23.03 (NAc CH3), 26.16 (γ-
CH2), 26.36 (NHCH3), 28.43 (3 x CH3) 29.89 (β-CH2), 39.36 (δ­CH2), 52.28 (α-CH), 
79.21 (C(CH3)3), 156.56 (NHCOBoc), 170.83 (amide CO), 173.13 (amide CO). 
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4.34 Ac­L­Arg(MC)­NHMe (192) 
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4.34.1 Method A 
A stirred solution of (191) (60.0 mg, 0.1 mmol) in DCM (2 mL) was treated with a 
mixture of TFA (0.28 mL) and DCM (0.30 mL) and stirred for 1.5 h. The reaction 
was concentrated in vacuo and dried thoroughly. A stirred solution of the resulting 
residue in DMF (1 mL) was treated with DBU (36 µL, 0.24 mmol), stirred for 5 
minutes at 40 °C after which succinimidyl-N-methylcarbamate (21.0 mg, 0.1 mmol) 
was added. The reaction was stirred for 5 hours at 40 °C, cooled to room temperature 
and concentrated in vacuo. Analysis of the crude material by MS and RP-HPLC did 
not indicate formation of the desired product with full recovery of unchanged starting 
material. 
4.34.2 Method B 
A stirred solution of (195) was treated with 4M HCl in dioxane (1.3 mL, 5.22 mmol) 
and stirred for 20 min at room temperature. The reaction mixture was concentrated in 
vacuo and dried thoroughly. The resulting residue was dissolved in DMF (6 mL) and 
treated with DBU (78 µL, 0.52 mmol), (196) (72.0 mg, 0.3 mmol, see section 2.3.2) 
and stirred for 72 h at room temperature. The reaction mixture was concentrated in 
vacuo. The reaction mixture was analysed by TLC, MS, RP-HPLC and 1H NMR 
which showed the presence Ac-Orn-NHMe only. 
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4.34.3 Method C211 
A stirred solution of (191) (31.0 mg, 0.1 mmol) in DCM (1 mL) was treated with a 
solution of TFA-DCM (1:1, 0.3 mL) and stirred for 2 h at 30 °C. The reaction mixture 
was concentrated in vacuo and the residue was dried thoroughly. The resulting residue 
was partitioned between DCM (2 mL) and water (2 mL). The organic extract was 
dried (MgSO4) and the solvent was evaporated to give crude Ac-L-Arg-NHCH3 as the 
TFA salt (15.0 mg), which was immediately neutralised with pre-washed Dowex 
hydroxide resin (0.20 g) in MeOH (2 mL) for 1 h. The resin was filtered off and 
reaction mixture was concentrated in vacuo to give Ac-Arg-NHCH3 as the free base 
(7.5 mg, 0.03 mmol assumed). A solution of this material in anhydrous DMF (0.35 
mL) was cooled to 0 °C and was treated with a 0.31 M solution of methylisocyanate 
in DMF (0.06 mL, 0.12 mmol). The reaction mixture was allowed to warm to room 
temperature, stirred for 18 h then concentrated in vacuo. The crude product was 
analysed by MS, which indicated partial conversion to (192) had occurred. The 
acylation reaction was repeated exactly as before, and the crude product now obtained 
was purified by RP semi-preparative HPLC (gradient 4, λ = 214 nm, tR = 11.4 min) to 
give (192) as the trifluoroacetate salt as a yellow solid (2.0 mg, 8% yield). RP-HPLC 
(analytical, system 1, gradient 1, λ = 214 nm): tR = 8.1 min. δH (400MHz, D2O): 
1.52-1.59 (2H, m, γ-CH2),1.65-1.69 (2H, m, β-CH2), 1.91 (3H, s, OCH3), 2.56 (3H, s, 
NHCH3), 2.60 (3H, s, NHCH3), 3.25 (2H, t, J = 8.8, δ CH2), 4.06 (1H, t, J = 8.4, α 
CH); δC (101 MHz, D2O): 24.12 (γ CH2), 25.81 (NHCH3), 26.18 (NHCH3), 28.31 (β 
CH2), 40.70 (δ CH2), 53.61 (α CH), 174.38 (C=O), 174.51 (C=O). [Found: (ES+) 
287.1812 [M+H]+, C11H23N6O3 requires 287.1826]. 
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4.35 N­Methyl­N'­methylguanylurea (198)
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4.35.1 Method A 
O 
A stirred solution of 1-methyl guanidine hydrochloride (50.0 mg, 0.5 mmol) in DMF 
(2 mL) at room temperature was treated with DBU (0.82 mL, 5.47 mmol) at 40 °C for 
10 minutes after which succinimidyl-N-methylcarbamate (0.47 g, 2.74 mmol) was 
added and stirred for 4 days. Analysis of the reaction mixture by MS and RP-HPLC 
showed the presence of unchanged starting material and no indication for the 
formation of the desired product. 
4.35.2 Method B 
Reaction was performed as described in 4.35.1 method A with the exception that 1-
methyl guanidine hydrochloride (0.13 g, 1.18 mmol) was neutralised with pre-washed 
(MeOH 3 x 15 mL) Dowex –OH resin (1.00 g). The filtrate was concentrated in vacuo 
to give a yellow oil of 1-methylguanidine (0.13 g, 1.74 mmol). A stirred solution of 1-
methylguanidine in MeOH (4 mL) at 40 °C was treated with DBU (2.00 mL, 3.48 
mmol) and succinimidyl-N-methylcarbamate (0.29 g, 1.74 mmol) for 3 days. Analysis 
of the reaction mixture by LRMS and RP-HPLC did not indicate any reaction or 
formation of the desired product, and only showed the presence of unchanged starting 
material. 
4.35.3 Method C 
A stirred solution of (196) (see section 2.3.3) (25.0 mg, 0.1 mmol), in DMF (2 mL), at 
room temperature was treated with methylamine (0.45 mL, 2.00 M in THF, 0.91 
mmol) and stirred for 72h. The reaction mixture was concentrated in vacuo and 
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showed exclusively, the presence of unchanged (196) upon analysis of the reaction 
mixture by TLC, MS, RP-HPLC and 1H NMR. 
4.35.4 Method D211 
A stirred solution of 1-methylguanidine hydrochloride (0.10 g, 0.91 mmol) in MeOH 
(6 mL) was treated with pre-washed Dowex hydroxide resin (0.95 g) for 1 h. The 
resin was filtered off and the reaction mixture was concentrated in vacuo. A solution 
of 1-methylguanidine (81.0 mg, 0.9 mmol assumed) in DMF (0.50 mL) was cooled to 
0 °C and treated with methylisocyanate (44 µL, 0.74 mmol). The reaction mixture was 
allowed to warm to room temperature and was stirred for 16 h and then concentrated 
in vacuo. The crude product was purified by preparative HPLC (gradient 5, λ = 214 
nm, tR = 9.3 min) to give (198) as the trifluoroacetate salt and as a white solid (55 mg, 
25%). RP-HPLC (analytical, system 2, gradient 6, λ = 214 nm): tR = 3.2 min. δH 
(270MHz, D2O): 2.67 (3H, s, CH3), 2.84 (3H, s, CH3), 2.86 (1H, s, NH), 3.14 (1H, s, 
NH), 3.20 (1H, s, NH), 3.36 (1H, s, C=NH); δC (67.5 MHz, D2O): 25.99 (CH3), 27.45 
(CH3), 114.28 (C=NH), 170.16 (C=O). [Found: (ES+) 131.0932 [M+H]+, C4H11N4O 
requires 131.0927]. 
4.36 Boc­L­Phe­NHMe (204) 
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A stirred solution of Boc-Phe-OH (1.00 g, 3.76 mmol), in 1:1 DCM/DMF (10 mL) at 
0 °C was treated with HOBt (0.71 g, 5.28 mmol) and EDC.HCl (0.73 g, 3.81 mmol) 
and stirred for 1 h after which methylamine hydrochloride (0.25 g, 3.76 mmol) and 
DIPEA (1.44 mL, 8.29 mmol) was added. The reaction was stirred and allowed to 
warm to room temperature overnight. The solvent was evaporated and the residue 
dissolved in EtOAc (25 ml), washed with 5% citric acid (20 mL), 5% NaHCO3 (20 
mL), water (20 mL) and brine (20 mL). The organic extract was dried (MgSO4) and 
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the solvent evaporated. The crude product was purified by column chromatography 
(Petrol/ EtOAc, 3:7) to give (204) as a clear oil (0.66 g, 63% yield); Rf 0.51 (EtOAc/ 
Petrol, 1:1); IR (DCM) 3431, 3360, 1710, 1677, 1495, 1453; [α]D + 10.3 (c 1.0 in 
MeOH) δH (270MHz, CDCl3): 1.38 (9H, s, 3 x CH3), 2.69 (3H, d, J = 4.6, NHCH3), 
3.02 (2H, d, J = 7.0, CH2Ph), 4.23 (1H, q, J = 7.1, α CH), 5.03 (1H, s, NHBoc), 5.71 
(1H, s, NHAc), 7.24-7.26 (5H, m, ArH); δC (101 MHz, CDCl3): 26.23 (NHCH3), 
28.35 (3 x CH3), 38.93 (CH2Ph), 56.06 (α CH), 79.50 ((CH3)3C), 126.97 (ArCH), 
128.68 (2 x ArCH), 129.36 (2 x ArCH), 136.91 (ArC), 155.50 (Boc C=O), 171.94 
(C=O). [Found (ES+) 279.1757 [M+H]+, C15H23N2O3 requires 279.1703]. 
4.37 Fmoc­L­Arg(Pmc)­L­Phe­NHMe (205) 
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A solution of (204) (0.30 g, 1.08 mmol) was treated with 4M HCl in dioxane (8.10 
mL, 32.25 mmol) and stirred at room temperature for 3 h after which, the reaction 
mixture was concentrated by evaporation of the solvent to give the amine 
hydrochloride as white crystals (0.21 g, 92% yield). A stirred solution of the resulting 
hydrochloride salt (0.21 g, 0.99 mmol) in DCM (6 mL) at room temperature was 
treated with Fmoc-Arg(Pmc)-OH (0.59 g, 0.90 mmol), PyBrOP (0.42 g, 0.90 mmol) 
and DIPEA (0.47 mL, 2.70 mmol) and stirred for 7 h. The reaction mixture was 
washed with 2M aq. HCl (3 mL), sat. aq. NaHCO3 (7 x 8 mL), brine (4 mL) and water 
(4 mL). The organic extract was dried (MgSO4), filtered and concentrated. The crude 
product was purified by column chromatography (3:97 DCM/MeOH) to give (205) as 
a white solid (0.38 g, 43% yield); Rf 0.44 (MeOH/DCM, 1:9); m. p. 137–140 °C; IR 
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(DCM) 3420, 3342, 1711, 1671, 1551, 1261, 1111; [α]D + 22 (c 1.0 in MeOH); δH 
(270MHz, CDCl3): 1.24 (6H, s, 2 x CH3), 1.47 (2H, m, CH2C(CH3)2), 1.72-1.81 (4H, 
m, β + γ CH2), 2.06 (3H, s, NHCH3), 2.56 (11H, d, J = 7.7, 3 x ArCH3 + CH2 Pmc), 
2.81-3.12 (4H, m, Phe CH2 + δ CH2), 4.06 (1H, m, α CH Arg), 4.23-4.39 (3H, m, 
Fmoc CH + CH2), 4.51-4.58 (1H, m, α CH Phe), 6.02 (1H, d, J = 7.7, NH), 6.18 (1H, 
m, NH), 6.44-6.51 (2H, m, NH2), 7.02-7.24 (5H, m, Phe ArCH), 7.33 (2H, d, J = 4.5, 
3 x ArCH), 7.49 (2H, d, J = 3.8, 2 x ArCH), 7.69 (2H, d, J = 7.4, 2 x ArCH); δC (68 
MHz, CDCl3): 12.24 (ArCH3), 17.68 (ArCH3), 18.73 (ArCH3), 21.89 (γ CH2), 26.29 
(Pmc CH2), 26.78 (NHCH3), 26.83 ( 2 x Pmc CH3), 29.81 (β CH2), 32.76 
(CH2C(CH3)2), 38.02 (δ CH2), 46.43 (Phe CH2), 47.08 (α CH Phe), 54.22 (Fmoc CH), 
55.67 (α CH Arg), 67.16 (Fmoc CH2), 118.07 (2 x C(CH3)), 120.01 (3 x ArCH), 
124.01 (CCH3), 125.23 (2 x ArCH), 126.88 (ArCH), 127.13 (2 x ArCH), 127.79 
(ArCH), 128.53 (3 x ArCH), 129.23 (ArCH), 132.49 (SO2C), 134.36 ( 2 x ArC), 
134.63 (ArC), 136.51 (ArC), 141.29 (ArC(Pmc)), 143.75 (ArC(Pmc)), 152.96 (Fmoc 
C=O), 156.64 (ArC), 160.92 (C=N), 171.89 (Arg C=O), 172.12 (Phe C=O). [Found 
(ES+) 823.3856 [M+H]+, C45H55N6O7S requires 823.3847]. 
4.38 Ac­L­Arg(Pmc)­L­Phe­NHMe (206) 
O 
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A stirred solution of (205) (0.36 g, 0.44 mmol) in DCM/DMF (5 mL, 1:1 v/v) at

room temperature was treated with diethylamine (0.42 mL, 4.40 mmol) and stirred for

45 minutes. The reaction mixture was concentrated in vacuo and dried thoroughly. A
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stirred solution of the resulting residue in DCM (5 mL) was cooled to 0 °C and treated 
with DIPEA (77 µL, 0.44 mmol), DMAP (54.0 mg, 0.4 mmol) and acetic anhydride 
(83 µL, 0.88 mmol). The reaction was warmed to room temperature and stirred for 16 
h after which, the reaction mixture was diluted with DCM (10 mL) and washed with 
5% aq. citric acid (10 mL), 5% aq. NaHCO3 (10 mL), H2O (10 mL) and brine (10 
mL). The organic extract was dried (MgSO4) and concentrated by evaporation of the 
solvent. The crude product was purified by column chromatography (DCM/MeOH, 
5:95) to give (206) as a white solid (0.28 g, 39% yield); Rf 0.28 (MeOH/DCM, 1:9); 
m. p. 155-157 °C; IR (DCM) 3437, 3330, 3934, 1658, 1551, 1265, 1111; [α]D + 15 (c 
1.0 in MeOH); δH (400MHz, CDCl3): 1.28 (6H, s, 2 x CH3), 1.41-1.44 (2H, m, γ-
CH2), 1.58-1.61 (2H, m, β-CH2), 1.75 (2H, t, J = 6.8, CH2C(CH3)2), 1.89 (3H, s, 
AcCH3), 2.08 (3H, s, NHCH3), 2.54-2.64 (11H, m, 3 x ArCH3 + δ-CH2), 2.92-3.15 
(4H, m, CH2CH2C(CH3)2 + PhCH2), 4.41 (1H, t, J = 5.6, α Arg CH), 4.58 (1H, t, J = 
7.2, α CH Phe), 6.38 (2H, s, NH2), 7.09-7.19 (5H, m, ArH), 7.39 (1H, d, J = 7.6, 
Amide NH), 7.74 (1H, d, J = 8.0, AcNH); δC (101 MHz, CDCl3): 12.09 (ArCH3), 
17.46 (ArCH3), 18.53 (ArCH3), 22.67 (γ-CH2), 25.99 (CH2CH2C(CH3)2), 26.69 (2 x 
CH3), 29.01 (β-CH2), 32.70 (NHCH3), 37.89 (CH2C(CH3)2), 40.16 (δ-CH2), 46.28 
(PhCH2), 53.05 (α Arg CH), 54.91 (α Phe CH), 73.66 (C(CH3)2), 118.01 (ArC Pmc), 
124.14 (ArC Pmc), 126.73 (ArC Pmc), 128.37 (2 x ArCH Phe), 129.18 (2 x ArCH 
Phe), 133.03 (ArC-S), 134.73 (ArC Pmc), 135.33 (ArC Pmc), 136.69 (ArC Phe), 
153.66 (ArC Pmc), 156.32 (N=C), 171.41 (C=O), 171.97 (Arg C=O), 172.31 (Amide 
C=O). [Found (ES+) 643.3251 [M+H]+, C32H47N6O6S requires 643.3272]. 
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4.39 Ac­L­Arg(MC)­L­Phe­NHCH3 (200) 
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A stirred solution of (206) (44.0 mg, 0.1 mmol) in DCM (1.5 mL) was treated with a 
solution of TFA (20.8 mmol, 0.2 mL) in DCM (0.17 mL) at 30 °C for 3h. The 
reaction was concentrated in vacuo and dried thoroughly. The residue was partitioned 
between DCM (5 mL) and water (3 mL). The aqueous extract was concentrated by 
evaporation of the solvent. A stirred solution of the resulting residue was treated with 
Dowex hydroxide resin (0.36 g) in MeOH (5 mL) for 1h. The resin was filtered and 
the reaction mixture was concentrated by evaporation of the solvent to give Ac-
ArgPhe-NHCH3 as a clear oil (28.0 mg, 0.1 mmol) and was used further without 
purification. A stirred solution of Ac-ArgPhe-NHCH3 (26.0 mg, 0.1 mmol) in DMF 
(1.2 mL), was treated with DBU (0.41 mmol, 62 µL) and succinimidyl-N-
methylcarbamate (36.0 mg, 0.2 mmol,) at 40 °C for 3h. The reaction mixture was 
concentrated by evaporation of the solvent and the crude product was purified by RP-
preparative HPLC (gradient 7 tR = 28.4 to give (200) as clear oil (23 mg, 77%). RP-
HPLC (analytical, system 1, gradient 1, λ = 214 nm): tR = 8.9 min (100 %). δH 
(270MHz, MeOD): 1.44 (2H, m, γ-CH2), 1.60 (2H, m, β-CH2), 1.96 (3H, s, AcCH3), 
2.66 (3H, s, NHCH3), 2.76 (3H, s, NHCH3 (MC)), 2.83-2.94 (1H, m, CHPhe), 3.10-
3.20 (3H, m, CHPhe + δ-CH2), 4.21 (3H, t, J = 6.8, α-CH Arg), 4.52 (3H, t, J = 6.1, 
α-CH Phe), 7.18-7.25 (5H, m, ArH); δC (101MHz, MeOD): 22.47 (AcCH3) 25.46 (γ-
CH2), 26.29 (NHCH3), 26.55 (NHCH3 (MC)), 29.68 (β-CH2), 38.71 (δ-CH2), 41.79 
(CH2), 54.53 (α-CH Arg), 56.00 (α-CH Phe), 127.77 (ArCH), 129.45 (2 x ArCH), 
130.26 (2 x ArCH), 138.42 (ArC), 155.79 (C=NH), 156.10 (C=O (MC)), 173.65 
(C=O Ac), 173.76 (C=O), 173.91 (C=O amide). [Found (ES+) 434.2505 [M+H]+, 
C20H32N7O4 requires 434.2510]. 
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4.40 Boc­L­MePhe­NHMe (208)
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H 
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The reaction was performed using the same conditions described in 4.36 using Boc-
NMePhe-OH (0.50 g, 1.79 mmol), HOBt (0.34 g, 2.51 mmol), EDC.HCl (0.34 g, 1.79 
mmol), methylamine hydrochloride (0.12 g, 1.79 mmol) and DIPEA (0.69 mL, 3.94 
mmol). The crude product was purified using column chromatography (Petrol/ 
EtOAc, 3:7) to give (208) as clear oil (0.36 g, 65% yield); Rf 0.59 (EtOAc/Petrol, 
1:1); IR (DCM) 3495, 3100, 1681, 1526, 1454; [α]D + 14 (c 1.0 in MeOH); δH 
(270MHz, CDCl3, 1:1 mixture of rotamers): 1.14, 1.28 (4.5H each, s, 3 x CH3, 
rotamers), 2.72 (6H, s, NHCH3 and NCH3), 2.77-2.93, 3.28-3.36 (1H each, m, 
CH2Ph), 4.65-4.68, 4.85-4.93 (0.5H, each, m, α CH), 5.92, 6.14 (0.5H each, s, NH), 
7.17-7.24 (5H, m, ArH); δC (101 MHz, CDCl3): 28.13 (NHCH3), 28.32 (9H, s, 3 x 
CH3), 30.84 (NCH3), 34.14 (CH2Ph), 59.59 (α CH), 101.23 ((CH3)C), 126. 51 
(ArCH), 128.64 (2 x ArCH), 129.10 (2 x ArCH), 137.67 (ArC), 154.30 (Boc C=O), 
172.20 (C=O). [Found (ES+) 293.1849 [M+H]+, C16H25N2O3 requires 293.1860]. 
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4.41 Fmoc­L­Arg(Pmc)­L­MePhe­NHMe (209)
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The reaction was performed as described in 4.37 using (208) (0.18 g, 0.63 mmol) and 
4M HCl in dioxane (4.7 mL, 18.78 mmol). The resulting hydrochloride salt (0.14 g, 
0.61 mmol) was treated with Fmoc-Arg(Pmc)-OH (0.40 g, 0.57 mmol), PyBrOP (0.28 
g, 0.57 mmol) and DIPEA (0.31 mL, 1.79 mmol). The reaction mixture was washed 
with 2M aq. HCl (2.5 mL), sat. aq. NaHCO3 (7 x 8 mL), brine (2.5 mL) and water (5 
mL). The organic extract was dried (MgSO4), filtered and concentrated by 
evaporation of the solvent. The crude product was purified by column 
chromatography (3:97 DCM/MeOH) to give (209) as a white solid (0.18 g, 35% 
yield); Rf 0.39 (MeOH/ DCM, 1:9); m. p. 121-124 °C; IR (DCM) 2928, 2855, 1717, 
1636, 1554, 1451, 1265, 1112; [α]D + 27 (c 1.0 in MeOH); δH (400MHz, CDCl3 2:1 
mixture of rotamers): 0.76-0.82 (2H, m, γ-CH2), 1.18 (6H, s, 2 x CH3), 1.64-1.69 
(4H, m, β-CH2 + CH2 Pmc), 2.01 (3H, d, J = 4.4, NHCH3), 2.48-2.54 (9H, m, 3 x 
ArCH3), 2.80 (1H, s, N-Me minor), 2.84 (2H, s, N-Me, major), 3.04-3.26 (4H, m, 
CH2Ph + δ-CH2), 3.93-3.96 (1H, m, Fmoc CH), 4.05-4.10 (1H, m, α-CH Arg), 4.17 
(2H, d, J = 7.2, Fmoc CH2), 4.32 (1H, t, J = 8.4, α-CH Phe), 4.59-4.62 (1H, m, NH), 
5.09 (1H, t, J = 8.4, NH), 5.28 (1H, d, J = 8.8, NH), 6.17-6.23 (2H, br, m, NH2), 
7.02-7.69 (13H, m, ArCH Phe + ArCH Fmoc); δC (101MHz, CDCl3): 12.10 
(ArCH3), 14.11 (ArCH3), 17.48 (ArCH3), 18.54 (γ-CH2), 21.40 (CH2CH2C(CH3)2), 
26.70 (NHCH3), 29.61 (2 x CH3 Pmc), 31.92 (β-CH2), 32.75 (N-CH3), 34.45 
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(CH2CH2C(CH3)2), 40.61 (CH2Ph), 46.33 (δ-CH2), 50.18 (α-CH Arg), 50.67 (Fmoc 
CH), 62.69 (α-CH Phe), 66.64 (Fmoc CH2), 73.69 (C(CH3)2), 117.91 (ArC Pmc), 
119.87 (ArC Pmc), 119.94 (ArC Pmc), 124.02 (ArCH Phe), 127.08 (2 x Fmoc ArCH), 
127.76 (2 x Phe ArCH), 128.55 (2 x Fmoc ArCH), 128.91 (2 x Fmoc ArCH), 129.30 
(2 x Phe ArCH), 133.30 (C-S), 134.89 (ArC Pmc), 134.90 (ArC Pmc), 137.89 (ArC 
Phe), 141.18 (2 x Fmoc C), 143.43 (2 x Fmoc C), 153.58 (Fmoc C=O), 153.69 (ArC 
Pmc), 156.05 (N=C), 156.25 (Arg C=O), 169.29 (Amide C=O). [Found (ES+) 
837.3997 [M+H]+, C46H57N6O7S requires 837.4004]. 
4.42 Ac­L­Arg(Pmc)­L­MePhe­NHMe (210) 
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The reaction was performed as described in 4.38 using (209) (0.18 g, 0.22 mmol) in 
DCM/DMF (5 ml, 1:1 v/v), diethylamine (0.20 mL, 2.19 mmol), DIPEA (38 µL, 0.22 
mmol), DMAP (16.0 mg, 0.2 mmol) and acetic anhydride (42 µL, 0.44 mmol). The 
reaction mixture was diluted with DCM (7 mL) and washed with 5% aq. citric acid (7 
mL), 5% aq. NaHCO3 (7 mL), H2O (10 mL) and brine (10 mL). The organic extract 
was dried (MgSO4) and concentrated by evaporation of the solvent. The crude product 
was purified by column chromatography (5:95 MeOH/DCM) to give (210) as a white 
solid (84 mg, 59% yield); Rf 0.28 (MeOH/ DCM, 1:9); m. p. 147-149 °C; IR (DCM) 
3430, 3332, 2930, 1634, 1552, 1453, 1264, 1111; [α]D + 18 (c 1.0 in MeOH); δH 
(400MHz, CDCl3, 3:1 mixture of rotamers): 0.84-0.87 (4H, m, γ-CH2 + β-CH2), 
1.25 (3H, s, CH3), 1.29 (3H s, CH3), 1.77-1.80 (2H, m, CH2C(CH3)2), 1.82 (3H, s, 
AcCH3), 2.08 (3H, s, ArCH3), 2.11 (3H, s, ArCH3), 2.53-2.57 (5H, m, NHCH3 + δ-
CH2), 2.61-2.64 (2H, m, CH2CH2C(CH3)2), 2.86 (2.25H, s, N-CH3 major), 2.91 
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(0.75H, s, N-CH3, minor), 3.12-3.18 (2H, m, CH2Ph), 4.11-4.12 (1H, m, α-CH Arg), 
4.74-4.75 (1H, m, α-CH Phe), 6.32 (2H. br, s, NH2), 7.08-7.26 (5H, m, ArH); δC 
(101MHz, CDCl3): 12.12 (ArCH3), 17.46 (ArCH3), 18.53 (ArCH3), 21.41 (AcCH3), 
22.12 (γ-CH2), 26.43 (CH2CH2C(CH3)2), 26.71 (2 x CH3), 27.82 (β-CH2), 29.67 
(NHCH3), 32.74 (N-CH3), 34.37 (CH2C(CH3)2), 40.47 (CH2Ph), 46.27 (δ-CH2), 48.81 
(α-CH Arg), 62.63 (α-CH Phe), 73.74 (C(CH3)3), 118.00 (ArC), 124.16 (ArC), 126.84 
(ArCH), 128.55 (2 x ArCH), 128.84 (2 x ArCH), 129.27 (ArC-S), 133.20 (ArC), 
134.81 (ArC), 135.44 (ArC), 138.00 (ArC Phe), 153.75 (ArC), 156.15 (C=N), 169.29 
(Ac C=O), 169.39 (Arg C=O), 173.03 (amide C=O). [Found (ES+) 657.3410 [M+H]+, 
C33H49N6O6S requires 657.3429]. 
4.43 Ac­L­Arg(MC)­L­MePhe­NHMe (201) 
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The reaction was performed using the same conditions as described in 4.39 using 
(210) (36.0 mg, 0.05 mmol,), a solution of TFA (1.63 mmol, 0.13 mL) in DCM (0.15 
mL), DBU (0.20 mmol, 31 µL) and N-succinimidyl-N-methylcarbamate (18.0 mg, 0.1 
mmol). The crude was purified by RP- preparative HPLC (gradient 8, λ = 214 nm, tR 
= 31.7 min) to give (201) as a clear oil (10 mg, 42%). RP-HPLC (analytical, system 1, 
gradient 1, λ = 214 nm): tR = 9.0 min (100 %). δH (270MHz, MeOD 1:1 mixture of 
rotamers): 1.45-1.81 (2H, m, γ-CH2 + 2H, m, β-CH2), 1.89 (3H, d, J = 6.8, AcCH3), 
2.67 (1.5H, s, NHCH3), 2.69 (1.5H, s, NHCH3), 2.76-2.79 (3H, m, NHCH3 (MC)), 
2.87 (1.5H, s, NCH3), 2.92-3.09 (3.5H, m, δ-CH2 + NCH3), 3.24-3.49 (2H, m, β-Phe 
CH2), 4.31-4.34 (1H, m, α-CH Arg), 4.69-4.73 (1H, m, α-CH Phe), 7.20-7.37 (ArH); 
δC (101MHz, MeOD 1:1 mixture of rotamers): 22.04, 22.31 (AcCH3), 24.20, 24.37 
(γ-CH2), 25.47, 26.41 (NHCH3), 26.56, 26.62 (MC-CH3), 28.79, 29.11 (β-CH2), 
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29.61, 30.35 (NCH3), 35.26, 35.46 (PhCH2), 41.93 (δ-CH2), 54.81 (α-CH Arg), 63.78 
(α-CH Phe), 127.71, 128.08 (1 x ArCH), 129.50, 129.97 (2 x ArCH), 130.06 130.68 
(2 x ArCH), 138.66, 139.45 (ArC), 155.98 (MC C=O), 156.04 (C=NH), 171.80, 
172.63 (Ac C=O), 173.55, 174.06 (NH C=O), 174.42, 174.55 (Arg C=O). [Found 
(ES+) 448.2667 [M+H]+, C21H34N7O4 requires 448.2667]. 
4.44 H­L­Asp(OBut)­D­Ala­Arg(Pmc)­L­MePhe­L­Asp(OBut)­OH 
(216) 
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Synthesis was performed manually on 2-chlorotrityl polystyrene resin (0.30 g, 0.39 
mmol). Loading of the resin was achieved by treating the resin with a solution of 
Fmoc-Asp(OBut)-OH (0.48 g, 1.17 mmol) and DIPEA (0.41 mL, 2.34 mmol) in dry 
DCM (5 mL) for 90 min. Fmoc deprotection was achieved by treatment of the resin 
with piperidine/DMF (v/v 1:4) for 4 x 4 min. Peptide couplings were performed using 
Fmoc-amino acid (3.0 equiv), PyBOP (1.9 equiv), HOBt (2.0 equiv) and DIPEA (6.0 
equiv) in DMF (5 mL) for 90 min, except for the coupling to MePhe, where Fmoc-
Arg(Pmc)-OH (3.0 equiv), PyBrOP (3.0 equiv), and DIPEA (6.0 equiv) in DMF (5 
mL) for 4 x 90 min were the conditions employed. Solid-phase reactions were 
monitored by use of a qualitative Kaiser test for the detection of primary amines and 
the chloranil test for the detection of secondary amines. Cleavage from the resin was 
achieved by treatment with TFA/DCM (v/v, 1:99, 4 mL) for 10 x 2 min. The cleavage 
solutions were immediately neutralised by addition to pyridine/MeOH (v/v 1:9, 10 
mL). The cleavage solution was concentrated in vacuo. The crude peptide was 
dissolved in the minimum amount of MeOH (4 mL) and added to cold water (35 mL). 
The precipitate was collected by centrifugation, dissolved in DCM (20 mL) and 
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washed with water (15 mL). The organic extract was dried (MgSO4) and concentrated 
in vacuo to give (216) as a white solid (172 mg, 44% yield, based on 0.39 mmol 
starting resin), m. p. 97- 99 °C RP-HPLC, (analytical, system 2, gradient 1, λ = 214 
nm): tR = 8.6 min (97%). Found (ES+) 1015.5179 [M+H]
+, C49H75N8O13S requires 
1015.5169]. 
4.45 cyclo­(L­Asp(OBut)­D­Ala­L­Arg(Pmc)­L­MePhe­L­Asp(OBut)) 
(217) 
N 
H 
N 
NH 
HN 
HN 
O 
N 
H 
N 
NH2 
S 
O 
O 
O 
O 
O 
O 
O 
O 
O 
O 
O 
A stirred solution of peptide (216) (0.17 g, 0.17 mmol) was treated with HATU (70.0 
mg, 0.2 mmol) in DCM (160 mL) and adjusted to pH 9 by the addition of DIPEA. 
The reaction mixture was stirred for 14 h at room temperature. The reaction mixture 
was concentrated in vacuo, dissolved in EtOAc (20 mL) and washed with 5% aq. 
citric acid (15 mL), sat. aq. NaHCO3 (3 x 15 mL), dried (MgSO4) and concentrated in 
vacuo to give (217) as a white solid (132 mg, 79%), m. p. 157-161 °C RP-HPLC 
(analytical, system 2, gradient 1, λ = 214 nm): tR = 11.1 min (100%). [Found: (ES+) 
997.5112 [M+H]+, C49H73N8O12S requires 997.5063]. 
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4.46 cyclo­(L­Asp­D­Ala­L­Arg­L­MePhe­L­Asp) (218)
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A stirred solution of peptide (217) (0.13 g, 0.13 mmol) was treated with a solution of 
TFA/TIS/H2O (95:2.5:2.5, 10 mL) and stirred at room temperature for 1 h. The 
reaction mixture was concentrated in vacuo, dissolved in TFA and precipitated by 
addition to ice-cold Et2O. The precipitate was collected by centrifugation to give 
(218) as a white solid as the trifluoroacetate salt (93 mg, 98%), m. p. 118–121 °C RP-
HPLC (analytical, system 2, gradient 1, λ = 214 nm): tR = 4.9 min (100%). [Found: 
(ES+) 619.2807 [M+H]+, C27H39N8O9 requires 619.2835]. 
4.47 cyclo­(L­Asp­D­Ala­L­Arg(MC)­L­MePhe­L­Asp) (219) 
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A stirred solution of peptide (218) (93.0 mg, 0.1 mmol) and DBU (0.10 mL, 0.7

mmol) in DMF (4 mL) was heated to 40 °C for 15 min then treated with a solution of

207 
N-succinimidyl-N-methyl carbamate (63.0 mg, 0.4 mmol) in DMF (0.6 mL) and 
stirred for 3 h. The reaction mixture was concentrated in vacuo and the crude product 
was purified by preparative RP-HPLC (gradient 2, tR = 20.7 min) to give (219) as the 
trifluoroacetate salt (16 mg, 17%). RP-HPLC (analytical, system 2, gradient 1, λ = 
214 nm): tR = 13.9 min (100%). δH (400MHz, H2O, 1:1 mixture of rotamers): 1.16 
(3H, d, J = 6.8, Ala β-CH3), 1.39-1.14 (1H, m, Arg γ-CHH), 1.52-1.56 (2H, m, Arg β-
CH2), 1.61-1.72 (1H, m, Arg γ-CHH), 2.53 (1.5H, s, MC-CH3 minor) 2.60 (1.5H, s, 
MC-CH3 major), 2.66 (1.5H, s, N-Me major), 2.72 (1.5H, s, N-Me minor), 2.82-2.94 
(4H, m, Asp β-CH2 + Arg δ-CH2), 2.96-3.12 (1H, m, Phe β-CH) 3.16-3.22 (3H, m, 
MePhe β-CH + β-Asp), 3.84-3.85 (0.5H, m, Arg α-CH minor) 3.98-4.02 (0.5H, m, 
Arg α-CH major), 4.43-4.21 (0.5H, m, Asp α-CH minor), 4.48-4.51, (0.5H, m, Asp α-
CH major), 4.42-4.52 (1H, m, Asp α-CH) 4.54 (1H, q, J = 5.6, Ala α-CH), 4.81-4.84 
(0.5H, m, MePhe α-CH major), 4.95-4.99 (0.5H, m, MePhe α-CH minor), 7.14-7.29 
(5H, m, ArCH). δC (101MHz, H2O 1:1 mixture of rotamers): 13.27, 17.39 (Ala 
CH3) 23.94 (Arg γ-CH2), 25.91, 26.21 (MC-CH3), 26.60 (Arg β-CH2), 32.57 (MePhe 
β-CH2) 34.79 (Arg δ-CH2), 35.06, 36.45 (N-CH3), 39.20 (Asp β-CH2), 40.34 (Asp β-
CH2), 48.16 (Ala α-CH), 49.91 (Asp α-CH), 50.30 (Asp α-CH), 50.68, 50.70 (Arg α-
CH), 67.12 (MePhe α-CH), 127.69 (ArCH), 128.70 (2 x ArCH), 129.32 (2 x ArCH), 
136.39 (ArC), 170.50 (Ala C=O), 171.89 (Asp C=O), 172.47 (Asp C=O), 173.45 
(MePhe C=O), 173.96 (Arg C=O), 174.63 (Asp C=O), 174.68 (Asp C=O). [Found 
(ES+) 676.3037 [M+H]+, C29H42N9O10 requires 676.3054]. 
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4.48 Preparation of H­L­Asp(OBn)­D­Ala­L­Arg(Z)2­L­MePhe­
Asp(OBn)­OH (232) 
H2N 
H 
N 
N 
H 
N 
N 
H 
OO 
O 
O 
NH 
N NH 
OO 
O 
O 
O 
O 
O O 
O 
OH 
Loading of the resin was achieved by treating a stirred solution of Fmoc-Asp-OBzl 
(1.65 mmol, 0.74 g) in DCM (10 mL) at 0 °C with DIC (0.83 mmol, 0.13 mL) for 25 
min. The reaction mixture was concentrated in vacuo, suspended in DMF (12 mL) 
and treated with DMAP (7.0 mg, 0.1 mmol). The reaction mixture was added to Wang 
resin (0.50 g, 0.55 mmol) and stirred gently for 90 minutes at room temperature after 
which, the resin was filtered and washed with DMF (5 x 5 mL) and DCM (3 x 5 mL). 
Synthesis of the linear peptide was performed by automated solid phase peptide 
synthesis. Fmoc deprotection was achieved by treatment with piperidine/DMF (v/v 
1:4) for 4 x 4 min. Peptide double couplings were performed using solutions of Fmoc-
amino acid (3.0 equiv), PyBOP (2.8 equiv), and DIPEA (6.0 equiv) in DMF (8 mL) 
for 40 min, except for the coupling to MePhe, where Fmoc-Arg(Z)2-OH (3.0 equiv), 
PyBrOP (2.8 equiv), and DIPEA (6.0 equiv) in DMF (8 mL) for 4 x 40 min were 
used. Cleavage from the resin was achieved by treatment with TFA/DCM (v/v, 1:1, 6 
mL) for 3 h. The cleavage solutions were immediately neutralised by addition to 
pyridine/MeOH (v/v 1:9, 10 mL).The cleavage solution was concentrated in vacuo. 
The crude peptide was dissolved in the minimum amount of MeOH (4.0 mL) and 
added to cold water (35 mL). The precipitate was collected by centrifugation, 
dissolved in DCM (20 mL) and washed with water (20 mL). The organic extract was 
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dried (MgSO4) and concentrated in vacuo to give the crude peptide (232) as a white 
solid (199 mg), m. p. 98-101 °C RP-HPLC, (analytical, system 2, gradient 1 with 
0.1% FA, λ = 214 nm): tR = 7.5 min. [Found (ES+) 1086.4237 [M+H]
+, 
C49H75N8O13S requires 1086.4241]. 
4.49 Preparation of cyclo­(L­Asp(OBn)­D­Ala­L­Arg(Z)2­L­MePhe­L­
Asp(OBn)) (234) 
N 
H 
N 
NH 
HN 
H 
N 
O 
N 
H 
N 
NH 
O 
O 
O 
O 
OO 
O 
O 
O 
O 
O O 
A stirred solution of crude peptide (232) (0.16 g, 0.15 mmol,), in DCM (150 mL) was 
treated with HATU (0.2 mmol, 57.0 mg). The reaction mixture was rendered to pH 9 
by the addition of DIPEA (2 mL) and stirred for 16 h after which, the reaction mixture 
was concentrated in vacuo, dissolved in EtOAc (20 mL), washed with 5% aq. citric 
acid (20 mL), 5% aq. NaHCO3 (20 mL), sat. aq. NaHCO3 (20 mL), water (20 mL) and 
brine (20 mL). The organic extract was dired (MgSO4) and concentrated in vacuo. 
The crude product was purified by preparative RP-HPLC (gradient 10, tR = 21.7 min) 
to give (234) as a clear oil (41 mg, 26%). RP-HPLC (analytical, system 2, gradient 1 
with 0.1% FA, λ = 214 nm): tR = 11.23 min (100%). [Found: (ES+) 1089.4307 
[M+Na]+, C57H62N8O13Na requires 1089.4329]. 
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4.50 Preparation of cyclo­(L­Asp­D­Ala­L­Arg­L­MePhe­L­Asp) (235)

N 
H 
N 
NH 
HN 
H 
N 
O 
N 
H 
NH 
NH2 
O 
O 
OHO 
O 
O 
HO 
O 
A stirred solution of peptide (234) (31.0 mg 0.03 mmol,) in AcOH: iPrOH (1:1 v/v, 20 
mL) was treated with Pd(OH)2/C (30 mg) and stirred for 16 h after which, the reaction 
mixture was filtered on Celite. The filtrate was concentrated in vacuo, to give peptide 
(235) as the acetate salt and as a yellow solid (16 mg, 78%). RP-HPLC (analytical, 
system 2, gradient 1 with 0.1% FA, λ = 214 nm): tR = 4.3 min (100%). [Found: (ES+) 
619.2840[M+H]+, C27H39N8O9 requires 619.2801, found 641.2633 [M+Na]
+, 
C27H38N8O9Na requires 641.2659]. 
4.51 Preparation of cyclo­(L­Asp­D­Ala­L­Arg(MC)­L­MePhe­L­Asp) 
(236) 
O
H 
NH OO N 
NH 
HO N N N 
O H H H 
O 
HN N 
O 
N 
H 
HO O 
O 
A stirred solution of peptide (235) as the acetate salt (16.0 mg, 0.02 mmol,) and DBU 
(0.14 mmol, 21 µL) in DMF (0.47 mL) was heated to 40 °C for 15 min then treated 
with a solution of succinimidyl-N-methylcarbamate (0.07 mmol, 12.0 mg) in DMF 
(78.0 µL) and stirred for 3 h. Analysis of the reaction mixture by analytical RP-HPLC 
indicated no reaction had occurred. Therefore, the reaction mixture was treated with 
further with DBU (0.28 mmol, 42.3 µL) and succinimidyl-N-methylcarbamate (0.1 
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mmol, 24.0 mg) for 16 h. The reaction mixture was concentrated in vacuo and the 
crude product was purified by semi-preparative RP-HPLC (gradient 10, tR = 13.1 
min) to (236) as the trifluoroacetate salt (2.4 mg, 14 %). RP-HPLC (analytical, system 
2, gradient 1 with 0.1% FA, λ = 214 nm): tR = 4.6 min (100%). δH (400MHz, H2O): -
0.41 (1H, m, Arg β-CHH), 0.92-1.12 (2H, m, Arg γ-CHH + β-CHH), 1.18 (3h, d, J = 
7.2, Ala β-CH3), 1.48-1.51 (1H, m, Arg γ-CHH), 2.28-2.39 (1H, m, β-Asp CHH), 2.76 
(3H, s, N-CH3), 2.86-3.07 (4H, m, Arg δ-CH2 + β-Asp CH2), 3.22 (1H, t, J = 7.2 
MePhe CHH), 3.31-3.33 (1H, m, MePhe, CHH), 4.03 (1H, q, J = 7.2, Ala α-CH), 
4.17 (1H, d, J = 8.0, α-Arg CH), 4.40 (1H, d, J = 12 α-AspCH), 4.96 (1H, d, J = 10.5, 
α-PheCH), 7.13-7.24 (5H, M, ArH). δC (101MHz, H2O): 16.84 (Ala CH3), 24.05 
(Arg γ-CH2), 26.11 (MC CH3), 26.69 (Arg β-CH2), 29.98 (N-CH3), 33.41 (Asp β-
CH2), 35.21 (MePhe β-CH2), 37.93 (Asp β-CH2), 40.76 (Arg δ-CH2), 48.80 (Ala α-
CH), 49.65 (Arg α-CH), 50.11 (Asp α-CH), 50.77 (Asp α-CH), 62.35 (Phe α-CH), 
127.34 (ArCH), 129.21 (2 x ArCH), 129.79 (2 x ArCH), 137.53 (ArC), 162.33 
(C=NH), 163.42 (MC C=O), 170.35 (Ala C=O), 171.37 (Phe C=O), 171.53 (Arg 
C=O), 174.41 (Asp C=O), 175.36 (Asp C=O), 175.72 (C=O Asp), 177.72 (Asp C=O). 
[Found: (ES+) 676.3033 [M+H]+, C29H42N9O10 requires 676.3054]. 
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6 Appendices 
6.1	 Appendix 1. Data curve for determining IC50 for tetrapeptide 
170, tripeptide 171, dipeptide 172, monopeptide 192 and 
dimethylguanyl urea 198 
The co-ordinates and structure factirs have been deposited with the PDB entries 
3CHP, 3CHC, 3CHD, 3CHE and 3CHF. 
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6.2 Appendix 2. IC50 curve for α­argifin against AMCase 
alpha argifin / AMCase 
[inhibitor], (M) 
Parameter Value Std. Error 
Y Range 1.01903 1.28324e­002

IC 50 6.81134e­004 2.15337e­005

6.3 Appendix 3. IC50 curve for α­argifin against AfChiB1 
AfChiB and alpha argifin 
10­5 10­4 10­3 
[inhibitor], (M) 
Parameter Value Std. Error 
YRange 1.08803 2.23559e­002

IC 50 1.48982e­004 3.07105e­006
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6.4 Appendix 4. IC50 curve for bayasin against AfChiB1 
AfChiB and Banyasin 
[inhibitor], (M) 
Parameter Value Std. Error 
YRange 1.05671 2.65202e­002

IC 50 1.05292e­004 1.02136e­006

6.5 Appendix 5. Data of 200 against AfChiB1 
10­5 10­4 10­3 
0 
0.2 
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0.6 
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Bound 
Mean 
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6.6 Appendix 6. IC50 curve for bayasin against AfChiB1 
228 
6.7 Appendix 7. X­ray crystal data for (128) 
Table 1. Crystal data and structure refinement for 128. 
Identification code k08farm6 
Empirical formula C20 H21 N O4 
Formula weight 339.38 
Temperature 150(2) K 
Wavelength 0.71073 Å 
Crystal system Monoclinic 
Space group P21 
Unit cell dimensions a = 6.2700(1)Å α = 90o 
b = 15.1080(3)Å β = 103.858(1)o 
c = 9.1690(2)Å γ = 90o 
Volume 843.27(3) Å3 
Z 2 
Density (calculated) 1.337 Mg/m3 
Absorption coefficient 0.093 mm-1 
F(000) 360 
Crystal size 0.35 x 0.35 x 0.30 mm 
Theta range for data collection 3.54 to 27.51 o . 
Index ranges -8<=h<=8; -19<=k<=19; -11<=l<=11 
Reflections collected 15920 
Independent reflections 3846 [R(int) = 0.0406] 
Reflections observed (>2σ) 3414 
Data Completeness 0.996 
Absorption correction Semi-empirical from equivalents 
Max. and min. transmission 0.98 and 0.94 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 3846 / 1 / 229 
Goodness-of-fit on F2 1.028 
Final R indices [I>2σ(I)] R1 = 0.0345 wR2 = 0.0790 
R indices (all data) R1 = 0.0459 wR2 = 0.0840 
Absolute structure parameter 1.8(7) 
Largest diff. peak and hole 0.220 and -0.245 eÅ-3 
Notes: Hydrogen bonding in lattice to give 1­D chains. 
Hydrogen 
deg. 
bonds with H..A < r(A) + 2.000 Angstroms and <DHA > 110 
D­H d(D­H) d(H..A) <DHA d(D..A) A 
O4­H4 0.840 2.213 157.64 3.007 O3 [ x+1, y, z ] 
229 
Table 2. Atomic coordinates ( x 104) and equivalent isotropic 
displacement parameters (Å2 x 103) for 1.U(eq) is defined 
as one third of the trace of the orthogonalized Uij tensor. 
Atom x y z U(eq) 
O(1) 3407(1) 3016(1) 370(1) 32(1) 
O(2) 6829(2) 3299(1) 1654(1) 35(1) 
O(3) 3552(2) 3578(1) 5140(1) 35(1) 
O(4) 10276(2) 3839(1) 7020(1) 57(1) 
N(1) 3913(2) 3255(1) 2827(1) 24(1) 
C(1) 4927(2) 3197(1) 1635(1) 26(1) 
C(2) 1221(2) 3047(1) 647(2) 32(1) 
C(3) 1604(2) 2974(1) 2354(2) 28(1) 
C(4) 1282(2) 2037(1) 2921(2) 33(1) 
C(5) 2668(2) 1337(1) 2421(2) 31(1) 
C(6) 1835(3) 817(1) 1162(2) 38(1) 
C(7) 3137(3) 191(1) 686(2) 44(1) 
C(8) 5293(3) 69(1) 1456(2) 47(1) 
C(9) 6143(3) 572(1) 2719(2) 46(1) 
C(10) 4844(3) 1200(1) 3202(2) 38(1) 
C(11) 4800(2) 3506(1) 4310(2) 27(1) 
C(12) 7231(2) 3700(1) 4818(2) 33(1) 
C(13) 7644(3) 4652(1) 4374(2) 52(1) 
C(14) 8038(2) 3567(1) 6528(2) 38(1) 
C(15) 7696(2) 2633(1) 7018(2) 35(1) 
C(16) 6058(2) 2448(1) 7764(2) 37(1) 
C(17) 5722(3) 1601(1) 8242(2) 48(1) 
C(18) 7002(4) 917(1) 7966(2) 58(1) 
C(19) 8650(4) 1082(2) 7242(2) 70(1) 
C(20) 9010(3) 1933(2) 6772(2) 58(1) 
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Table 3. Bond lengths [Å] and angles [o] for 128. 
O(1)-C(1) 1.3408(16) O(1)-C(2) 1.4535(16) 
O(2)-C(1) 1.1983(15) O(3)-C(11) 1.2205(16) 
O(4)-C(14) 1.4278(18) O(4)-H(4) 0.8400 
N(1)-C(11) 1.3927(17) N(1)-C(1) 1.3933(16) 
N(1)-C(3) 1.4705(16) C(2)-C(3) 1.5292(19) 
C(2)-H(2A) 0.9900 C(2)-H(2B) 0.9900 
C(3)-C(4) 1.537(2) C(3)-H(3) 1.0000 
C(4)-C(5) 1.508(2) C(4)-H(4A) 0.9900 
C(4)-H(4B) 0.9900 C(5)-C(6) 1.391(2) 
C(5)-C(10) 1.397(2) C(6)-C(7) 1.387(3) 
C(6)-H(6) 0.9500 C(7)-C(8) 1.379(3) 
C(7)-H(7) 0.9500 C(8)-C(9) 1.381(3) 
C(8)-H(8) 0.9500 C(9)-C(10) 1.391(2) 
C(9)-H(9) 0.9500 C(10)-H(10) 0.9500 
C(11)-C(12) 1.5116(19) C(12)-C(13) 1.534(3) 
C(12)-C(14) 1.541(2) C(12)-H(12) 1.0000 
C(13)-H(13A) 0.9800 C(13)-H(13B) 0.9800 
C(13)-H(13C) 0.9800 C(14)-C(15) 1.511(3) 
C(14)-H(14) 1.0000 C(15)-C(16) 1.392(2) 
C(15)-C(20) 1.392(2) C(16)-C(17) 1.385(3) 
C(16)-H(16) 0.9500 C(17)-C(18) 1.369(3) 
C(17)-H(17) 0.9500 C(18)-C(19) 1.378(3) 
C(18)-H(18) 0.9500 C(19)-C(20) 1.390(4) 
C(19)-H(19) 0.9500 C(20)-H(20) 0.9500 
C(1)-O(1)-C(2) 110.33(10) C(14)-O(4)-H(4) 109.5 
C(11)-N(1)-C(1) 129.21(10) C(11)-N(1)-C(3) 120.12(10) 
C(1)-N(1)-C(3) 110.64(10) O(2)-C(1)-O(1) 122.50(12) 
O(2)-C(1)-N(1) 128.36(12) O(1)-C(1)-N(1) 109.13(10) 
O(1)-C(2)-C(3) 104.63(10) O(1)-C(2)-H(2A) 110.8 
C(3)-C(2)-H(2A) 110.8 O(1)-C(2)-H(2B) 110.8 
C(3)-C(2)-H(2B) 110.8 H(2A)-C(2)-H(2B) 108.9 
N(1)-C(3)-C(2) 100.58(10) N(1)-C(3)-C(4) 111.46(11) 
C(2)-C(3)-C(4) 114.32(13) N(1)-C(3)-H(3) 110.0 
C(2)-C(3)-H(3) 110.0 C(4)-C(3)-H(3) 110.0 
C(5)-C(4)-C(3) 114.23(11) C(5)-C(4)-H(4A) 108.7 
C(3)-C(4)-H(4A) 108.7 C(5)-C(4)-H(4B) 108.7 
C(3)-C(4)-H(4B) 108.7 H(4A)-C(4)-H(4B) 107.6 
C(6)-C(5)-C(10) 117.94(15) C(6)-C(5)-C(4) 121.30(13) 
C(10)-C(5)-C(4) 120.75(14) C(7)-C(6)-C(5) 120.95(16) 
C(7)-C(6)-H(6) 119.5 C(5)-C(6)-H(6) 119.5 
C(8)-C(7)-C(6) 120.59(17) C(8)-C(7)-H(7) 119.7 
C(6)-C(7)-H(7) 119.7 C(7)-C(8)-C(9) 119.32(17) 
C(7)-C(8)-H(8) 120.3 C(9)-C(8)-H(8) 120.3 
C(8)-C(9)-C(10) 120.37(17) C(8)-C(9)-H(9) 119.8 
C(10)-C(9)-H(9) 119.8 C(9)-C(10)-C(5) 120.82(16) 
C(9)-C(10)-H(10) 119.6 C(5)-C(10)-H(10) 119.6 
O(3)-C(11)-N(1) 117.86(11) O(3)-C(11)-C(12) 122.70(13) 
N(1)-C(11)-C(12) 119.42(11) C(11)-C(12)-C(13) 108.76(14) 
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C(11)-C(12)-C(14) 110.46(11) C(13)-C(12)-C(14) 110.89(13) 
C(11)-C(12)-H(12) 108.9 C(13)-C(12)-H(12) 108.9 
C(14)-C(12)-H(12) 108.9 C(12)-C(13)-H(13A) 109.5 
C(12)-C(13)-H(13B) 109.5 H(13A)-C(13)-
H(13B) 
109.5 
C(12)-C(13)-H(13C) 109.5 H(13A)-C(13)-
H(13C) 
109.5 
H(13B)-C(13)-
H(13C) 
109.5 O(4)-C(14)-C(15) 111.96(14) 
O(4)-C(14)-C(12) 110.03(12) C(15)-C(14)-C(12) 112.84(13) 
O(4)-C(14)-H(14) 107.2 C(15)-C(14)-H(14) 107.2 
C(12)-C(14)-H(14) 107.2 C(16)-C(15)-C(20) 117.50(18) 
C(16)-C(15)-C(14) 120.49(14) C(20)-C(15)-C(14) 122.00(15) 
C(17)-C(16)-C(15) 121.80(16) C(17)-C(16)-H(16) 119.1 
C(15)-C(16)-H(16) 119.1 C(18)-C(17)-C(16) 119.93(18) 
C(18)-C(17)-H(17) 120.0 C(16)-C(17)-H(17) 120.0 
C(17)-C(18)-C(19) 119.5(2) C(17)-C(18)-H(18) 120.2 
C(19)-C(18)-H(18) 120.2 C(18)-C(19)-C(20) 120.88(18) 
C(18)-C(19)-H(19) 119.6 C(20)-C(19)-H(19) 119.6 
C(19)-C(20)-C(15) 120.37(19) C(19)-C(20)-H(20) 119.8 
C(15)-C(20)-H(20) 119.8 
Symmetry transformations used to generate equivalent atoms:
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Table 4. Anisotropic displacement parameters (Å2 x 103) for 128. The anisotropic 
displacement 
factor exponent takes the form: -2 gpi2 [ h2 a*2 U11 + ... + 2 h k a* b* U 
Atom U11 U22 U33 U23 U13 U12 
O(1) 20(1) 51(1) 23(1) 2(1) 4(1) 1(1) 
O(2) 19(1) 60(1) 28(1) 2(1) 9(1) 0(1) 
O(3) 24(1) 54(1) 29(1) -6(1) 11(1) -1(1) 
O(4) 27(1) 111(1) 32(1) -15(1) 6(1) -21(1) 
N(1) 15(1) 35(1) 23(1) 0(1) 6(1) 1(1) 
C(1) 20(1) 34(1) 23(1) 4(1) 5(1) 3(1) 
C(2) 18(1) 48(1) 28(1) 2(1) 3(1) 2(1) 
C(3) 15(1) 42(1) 25(1) -1(1) 5(1) -1(1) 
C(4) 27(1) 43(1) 31(1) -2(1) 10(1) -7(1) 
C(5) 31(1) 35(1) 29(1) 6(1) 9(1) -6(1) 
C(6) 36(1) 42(1) 36(1) 2(1) 7(1) -7(1) 
C(7) 57(1) 38(1) 41(1) 1(1) 17(1) -7(1) 
C(8) 55(1) 32(1) 60(1) 11(1) 28(1) 4(1) 
C(9) 39(1) 35(1) 62(1) 15(1) 8(1) 3(1) 
C(10) 37(1) 33(1) 40(1) 7(1) 1(1) -2(1) 
C(11) 21(1) 35(1) 25(1) -1(1) 6(1) -1(1) 
C(12) 22(1) 53(1) 26(1) -5(1) 8(1) -8(1) 
C(13) 51(1) 65(1) 40(1) -5(1) 12(1) -31(1) 
C(14) 22(1) 66(1) 26(1) -9(1) 7(1) -10(1) 
C(15) 24(1) 62(1) 18(1) -8(1) 1(1) 5(1) 
C(16) 28(1) 48(1) 36(1) -5(1) 9(1) 1(1) 
C(17) 41(1) 52(1) 47(1) 5(1) 2(1) 1(1) 
C(18) 75(1) 53(1) 39(1) 0(1) -2(1) 14(1) 
C(19) 93(2) 80(2) 33(1) -1(1) 5(1) 55(1) 
C(20) 51(1) 98(2) 27(1) 3(1) 11(1) 38(1) 
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Table 5. Hydrogen coordinates ( x 104) and isotropic displacement 
parameters (Å2 x 103) for 128. 
Atom x y z U(eq) 
H(4) 11005 3629 6443 68 
H(2A) 311 2549 142 38 
H(2B) 477 3611 281 38 
H(3) 643 3403 2727 33 
H(4A) 1634 2046 4033 39 
H(4B) -284 1872 2564 39 
H(6) 352 892 620 45 
H(7) 2540 -157 -179 53 
H(8) 6184 -358 1122 56 
H(9) 7622 488 3260 55 
H(10) 5446 1541 4075 46 
H(12) 8045 3284 4296 40 
H(13A) 7123 4720 3284 78 
H(13B) 9221 4780 4674 78 
H(13C) 6853 5064 4881 78 
H(14) 7147 3967 7019 45 
H(16) 5145 2916 7951 44 
H(17) 4604 1495 8760 57 
H(18) 6757 333 8272 70 
H(19) 9551 609 7062 84 
H(20) 10160 2036 6281 70 
234 
Table 6. Dihedral angles [o] for 128. 
Atom1 - Atom2 - Atom3 - Atom4 Dihedral 
C(2) - O(1) - C(1) - O(2) -172.32(14) 
C(2) - O(1) - C(1) - N(1) 6.69(15) 
C(11) - N(1) - C(1) - O(2) 5.3(2) 
C(3) - N(1) - C(1) - O(2) -172.83(15) 
C(11) - N(1) - C(1) - O(1) -173.64(13) 
C(3) - N(1) - C(1) - O(1) 8.23(15) 
C(1) - O(1) - C(2) - C(3) -18.03(16) 
C(11) - N(1) - C(3) - C(2) 163.45(12) 
C(1) - N(1) - C(3) - C(2) -18.23(14) 
C(11) - N(1) - C(3) - C(4) -74.98(15) 
C(1) - N(1) - C(3) - C(4) 103.34(13) 
O(1) - C(2) - C(3) - N(1) 20.93(14) 
O(1) - C(2) - C(3) - C(4) -98.59(13) 
N(1) - C(3) - C(4) - C(5) -57.53(16) 
C(2) - C(3) - C(4) - C(5) 55.68(16) 
C(3) - C(4) - C(5) - C(6) -95.85(16) 
C(3) - C(4) - C(5) - C(10) 83.32(17) 
C(10) - C(5) - C(6) - C(7) -0.9(2) 
C(4) - C(5) - C(6) - C(7) 178.29(14) 
C(5) - C(6) - C(7) - C(8) 0.2(2) 
C(6) - C(7) - C(8) - C(9) 0.6(2) 
C(7) - C(8) - C(9) - C(10) -0.5(2) 
C(8) - C(9) - C(10) - C(5) -0.2(2) 
C(6) - C(5) - C(10) - C(9) 0.9(2) 
C(4) - C(5) - C(10) - C(9) -178.25(14) 
C(1) - N(1) - C(11) - O(3) 174.08(14) 
C(3) - N(1) - C(11) - O(3) -8.0(2) 
C(1) - N(1) - C(11) - C(12) -4.4(2) 
C(3) - N(1) - C(11) - C(12) 173.53(13) 
O(3) - C(11) - C(12) - C(13) -95.92(18) 
N(1) - C(11) - C(12) - C(13) 82.52(16) 
O(3) - C(11) - C(12) - C(14) 26.0(2) 
N(1) - C(11) - C(12) - C(14) -155.57(14) 
C(11) - C(12) - C(14) - O(4) -173.96(13) 
C(13) - C(12) - C(14) - O(4) -53.31(19) 
C(11) - C(12) - C(14) - C(15) 60.20(17) 
C(13) - C(12) - C(14) - C(15) -179.15(13) 
O(4) - C(14) - C(15) - C(16) 128.51(15) 
C(12) - C(14) - C(15) - C(16) -106.70(15) 
O(4) - C(14) - C(15) - C(20) -50.25(19) 
C(12) - C(14) - C(15) - C(20) 74.54(19) 
C(20) - C(15) - C(16) - C(17) -0.4(2) 
C(14) - C(15) - C(16) - C(17) -179.22(15) 
C(15) - C(16) - C(17) - C(18) -0.8(3) 
C(16) - C(17) - C(18) - C(19) 1.4(3) 
C(17) - C(18) - C(19) - C(20) -0.8(3) 
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C(18) - C(19) - C(20) - C(15) -0.4(3) 
C(16) - C(15) - C(20) - C(19) 1.0(3) 
C(14) - C(15) - C(20) - C(19) 179.82(17) 
Symmetry transformations used to generate equivalent atoms:
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6.8 Appendix 8. X­ray crystal data for (126) 
Table 1. Crystal data and structure refinement for 126. 
Identification code h08farm2 
Empirical formula C20 H21 N O4 
Formula weight 339.38 
Temperature 150(2) K 
Wavelength 0.71073 Å 
Crystal system Orthorhombic 
Space group P212121 
Unit cell dimensions a = 6.6020(3)Å α = 90o 
b = 16.0450(8)Å β = 90o 
c = 16.3920(5)Å γ = 90o 
Volume 1736.39(13) Å3 
Z 4 
Density (calculated) 1.298 Mg/m3 
Absorption coefficient 0.090 mm-1 
F(000) 720 
Crystal size 0.15 x 0.15 x 0.12 mm 
Theta range for data collection 3.55 to 26.99o 
Index ranges -8<=h<=8; -20<=k<=20; -19<=l<=20 
Reflections collected 11969 
Independent reflections 3743 [R(int) = 0.1070] 
Reflections observed (>2σ) 2720 
Data Completeness 0.986 
Absorption correction Semi-empirical from equivalents 
Max. and min. transmission 1.091 and 0.741 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 3743 / 0 / 229 
Goodness-of-fit on F2 1.093 
Final R indices [I>2σ(I)] R1 = 0.0599 wR2 = 0.1375 
R indices (all data) R1 = 0.0933 wR2 = 0.1637 
Absolute structure parameter 2.0(17) 
Largest diff. peak and hole 0.450 and -0.371 eÅ-3 
Notes: H­bonded 1­D polymers in lattice. 
Hydrogen 
deg. 
bonds with H..A < r(A) + 2.000 Angstroms and <DHA > 110 
D­H d(D­H) d(H..A) <DHA d(D..A) A 
O4­H4 
O4­H4 
0.840 
0.840 
2.065 
2.419 
133.57 
132.25 
2.714 
3.048 
O3 
O1 [ x­1, y, z ] 
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Table 2. Atomic coordinates ( x 104) and equivalent isotropic 
displacement parameters (Å2 x 103) for 1.U(eq) is defined 
as one third of the trace of the orthogonalized Uij tensor. 
Atom x y z U(eq) 
O(1) 10684(4) 996(1) 6186(1) 58(1) 
O(2) 10941(3) -36(1) 5269(1) 52(1) 
O(3) 4905(3) 1152(1) 5142(1) 54(1) 
O(4) 3450(4) 2498(2) 5954(2) 98(1) 
N(1) 8011(4) 635(1) 5339(1) 36(1) 
C(1) 9951(5) 587(2) 5653(2) 44(1) 
C(2) 9775(5) -323(2) 4581(2) 44(1) 
C(3) 7616(5) -54(2) 4760(2) 37(1) 
C(4) 6330(5) -740(2) 5147(2) 40(1) 
C(5) 5845(4) -1420(2) 4540(2) 34(1) 
C(6) 4429(4) -1288(2) 3928(2) 42(1) 
C(7) 4003(5) -1900(2) 3362(2) 54(1) 
C(8) 4974(5) -2659(2) 3399(2) 53(1) 
C(9) 6391(5) -2803(2) 3996(2) 47(1) 
C(10) 6832(5) -2187(2) 4567(2) 40(1) 
C(11) 6520(4) 1225(2) 5502(2) 39(1) 
C(12) 6859(5) 1897(2) 6138(2) 38(1) 
C(13) 6378(6) 1538(2) 6983(2) 62(1) 
C(14) 5544(5) 2665(2) 5939(2) 48(1) 
C(15) 5944(5) 3368(2) 6538(2) 39(1) 
C(16) 4399(5) 3664(2) 7032(2) 44(1) 
C(17) 4761(6) 4300(2) 7586(2) 54(1) 
C(18) 6674(7) 4640(2) 7655(2) 59(1) 
C(19) 8216(6) 4348(2) 7164(2) 52(1) 
C(20) 7852(5) 3720(2) 6603(2) 44(1) 
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Table 3. Bond lengths [Å] and angles [o] for 126. 
O(1)-C(1) 1.195(3) O(2)-C(1) 1.351(3) 
O(2)-C(2) 1.441(4) O(3)-C(11) 1.224(3) 
O(4)-C(14) 1.408(4) O(4)-H(4) 0.8400 
N(1)-C(1) 1.383(4) N(1)-C(11) 1.392(3) 
N(1)-C(3) 1.479(3) C(2)-C(3) 1.518(4) 
C(2)-H(2A) 0.9900 C(2)-H(2B) 0.9900 
C(3)-C(4) 1.529(4) C(3)-H(3) 1.0000 
C(4)-C(5) 1.510(4) C(4)-H(4A) 0.9900 
C(4)-H(4B) 0.9900 C(5)-C(6) 1.387(4) 
C(5)-C(10) 1.393(4) C(6)-C(7) 1.381(4) 
C(6)-H(6) 0.9500 C(7)-C(8) 1.377(5) 
C(7)-H(7) 0.9500 C(8)-C(9) 1.373(5) 
C(8)-H(8) 0.9500 C(9)-C(10) 1.392(4) 
C(9)-H(9) 0.9500 C(10)-H(10) 0.9500 
C(11)-C(12) 1.517(3) C(12)-C(13) 1.533(4) 
C(12)-C(14) 1.542(4) C(12)-H(12) 1.0000 
C(13)-H(13A) 0.9800 C(13)-H(13B) 0.9800 
C(13)-H(13C) 0.9800 C(14)-C(15) 1.520(4) 
C(14)-H(14) 1.0000 C(15)-C(20) 1.385(4) 
C(15)-C(16) 1.386(4) C(16)-C(17) 1.388(4) 
C(16)-H(16) 0.9500 C(17)-C(18) 1.380(5) 
C(17)-H(17) 0.9500 C(18)-C(19) 1.380(5) 
C(18)-H(18) 0.9500 C(19)-C(20) 1.385(4) 
C(19)-H(19) 0.9500 C(20)-H(20) 0.9500 
C(1)-O(2)-C(2) 110.0(2) C(14)-O(4)-H(4) 109.5 
C(1)-N(1)-C(11) 128.4(2) C(1)-N(1)-C(3) 111.2(2) 
C(11)-N(1)-C(3) 120.4(2) O(1)-C(1)-O(2) 123.4(3) 
O(1)-C(1)-N(1) 128.2(3) O(2)-C(1)-N(1) 108.4(2) 
O(2)-C(2)-C(3) 105.0(2) O(2)-C(2)-H(2A) 110.7 
C(3)-C(2)-H(2A) 110.7 O(2)-C(2)-H(2B) 110.7 
C(3)-C(2)-H(2B) 110.7 H(2A)-C(2)-H(2B) 108.8 
N(1)-C(3)-C(2) 99.8(2) N(1)-C(3)-C(4) 111.7(2) 
C(2)-C(3)-C(4) 113.4(2) N(1)-C(3)-H(3) 110.5 
C(2)-C(3)-H(3) 110.5 C(4)-C(3)-H(3) 110.5 
C(5)-C(4)-C(3) 111.4(2) C(5)-C(4)-H(4A) 109.3 
C(3)-C(4)-H(4A) 109.3 C(5)-C(4)-H(4B) 109.3 
C(3)-C(4)-H(4B) 109.3 H(4A)-C(4)-H(4B) 108.0 
C(6)-C(5)-C(10) 118.2(2) C(6)-C(5)-C(4) 120.6(2) 
C(10)-C(5)-C(4) 121.2(2) C(7)-C(6)-C(5) 121.0(3) 
C(7)-C(6)-H(6) 119.5 C(5)-C(6)-H(6) 119.5 
C(8)-C(7)-C(6) 120.2(3) C(8)-C(7)-H(7) 119.9 
C(6)-C(7)-H(7) 119.9 C(9)-C(8)-C(7) 119.9(3) 
C(9)-C(8)-H(8) 120.0 C(7)-C(8)-H(8) 120.0 
C(8)-C(9)-C(10) 120.0(3) C(8)-C(9)-H(9) 120.0 
C(10)-C(9)-H(9) 120.0 C(9)-C(10)-C(5) 120.6(3) 
C(9)-C(10)-H(10) 119.7 C(5)-C(10)-H(10) 119.7 
O(3)-C(11)-N(1) 117.3(2) O(3)-C(11)-C(12) 121.9(2) 
N(1)-C(11)-C(12) 120.8(2) C(11)-C(12)-C(13) 108.8(2) 
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C(11)-C(12)-C(14) 109.8(2) C(13)-C(12)-C(14) 112.0(3) 
C(11)-C(12)-H(12) 108.7 C(13)-C(12)-H(12) 108.7 
C(14)-C(12)-H(12) 108.7 C(12)-C(13)-H(13A) 109.5 
C(12)-C(13)-H(13B) 109.5 H(13A)-C(13)-
H(13B) 
109.5 
C(12)-C(13)-H(13C) 109.5 H(13A)-C(13)-
H(13C) 
109.5 
H(13B)-C(13)-
H(13C) 
109.5 O(4)-C(14)-C(15) 107.4(3) 
O(4)-C(14)-C(12) 113.4(3) C(15)-C(14)-C(12) 111.0(2) 
O(4)-C(14)-H(14) 108.3 C(15)-C(14)-H(14) 108.3 
C(12)-C(14)-H(14) 108.3 C(20)-C(15)-C(16) 119.0(3) 
C(20)-C(15)-C(14) 120.7(3) C(16)-C(15)-C(14) 120.3(3) 
C(15)-C(16)-C(17) 120.5(3) C(15)-C(16)-H(16) 119.8 
C(17)-C(16)-H(16) 119.8 C(18)-C(17)-C(16) 120.2(3) 
C(18)-C(17)-H(17) 119.9 C(16)-C(17)-H(17) 119.9 
C(17)-C(18)-C(19) 119.6(3) C(17)-C(18)-H(18) 120.2 
C(19)-C(18)-H(18) 120.2 C(18)-C(19)-C(20) 120.4(3) 
C(18)-C(19)-H(19) 119.8 C(20)-C(19)-H(19) 119.8 
C(15)-C(20)-C(19) 120.4(3) C(15)-C(20)-H(20) 119.8 
C(19)-C(20)-H(20) 119.8 
Symmetry transformations used to generate equivalent atoms:
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Table 4. Anisotropic displacement parameters (Å2 x 103) for 126. The anisotropic 
displacement 
factor exponent takes the form: -2 gpi2 [ h2 a*2 U11 + ... + 2 h k a* b* U 
Atom U11 U22 U33 U23 U13 U12 
O(1) 46(1) 41(1) 88(2) -14(1) -25(1) 4(1) 
O(2) 31(1) 37(1) 89(2) -8(1) -5(1) 4(1) 
O(3) 40(1) 53(1) 70(1) -26(1) -17(1) 11(1) 
O(4) 36(1) 70(2) 187(3) -75(2) -23(2) 14(1) 
N(1) 34(1) 31(1) 44(1) -6(1) -5(1) 4(1) 
C(1) 34(2) 30(1) 69(2) 1(1) -2(1) 2(1) 
C(2) 41(2) 34(1) 57(2) -2(1) 8(1) 2(1) 
C(3) 42(2) 29(1) 40(1) -4(1) 2(1) 5(1) 
C(4) 42(2) 39(1) 39(1) -6(1) 5(1) 2(1) 
C(5) 32(1) 36(1) 34(1) -1(1) 5(1) 1(1) 
C(6) 37(2) 42(1) 47(1) 0(1) -1(1) 7(1) 
C(7) 50(2) 66(2) 44(2) -5(1) -13(2) -4(2) 
C(8) 56(2) 54(2) 48(2) -19(1) 5(2) -6(2) 
C(9) 44(2) 38(1) 60(2) -7(1) 7(2) 6(1) 
C(10) 32(1) 37(1) 50(1) -1(1) -2(1) 2(1) 
C(11) 36(2) 37(1) 45(1) -8(1) -2(1) 3(1) 
C(12) 37(2) 33(1) 43(1) -5(1) -1(1) -3(1) 
C(13) 93(3) 42(2) 50(2) -6(1) 12(2) -18(2) 
C(14) 39(2) 44(2) 60(2) -18(1) -12(1) 10(1) 
C(15) 47(2) 32(1) 37(1) -1(1) -2(1) 1(1) 
C(16) 54(2) 34(1) 44(1) 1(1) 6(1) 1(1) 
C(17) 76(3) 45(2) 42(1) -6(1) 6(2) 14(2) 
C(18) 94(3) 35(2) 47(2) -8(1) -20(2) 15(2) 
C(19) 58(2) 36(1) 62(2) 7(1) -24(2) -5(2) 
C(20) 49(2) 44(2) 40(1) 2(1) -2(1) 4(2) 
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Table 5. Hydrogen coordinates ( x 104) and isotropic displacement 
parameters (Å2 x 103) for 126. 
Atom x y z U(eq) 
H(4) 3244 2004 5809 117 
H(2A) 9862 -936 4528 53 
H(2B) 10269 -65 4069 53 
H(3) 6951 163 4254 44 
H(4A) 7071 -983 5615 48 
H(4B) 5053 -497 5354 48 
H(6) 3742 -769 3899 50 
H(7) 3037 -1797 2944 64 
H(8) 4664 -3081 3013 63 
H(9) 7071 -3325 4019 57 
H(10) 7815 -2290 4978 48 
H(12) 8316 2066 6125 45 
H(13A) 4972 1341 6993 92 
H(13B) 6562 1971 7397 92 
H(13C) 7291 1071 7097 92 
H(14) 5909 2863 5380 57 
H(16) 3081 3429 6990 53 
H(17) 3690 4502 7919 65 
H(18) 6927 5072 8038 70 
H(19) 9536 4579 7211 62 
H(20) 8917 3529 6261 53 
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Table 6. Dihedral angles [o] for 126. 
Atom1 - Atom2 - Atom3 - Atom4 Dihedral 
C(2) - O(2) - C(1) - O(1) -171.4(3) 
C(2) - O(2) - C(1) - N(1) 10.3(3) 
C(11) - N(1) - C(1) - O(1) 7.8(5) 
C(3) - N(1) - C(1) - O(1) -172.5(3) 
C(11) - N(1) - C(1) - O(2) -174.1(2) 
C(3) - N(1) - C(1) - O(2) 5.6(3) 
C(1) - O(2) - C(2) - C(3) -21.5(3) 
C(1) - N(1) - C(3) - C(2) -17.7(3) 
C(11) - N(1) - C(3) - C(2) 162.0(2) 
C(1) - N(1) - C(3) - C(4) 102.4(3) 
C(11) - N(1) - C(3) - C(4) -77.8(3) 
O(2) - C(2) - C(3) - N(1) 22.5(3) 
O(2) - C(2) - C(3) - C(4) -96.4(2) 
N(1) - C(3) - C(4) - C(5) 177.2(2) 
C(2) - C(3) - C(4) - C(5) -71.0(3) 
C(3) - C(4) - C(5) - C(6) -73.9(3) 
C(3) - C(4) - C(5) - C(10) 104.6(3) 
C(10) - C(5) - C(6) - C(7) 0.2(4) 
C(4) - C(5) - C(6) - C(7) 178.7(3) 
C(5) - C(6) - C(7) - C(8) 0.5(5) 
C(6) - C(7) - C(8) - C(9) -0.9(5) 
C(7) - C(8) - C(9) - C(10) 0.6(5) 
C(8) - C(9) - C(10) - C(5) 0.1(4) 
C(6) - C(5) - C(10) - C(9) -0.5(4) 
C(4) - C(5) - C(10) - C(9) -179.0(3) 
C(1) - N(1) - C(11) - O(3) 178.9(3) 
C(3) - N(1) - C(11) - O(3) -0.8(4) 
C(1) - N(1) - C(11) - C(12) -4.6(4) 
C(3) - N(1) - C(11) - C(12) 175.7(2) 
O(3) - C(11) - C(12) - C(13) 93.5(3) 
N(1) - C(11) - C(12) - C(13) -82.9(3) 
O(3) - C(11) - C(12) - C(14) -29.5(4) 
N(1) - C(11) - C(12) - C(14) 154.2(2) 
C(11) - C(12) - C(14) - O(4) 62.3(3) 
C(13) - C(12) - C(14) - O(4) -58.8(3) 
C(11) - C(12) - C(14) - C(15) -176.7(2) 
C(13) - C(12) - C(14) - C(15) 62.2(3) 
O(4) - C(14) - C(15) - C(20) -174.2(3) 
C(12) - C(14) - C(15) - C(20) 61.3(3) 
O(4) - C(14) - C(15) - C(16) 6.1(4) 
C(12) - C(14) - C(15) - C(16) -118.4(3) 
C(20) - C(15) - C(16) - C(17) -0.3(4) 
C(14) - C(15) - C(16) - C(17) 179.3(3) 
C(15) - C(16) - C(17) - C(18) -0.5(4) 
C(16) - C(17) - C(18) - C(19) 0.6(4) 
C(17) - C(18) - C(19) - C(20) 0.2(4) 
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C(16) - C(15) - C(20) - C(19) 1.1(4) 
C(14) - C(15) - C(20) - C(19) -178.5(2) 
C(18) - C(19) - C(20) - C(15) -1.1(4) 
Symmetry transformations used to generate equivalent atoms:
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